{"docstore/data": {"9e1448a7-40c0-439a-b715-fb5e0626a7ed": {"__data__": {"id_": "9e1448a7-40c0-439a-b715-fb5e0626a7ed", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e4caecd-0c8d-434e-b1cc-67d7fa008bca", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "original_text": "On the basis of U.S. "}, "hash": "cf49c66f9374f42519ce71e6360c754f8c3faac7b978542cadad65f5357a53ca", "class_name": "RelatedNodeInfo"}}, "text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. ", "start_char_idx": 0, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e4caecd-0c8d-434e-b1cc-67d7fa008bca": {"__data__": {"id_": "4e4caecd-0c8d-434e-b1cc-67d7fa008bca", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e1448a7-40c0-439a-b715-fb5e0626a7ed", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f6f6503cc6b6cc972f2ea0283691224d0987d5b5b60af32295d2ce123b061f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "753aa288-fa05-4a7e-84f6-daa6697c6ae2", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter. "}, "hash": "5930e40d7180bd72fa0fd959810adbe23d3c72205054855b253ef0c85ffaaecd", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 563, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "753aa288-fa05-4a7e-84f6-daa6697c6ae2": {"__data__": {"id_": "753aa288-fa05-4a7e-84f6-daa6697c6ae2", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e4caecd-0c8d-434e-b1cc-67d7fa008bca", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a64114eaf9303d2eda40a42d15eda69998842be524bd99891c5c61d7300db82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3fc6c82-927f-4bd1-841b-c7da2fa2333d", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n"}, "hash": "f9c131001fc31f7fd396ca2f2fdde5efb00e5876d98dea893f33bf2ea5f41fd6", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter. ", "start_char_idx": 584, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3fc6c82-927f-4bd1-841b-c7da2fa2333d": {"__data__": {"id_": "b3fc6c82-927f-4bd1-841b-c7da2fa2333d", "embedding": null, "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "753aa288-fa05-4a7e-84f6-daa6697c6ae2", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "original_text": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69b46a49640449a4785adee5b4fc8673885ddca64394018f4322a452e73841cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd85bdce-4434-42b7-92c2-94d1d55ce57b", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "original_text": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n"}, "hash": "bdbfadbbf34cc6350e04cac6a17379bdc37272bd04e40c362cc95a4d13e48c0a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "start_char_idx": 759, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd85bdce-4434-42b7-92c2-94d1d55ce57b": {"__data__": {"id_": "fd85bdce-4434-42b7-92c2-94d1d55ce57b", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "original_text": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3fc6c82-927f-4bd1-841b-c7da2fa2333d", "node_type": "1", "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "337bf452ed6a67c2ab65a3ce0446b36ab7af444f9f77a8db22257154450ead31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c0cd43-72e8-417f-be3b-aec5602f3643", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n"}, "hash": "1ffb0c71a7c69dfbafb33e177f6c13d3afa210d15b4714a86e05ba7379447c4a", "class_name": "RelatedNodeInfo"}}, "text": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "start_char_idx": 908, "end_char_idx": 1040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c0cd43-72e8-417f-be3b-aec5602f3643": {"__data__": {"id_": "42c0cd43-72e8-417f-be3b-aec5602f3643", "embedding": null, "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd85bdce-4434-42b7-92c2-94d1d55ce57b", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "original_text": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aac8cca3c499b7975555a57d05f9bce758f609e0e657aee5a14012058ed1ec96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0332363-ae4c-4167-ace6-f9b47de977e5", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n"}, "hash": "9e799895f947e7e7cb40ccf6b9f875efdd1ef19acce07611a18c929dbabeb2cb", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "start_char_idx": 1040, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0332363-ae4c-4167-ace6-f9b47de977e5": {"__data__": {"id_": "e0332363-ae4c-4167-ace6-f9b47de977e5", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c0cd43-72e8-417f-be3b-aec5602f3643", "node_type": "1", "metadata": {"window": "generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "original_text": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5b8e6bd4d7ceda27bed038b27fd8ee9bdef47992690a2700b522dff07e6f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8012f630-7aaf-4bbf-b3b7-d9b154fd085c", "node_type": "1", "metadata": {"window": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "original_text": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n"}, "hash": "bc607a7c1965a475265fff5e61e764a47aae3e48d7839f9407d7e44d6993add9", "class_name": "RelatedNodeInfo"}}, "text": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "start_char_idx": 1164, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8012f630-7aaf-4bbf-b3b7-d9b154fd085c": {"__data__": {"id_": "8012f630-7aaf-4bbf-b3b7-d9b154fd085c", "embedding": null, "metadata": {"window": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "original_text": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0332363-ae4c-4167-ace6-f9b47de977e5", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued. ", "original_text": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2af841ecc34359b29b495581579ce14ad93e72813ad2db9ea44be4979e6feb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8f9f0b-7e43-4599-b02a-c223f7065690", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. "}, "hash": "329e5e2ff921dc61e9ea16b8d36446025f1791734b462f9b8088eee1f80ab770", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "start_char_idx": 1560, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd8f9f0b-7e43-4599-b02a-c223f7065690": {"__data__": {"id_": "bd8f9f0b-7e43-4599-b02a-c223f7065690", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8012f630-7aaf-4bbf-b3b7-d9b154fd085c", "node_type": "1", "metadata": {"window": "The Company revised its adjusted diluted EPS guidance for fiscal 2020 to a range of $7.35 to $7.65, from $7.55 to $7.80 previously.\n The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "original_text": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7a70f2e00990050eafa075ba2df47fcf9e807dfb8c724e8879c26fbe276f027", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d6a6350-4de4-46ec-ac4f-61a38b354ed9", "node_type": "1", "metadata": {"window": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Collis continued. "}, "hash": "38ba65f54af3f2b7216fe270b311b7110a54445f938d69016d7878129bb1abd1", "class_name": "RelatedNodeInfo"}}, "text": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "start_char_idx": 1847, "end_char_idx": 2013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d6a6350-4de4-46ec-ac4f-61a38b354ed9": {"__data__": {"id_": "3d6a6350-4de4-46ec-ac4f-61a38b354ed9", "embedding": null, "metadata": {"window": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8f9f0b-7e43-4599-b02a-c223f7065690", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a GAAP basis, as discussed below in Fiscal Year 2020 Expectations.\n \"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63fcf0abf7c64c21e4d9b7b0966cf9922befb3968a0365ebbe849a4222242aae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n"}, "hash": "4347b8ea739b56fa9df6ea68c7e2bd16a6c89ba29d042c756f5add7cb7bbc71f", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 2013, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd": {"__data__": {"id_": "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd", "embedding": null, "metadata": {"window": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d6a6350-4de4-46ec-ac4f-61a38b354ed9", "node_type": "1", "metadata": {"window": "\"While we are pleased to report another quarter of strong revenue and adjusted diluted EPS growth in the second quarter of fiscal\n2020, we are even prouder of the impressive work being done across our company to ensure continued patient access to\npharmaceuticals in the midst of the COVID-19 pandemic,\" said Steven H. Collis, Chairman, President and Chief Executive Officer of\nAmerisourceBergen.\n AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e2a1cfc1f641f871fd77f734ef9870a1becd4ddae2afafd62a36e2c0b6dae07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca4bd51-7540-4db7-9ac5-d7b29d24c287", "node_type": "1", "metadata": {"window": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1"}, "hash": "2c7e9f5f6ea82ed72f3d92ea34c7a73306dd33ccad0af69603e8ff50e4fcd0f3", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "start_char_idx": 2031, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca4bd51-7540-4db7-9ac5-d7b29d24c287": {"__data__": {"id_": "8ca4bd51-7540-4db7-9ac5-d7b29d24c287", "embedding": null, "metadata": {"window": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2f0b870b-482e-4ab8-917a-46f750ffef65", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecec500f2ec69799d529c4b74106de22b9100bcfbc15360ba45274253a4453f2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen\u2019s protocols to protect and support the health and wellness of its associates have been enhanced during the\nCOVID-19 pandemic and the Company has business continuity plans in place that are designed to help ensure the continued\noperation of critical business functions.\n \"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "\"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c5458d4aa932cf7b6bedb0a0ac27b560263c1dcb34357494d8f9782a90cfae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1178edf3-42ca-48cd-b615-e81837651457", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "b9c6e82ef75d5a763d0f7de4679812dce1e6091aca3fa9243686db9a8de6bd2d", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "start_char_idx": 2265, "end_char_idx": 2523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1178edf3-42ca-48cd-b615-e81837651457": {"__data__": {"id_": "1178edf3-42ca-48cd-b615-e81837651457", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca4bd51-7540-4db7-9ac5-d7b29d24c287", "node_type": "1", "metadata": {"window": "\"I have been inspired by the actions of our associates to be innovative and solution-oriented to meet the complex needs of our\nupstream and downstream partners,\" Mr.  Collis continued.  \"AmerisourceBergen's diligence, actions and thoughtfulness in navigating\nthis pandemic have been guided by our purpose of being united in our responsibility to create healthier futures and have proven\nvital for all our stakeholders.\"\n Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "original_text": "Second Quar ter Fiscal Y ear 2020 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $47.4B $47.4B\nGross Pr ofit $1.4B $1.4B\nOperating Expenses $1,079M $745M\nOperating Income $310M $672M\nInterest Expense, Net $34M $34M\nEffectiv e Tax Rat e (251.6)% 21.5%\n1", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5f9c121c89e8c7f5f253575c2683e7f0432dc8744579222881d41e1fc541fe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a920da31-fb34-414c-b9e1-44e4704d7b5c", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "1875e112c5fcc34b2e3709d1e69790803973c3a9e5ef6a399dbbd25df05401b0", "class_name": "RelatedNodeInfo"}}, "text": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a920da31-fb34-414c-b9e1-44e4704d7b5c": {"__data__": {"id_": "a920da31-fb34-414c-b9e1-44e4704d7b5c", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1178edf3-42ca-48cd-b615-e81837651457", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcab8f998ed91ff6e2fb7dca56f6f52f67c989d5e18d722c7ec832ced7212d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9af51a1-862c-4d58-a236-54e792d5fa58", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n"}, "hash": "513f7a2102c66b87db53b0a691a6c3dcd0cfa85b8389578ca55f17dc1fd2d9a5", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 247, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9af51a1-862c-4d58-a236-54e792d5fa58": {"__data__": {"id_": "c9af51a1-862c-4d58-a236-54e792d5fa58", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a920da31-fb34-414c-b9e1-44e4704d7b5c", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f575e7a86e43d3af50c0e2bd4a97a2f0ea3dfb7f1fdf97386011d394c96c516e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09771bcc-4962-4a1e-9c49-8b70f26269d1", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n"}, "hash": "08a9e9440a5bcaec325980e16950a25f949fdc3285ac17f4ac7aeeadaad12f07", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "start_char_idx": 339, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09771bcc-4962-4a1e-9c49-8b70f26269d1": {"__data__": {"id_": "09771bcc-4962-4a1e-9c49-8b70f26269d1", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9af51a1-862c-4d58-a236-54e792d5fa58", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f7e03e7c496892ab2cf67ebc5cb445adaeebbf6c4826ab495f38e189662afc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c72f756-f67d-438b-8e91-2451b8a7b2ae", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. "}, "hash": "ea131042949f5644135e572f8460b907d3e0f28319cec1033a5c94d4492625e8", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "start_char_idx": 559, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c72f756-f67d-438b-8e91-2451b8a7b2ae": {"__data__": {"id_": "1c72f756-f67d-438b-8e91-2451b8a7b2ae", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09771bcc-4962-4a1e-9c49-8b70f26269d1", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "134aee5f557061b0398a1495254b31059a659be011d21c9de4a7cb5bb23a1ad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36703ad5-4147-49ad-a4ad-2004b9014cfe", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. "}, "hash": "ce02a77aca1d7f7bda230b0366e9f3f660cca65e1c2acb7bb9cf60b233af051e", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 872, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36703ad5-4147-49ad-a4ad-2004b9014cfe": {"__data__": {"id_": "36703ad5-4147-49ad-a4ad-2004b9014cfe", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c72f756-f67d-438b-8e91-2451b8a7b2ae", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55fca2850d0523b66fcb9ec16fa2c3ed1a3dbf613fe19c2665e57982c39da9c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n"}, "hash": "b639baf51154be6abb969938eda6138dadb8584665c712b60d2b3fb3156e321e", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "start_char_idx": 1032, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a": {"__data__": {"id_": "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a", "embedding": null, "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36703ad5-4147-49ad-a4ad-2004b9014cfe", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "original_text": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5e95ab83aa9f533e700d4bb46bfefdb6b8be839afbbb2b273d4c94d483bfaee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a8571c-e76f-43ef-a14b-b7d7d56db1a2", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. "}, "hash": "a8515b6f8b974ca9dc8ae5f6e7f97e250f3df3be9f73bef0c82658f7a07dd4b4", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "start_char_idx": 1334, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a8571c-e76f-43ef-a14b-b7d7d56db1a2": {"__data__": {"id_": "71a8571c-e76f-43ef-a14b-b7d7d56db1a2", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "original_text": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d8549354a5ba6ecb5fc786365f27a5da002048ef1a68df829f4e887309c86f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78329396-c816-4716-a1a8-caf1fe82ce78", "node_type": "1", "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. "}, "hash": "49bcc5710c69ea505966554ed63f6d0d241babffa1e707454467db1648e0466e", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "start_char_idx": 1451, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78329396-c816-4716-a1a8-caf1fe82ce78": {"__data__": {"id_": "78329396-c816-4716-a1a8-caf1fe82ce78", "embedding": null, "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a8571c-e76f-43ef-a14b-b7d7d56db1a2", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2020 second quarter was $1.4 billion, a 2.6 percent decrease compared to the same\nperiod in the previous fiscal year.  Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "original_text": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e1cbd559d2d800e68664402bb8ee07b44f17bacdf7358138748f35f9f4f30e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9c45057-640d-484b-9682-947d80462202", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n"}, "hash": "11556e89b174c7de060cfe59b6303b1101d00d1cdc3e5bb6645961005c446629", "class_name": "RelatedNodeInfo"}}, "text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "start_char_idx": 1618, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9c45057-640d-484b-9682-947d80462202": {"__data__": {"id_": "f9c45057-640d-484b-9682-947d80462202", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78329396-c816-4716-a1a8-caf1fe82ce78", "node_type": "1", "metadata": {"window": "Gross profit in the current year quarter was unfavorably impacted by LIFO expense in\ncomparison to a LIFO credit in the prior year period and significantly lower gains from antitrust litigation settlements, offset in\npart by increases in gross profit in Pharmaceutical Distribution Services and Other.  Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "original_text": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f87f63c2b970801634a00f40af8ab3813f0b9ed87cdcddae59fe114de358d2f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "787a3382-e992-4bcf-8773-c8ebf2a33123", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. "}, "hash": "3900f503abd2e8a7fbceda056453545f268310bce57140cbd039926ea0f7c52f", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "start_char_idx": 1838, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "787a3382-e992-4bcf-8773-c8ebf2a33123": {"__data__": {"id_": "787a3382-e992-4bcf-8773-c8ebf2a33123", "embedding": null, "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9c45057-640d-484b-9682-947d80462202", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue\nwas 2.93 percent, a decrease of 36 basis points from the prior year quarter.\n Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "original_text": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f5d34bff6d879a28bf87ed63ff522ca03a0260c91ef4fa28cb7a77f008a1785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e39ecdd-2c12-4d95-987e-9da4e5c9237e", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "original_text": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n"}, "hash": "fa0e027ea4c2d3a01a3a89543c78dd24234ae5d848d53a3086c1f6462a71d525", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "start_char_idx": 2010, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e39ecdd-2c12-4d95-987e-9da4e5c9237e": {"__data__": {"id_": "6e39ecdd-2c12-4d95-987e-9da4e5c9237e", "embedding": null, "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "original_text": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "787a3382-e992-4bcf-8773-c8ebf2a33123", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2020, operating expenses were $1,078.6 million, compared to $1,377.2\nmillion in the same period last fiscal year.  The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "original_text": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bd8694ee57d6da43d37ee51ac363d6a18bc902cd287eedf29f16fa0e1114f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a6f58c-9cd7-44da-8cca-ba4af112ec04", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n"}, "hash": "c4f7fec1fce77c4189a957df18951665d1a96ddbf04716a983f0cd8442322b1d", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "start_char_idx": 2197, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a6f58c-9cd7-44da-8cca-ba4af112ec04": {"__data__": {"id_": "16a6f58c-9cd7-44da-8cca-ba4af112ec04", "embedding": null, "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e39ecdd-2c12-4d95-987e-9da4e5c9237e", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $223.7 million\nimpairment of PharMEDium's assets compared to a $570.0 million impairment of PharMEDium's assets in the same period in\nthe previous fiscal year.  Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "original_text": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e731c55878d469a920adc5b88175b128a52792dd56117ab21fda4765c1229a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f0554ce-7b3c-4bee-aa16-a04d31f44412", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. "}, "hash": "658e18f91312b57ae25a5731b514b063252a258333dcaae242ff62bead374270", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "start_char_idx": 2370, "end_char_idx": 2676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f0554ce-7b3c-4bee-aa16-a04d31f44412": {"__data__": {"id_": "9f0554ce-7b3c-4bee-aa16-a04d31f44412", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a6f58c-9cd7-44da-8cca-ba4af112ec04", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 2.27 percent,\ncompared to 3.18 percent for the same period in the previous fiscal year.\n Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "original_text": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2615d0b15d7d28dd23b1ce5312b275cb4f4482eb2d9fc4fae238ee79319b7e53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a3fb84d-3c8d-45b5-b655-27e17409e162", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. "}, "hash": "9309a45d6bf654d0c3c0e2d3febb224b80ef117989f4ce4771893965068c2c83", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "start_char_idx": 2676, "end_char_idx": 2779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a3fb84d-3c8d-45b5-b655-27e17409e162": {"__data__": {"id_": "2a3fb84d-3c8d-45b5-b655-27e17409e162", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f0554ce-7b3c-4bee-aa16-a04d31f44412", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2020 second quarter, operating income increased to $309.5 million from $47.6 million in the\nprior year quarter due to the decrease in operating expenses.  Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "original_text": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f6069014196dfc783214af74d21455660bf3c69fa79b6bb2d9427257c5a29ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77f912a3-ef78-4315-aaa1-7e0b2f84223f", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n"}, "hash": "9b18043accf23101b272f7f0ef0f0b6a9bf1c41d19f481fc79c2049f2d9311c4", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "start_char_idx": 2779, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77f912a3-ef78-4315-aaa1-7e0b2f84223f": {"__data__": {"id_": "77f912a3-ef78-4315-aaa1-7e0b2f84223f", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a3fb84d-3c8d-45b5-b655-27e17409e162", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.65 percent\nin the second quarter of fiscal 2020, compared to 0.11 percent for the same period in the previous fiscal year.\n Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "original_text": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84e297ba5918db02a295e780abcad09a9490e4cfe36b93e3bec758bf256a5fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4547c220-68dc-4f99-9ea6-6d87537d2d3d", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. "}, "hash": "3387b503d6df50a7f9f7c33e2cec2909e8dd5ddc48782039106f63705dd38d16", "class_name": "RelatedNodeInfo"}}, "text": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "start_char_idx": 2952, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4547c220-68dc-4f99-9ea6-6d87537d2d3d": {"__data__": {"id_": "4547c220-68dc-4f99-9ea6-6d87537d2d3d", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77f912a3-ef78-4315-aaa1-7e0b2f84223f", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2020 second quarter, net interest expense of $34.4 million was down 20.5 percent versus\nthe prior year quarter primarily due to certain build-to-suit leases now being accounted for as operating leases, resulting\nfrom the adoption of the new lease accounting standard.\n Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b17cfeb0d99bd670325c561ac10f2c68cde8924ffa49f4e94072c05569441b57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9", "node_type": "1", "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n"}, "hash": "21de6f46540fdb29e700248722646e5fa710f8c8c886aeb8ec3cd02506637a25", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "start_char_idx": 3101, "end_char_idx": 3268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9": {"__data__": {"id_": "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9", "embedding": null, "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4547c220-68dc-4f99-9ea6-6d87537d2d3d", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was (251.6) percent for the second quarter of fiscal 2020.  The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abfe86377da82527f231a5ad27aab0817fc1546047dd0f48802ea3050eb4b66f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32ec9f13-1442-4638-b7ee-429d2efb33c9", "node_type": "1", "metadata": {"window": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n"}, "hash": "c6b3b58b3593873d3c284687ce3aaa01951b8a343d913cae2cfc2f67d2612b7b", "class_name": "RelatedNodeInfo"}}, "text": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "start_char_idx": 3268, "end_char_idx": 3375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32ec9f13-1442-4638-b7ee-429d2efb33c9": {"__data__": {"id_": "32ec9f13-1442-4638-b7ee-429d2efb33c9", "embedding": null, "metadata": {"window": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9", "node_type": "1", "metadata": {"window": "The effective tax rate in the\nquarter was primarily impacted by tax benefits associated with the Company's decision to permanently exit the PharMEDium\ncompounding business.  The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0ddc064c2dc1f8bc49e3b3dd63f28236b250734f7e979877a84f6366c9d8103", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b291c37-1dd5-4941-85b5-a2e1d75c0f80", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n"}, "hash": "b99e72a7491bc6d6fd97912f03203cfa3574781b712878a6fc48f76529adb4b3", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "start_char_idx": 3375, "end_char_idx": 3608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b291c37-1dd5-4941-85b5-a2e1d75c0f80": {"__data__": {"id_": "0b291c37-1dd5-4941-85b5-a2e1d75c0f80", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32ec9f13-1442-4638-b7ee-429d2efb33c9", "node_type": "1", "metadata": {"window": "The prior year's second quarter effective tax rate of (49.5) percent was favorably impacted by the\n$570.0 million impairment of PharMEDium's assets.\n Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f1a83f4bc3418451c8f5804e018dddf555e8487ff48313e9986407fbd1b9278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08297ad3-8f60-40d5-b3ca-c4426de1517a", "node_type": "1", "metadata": {"window": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "cd9f4ca13243512af1f86e043a00e45179c192bbb99845576e72b11d64ed22ef", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "start_char_idx": 3608, "end_char_idx": 4101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08297ad3-8f60-40d5-b3ca-c4426de1517a": {"__data__": {"id_": "08297ad3-8f60-40d5-b3ca-c4426de1517a", "embedding": null, "metadata": {"window": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b291c37-1dd5-4941-85b5-a2e1d75c0f80", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $4.64 in the second quarter of fiscal 2020 compared to $0.13 in\nthe previous fiscal year\u2019s second quarter.  This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71b8a57d933a2ca642541edc627697233246a07e818908886e8fa5d912ae2f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "200fc712-b8a8-4317-a029-4c2335a22cc1", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n"}, "hash": "bba79afc22e0ce60db65eeef4375b94ca44dd6bd4515afa81b11f9042fe0ca3f", "class_name": "RelatedNodeInfo"}}, "text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 4101, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "200fc712-b8a8-4317-a029-4c2335a22cc1": {"__data__": {"id_": "200fc712-b8a8-4317-a029-4c2335a22cc1", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08297ad3-8f60-40d5-b3ca-c4426de1517a", "node_type": "1", "metadata": {"window": "This increase was primarily due to the discrete income tax benefits recognized in the\ncurrent year period.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "Revenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4deeecd2c5d4dd98dbb1b1389866900b862aae36e53fc33826b61bea8ce82ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "961af97c-cb15-40e4-9e11-72ca23f7975f", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "2"}, "hash": "6d4239c5d2ab65df68ebddabab7c4f8269ff3fa7434332705b8e970564d787ea", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "start_char_idx": 4173, "end_char_idx": 4446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "961af97c-cb15-40e4-9e11-72ca23f7975f": {"__data__": {"id_": "961af97c-cb15-40e4-9e11-72ca23f7975f", "embedding": null, "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e0829619278a3a9a0e41a1e7ac076e8a4fa28670f54d4a99c04147a648492d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "200fc712-b8a8-4317-a029-4c2335a22cc1", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2020 were 207.1\nmillion, a 2.6 percent decline versus the prior fiscal year second quarter primarily due to share repurchases.\n Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c26e16a34d3e8485fe23279b245ec77e437dea5e6d89fb15574d3db87ac7b094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2de0f251-9ad8-448e-8920-4b16a374bf29", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. "}, "hash": "611de717a9a073796030e1ff23f074f206d16513f6c5cda531047a344cafebe4", "class_name": "RelatedNodeInfo"}}, "text": "2", "start_char_idx": 82, "end_char_idx": 83, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2de0f251-9ad8-448e-8920-4b16a374bf29": {"__data__": {"id_": "2de0f251-9ad8-448e-8920-4b16a374bf29", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "961af97c-cb15-40e4-9e11-72ca23f7975f", "node_type": "1", "metadata": {"window": "Second Quar ter Adjust ed (non-GAAP) R esults\nThe comments below compare adjusted results, which exclude: gain from antitrust litigation settlements; LIFO expense/credit;\nPharMEDium remediation and shutdown costs; New York State Opioid Stewardship Act; contingent consideration adjustment;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium's assets; certain\ndiscrete tax benefits; and a gain on the sale of an equity investment.\n Revenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2020, revenue was\n$47.4 billion, up 9.5 percent compared to the same quarter in the previous fiscal year, reflecting a 9.3 percent increase in\nPharmaceutical Distribution Services revenue and a 12.7 percent increase in revenue within Other.\n 2", "original_text": "2", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee30d475a5f6c7c4ee629707e864d9546768b0143a8d8d68c28191e82678d67d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea4e833-0c56-4c6e-ba76-91a365333ea1", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n"}, "hash": "b1dd22d756e5ef9991b18c6993966c7604ff259a52928bfc5b4e6d70352e01f4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "start_char_idx": 0, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea4e833-0c56-4c6e-ba76-91a365333ea1": {"__data__": {"id_": "dea4e833-0c56-4c6e-ba76-91a365333ea1", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2de0f251-9ad8-448e-8920-4b16a374bf29", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21f36947e4d13f9768ddca3b07844e87f897e2d49f50dbb58c2b8ed196c2384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce2062ea-a77c-4fad-a192-878793f3bc40", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith. "}, "hash": "3e16b85f192f62b1ff384399fe2f81d94ddbcd43fe98a93cdcb3306cc4608b9c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n", "start_char_idx": 261, "end_char_idx": 420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce2062ea-a77c-4fad-a192-878793f3bc40": {"__data__": {"id_": "ce2062ea-a77c-4fad-a192-878793f3bc40", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea4e833-0c56-4c6e-ba76-91a365333ea1", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0e3a03cee0e892d262be3b608a02e5a573024dd4a9432def0c1d1fc6d336041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "952fda2f-edc8-43e6-8ca2-ad5554f0c7df", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n"}, "hash": "5945b32c5f0d1c3c11534d57312ac327355da0b1dab3645d6e05004b2099ea02", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith. ", "start_char_idx": 420, "end_char_idx": 798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "952fda2f-edc8-43e6-8ca2-ad5554f0c7df": {"__data__": {"id_": "952fda2f-edc8-43e6-8ca2-ad5554f0c7df", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce2062ea-a77c-4fad-a192-878793f3bc40", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ae12344407bb2cc006290661ab30593247d6f5078ea985b64f9886ae4a8d0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. "}, "hash": "133a54271675b62cccfd16e440ef4b2df139414a92458df195887d1c1327e431", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "start_char_idx": 798, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be": {"__data__": {"id_": "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "952fda2f-edc8-43e6-8ca2-ad5554f0c7df", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a43bd05ecc6677543a5bc4c02d2cea7136e66e420874f498c8b0885e5e6439ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b4fbe22-c161-4c59-a452-c2cec8136a71", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n"}, "hash": "f25e10aea524cf42f4fa97de55f7f06c6ef33af485580a94ed7aecc1964bd8ac", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "start_char_idx": 979, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b4fbe22-c161-4c59-a452-c2cec8136a71": {"__data__": {"id_": "3b4fbe22-c161-4c59-a452-c2cec8136a71", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9b261fb829bfb394dd93ea34ee3292150bb2aeb51351c2acc984f14099eb0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "260645d6-7ba2-481e-a109-4ee5c3093afc", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "cc56baec94636570c12ee560c878a2246eac07e71efab84034a03972e4fdc909", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 1292, "end_char_idx": 1455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "260645d6-7ba2-481e-a109-4ee5c3093afc": {"__data__": {"id_": "260645d6-7ba2-481e-a109-4ee5c3093afc", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b4fbe22-c161-4c59-a452-c2cec8136a71", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "original_text": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbbe98b1f1c7e2ad640b078ebb11a22ef656e61fdd44b866d9827ed1523b8feb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0037409a-ea96-415d-9771-2f0f0a80e866", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n"}, "hash": "37b01e2c4ac4dcae7ff8a9eaecc9c229a8fe4dda3a78b66c63354cc2e02f4fe4", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1455, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0037409a-ea96-415d-9771-2f0f0a80e866": {"__data__": {"id_": "0037409a-ea96-415d-9771-2f0f0a80e866", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "260645d6-7ba2-481e-a109-4ee5c3093afc", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15420b012b55bb63a31b1bd32ede0dca6ac731f6b55359adbfb85c2dcd09f537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d9ff01e-9059-43ae-ad6c-bbca1cc56176", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n"}, "hash": "2bf5274ad949258bf2ebbc75f7cc1cc265d2c23fa5cca38317e351197fdf1723", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "start_char_idx": 1554, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d9ff01e-9059-43ae-ad6c-bbca1cc56176": {"__data__": {"id_": "1d9ff01e-9059-43ae-ad6c-bbca1cc56176", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0037409a-ea96-415d-9771-2f0f0a80e866", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2020 second quarter, adjusted operating income of $671.7 million increased 8.9\npercent from the prior year period due to an 8.9 percent increase in operating income within Pharmaceutical Distribution\nServices and an 8.4 percent increase in operating income within Other.  Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12d18c66ed131e50091388c31ef972d6203a5df11009c65b8cf340fffcd5116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f9de117-d441-4540-bf27-3cc57e308eed", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n"}, "hash": "0ed89870b02ed46d3a5c0902bcebbbf8c04200c9d766c83e8bb96ad0d3c9745c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "start_char_idx": 1836, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f9de117-d441-4540-bf27-3cc57e308eed": {"__data__": {"id_": "4f9de117-d441-4540-bf27-3cc57e308eed", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d9ff01e-9059-43ae-ad6c-bbca1cc56176", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of\nrevenue was 1.42 percent in the fiscal 2020 second quarter, unchanged from the previous fiscal year\u2019s second quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1639f6a50893ff790cb15d951d81f1552a755a1b4afce77b6b8666dcce5fcfb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6050150-248b-4f43-9dae-c94771ce27f9", "node_type": "1", "metadata": {"window": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "4fde708bc4af669cab62549465b9dfe27cafda2244069a15f858e2095e05728c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "start_char_idx": 2005, "end_char_idx": 2321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6050150-248b-4f43-9dae-c94771ce27f9": {"__data__": {"id_": "c6050150-248b-4f43-9dae-c94771ce27f9", "embedding": null, "metadata": {"window": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f9de117-d441-4540-bf27-3cc57e308eed", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4acf24b8fa3e76bea4de463f3b0d1277be11dea253ff3513440ba85fa116cfdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1917b774-682c-4b68-9581-74bbf7b1aa86", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n"}, "hash": "536846d52218bf58b766bec4de4b3cbdc4facc7059cb1f083ac287856d162bad", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2321, "end_char_idx": 2431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1917b774-682c-4b68-9581-74bbf7b1aa86": {"__data__": {"id_": "1917b774-682c-4b68-9581-74bbf7b1aa86", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6050150-248b-4f43-9dae-c94771ce27f9", "node_type": "1", "metadata": {"window": "In the fiscal 2020 second\nquarter, net interest expense of $34.4 million was down 20.5 percent versus the prior year quarter primarily due to certain\nbuild-to-suit leases now being accounted for as operating leases, resulting from the adoption of the new lease accounting\nstandard.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de303c1910356903642c3302577dd11bc0b1796c8e945a0d646aceb88f095987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e8a05ee-9314-4b30-bf4a-b0f66a5172af", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. "}, "hash": "768dac67484dae2094da17c1ec0b94e528ab30e4020a4bb2ad1596f0fbbf5a18", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "start_char_idx": 2431, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e8a05ee-9314-4b30-bf4a-b0f66a5172af": {"__data__": {"id_": "4e8a05ee-9314-4b30-bf4a-b0f66a5172af", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1917b774-682c-4b68-9581-74bbf7b1aa86", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.5 percent for the second quarter of fiscal 2020, same as the\nprevious fiscal year\u2019s second quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbb279de07da1949a4bec87bbac380f1083e5e774a05baaf7faa69d0e4823d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80707ad6-1962-4234-a7b3-77a76044307a", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n"}, "hash": "1b12814ba03264a79956e0dbe3ef58797cdf0f0653d6a5943b4ad176ae5f8782", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "start_char_idx": 2635, "end_char_idx": 2963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80707ad6-1962-4234-a7b3-77a76044307a": {"__data__": {"id_": "80707ad6-1962-4234-a7b3-77a76044307a", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e8a05ee-9314-4b30-bf4a-b0f66a5172af", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 13.7 percent to $2.40 in the second quarter\nof fiscal 2020 compared to $2.11 in the previous fiscal year\u2019s second quarter, driven primarily by the increase in adjusted\noperating income and a lower number of diluted shares outstanding.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6456674460a5d887194524e91b5e7762d43711be79eeca110db8e83bce4a07e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c1754c0-c4c2-4500-a068-9fab2bf9bc67", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. "}, "hash": "2811abac22baf435520f1c1f565450543d1eee18dcda245a84cefef8e1402a34", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "start_char_idx": 2963, "end_char_idx": 3168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c1754c0-c4c2-4500-a068-9fab2bf9bc67": {"__data__": {"id_": "8c1754c0-c4c2-4500-a068-9fab2bf9bc67", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80707ad6-1962-4234-a7b3-77a76044307a", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "original_text": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16afe108723a3dfaa95c3d00c3fa86e020fcb7210f91ad6b825510a1a0e09d00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n", "original_text": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n"}, "hash": "36a42feca2d099d5ce7187ca667684dbd9f068e5f0286544d7ba552c8cf57fb8", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "start_char_idx": 3168, "end_char_idx": 3485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1": {"__data__": {"id_": "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n", "original_text": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c1754c0-c4c2-4500-a068-9fab2bf9bc67", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2020 were 207.1 million, a 2.6 percent decline versus the\nprior fiscal year second quarter primarily due to share repurchases.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a39914bccc17430dffb4b2899242a7112e4565425a5b1997d3753fad1eb78dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fc3b9f9-0c41-4f58-9922-2234d4979296", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. "}, "hash": "88beaad24185f2b5a5d7dd635c2da2823bacd0711d959d894f6da30887aaacc8", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "start_char_idx": 3485, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fc3b9f9-0c41-4f58-9922-2234d4979296": {"__data__": {"id_": "3fc3b9f9-0c41-4f58-9922-2234d4979296", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n", "original_text": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "361c3301cc30b09edd8d7adfabd6485d0e156c67a6f33834dd51b91a78bb8e18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138bd8a6-4659-4709-9912-f3b6e9c8305c", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. "}, "hash": "15a429a3ab5165ff7ae0a3b7193143f11967be22e8f056c8669fb3b1d4bbc426", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "start_char_idx": 3725, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138bd8a6-4659-4709-9912-f3b6e9c8305c": {"__data__": {"id_": "138bd8a6-4659-4709-9912-f3b6e9c8305c", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fc3b9f9-0c41-4f58-9922-2234d4979296", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services and animal health and includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI\nAnimal Health (MWI).\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ba0efabd00ee514213832f794cbf1d8c198c5d9b66c927615fe874405f10aea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "589b0799-606e-44bf-a2a9-5b9d96aedae6", "node_type": "1", "metadata": {"window": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "This increase was primarily due to the performance of\nMWI and World Courier.\n"}, "hash": "be52ba398f3257eb555fdcc3890b968b3f1c156b79ff2f1a2cb042bd32ff2803", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "start_char_idx": 3961, "end_char_idx": 4065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "589b0799-606e-44bf-a2a9-5b9d96aedae6": {"__data__": {"id_": "589b0799-606e-44bf-a2a9-5b9d96aedae6", "embedding": null, "metadata": {"window": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "This increase was primarily due to the performance of\nMWI and World Courier.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138bd8a6-4659-4709-9912-f3b6e9c8305c", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $45.6 billion, an increase of 9.3 percent compared to the same quarter in the prior\nfiscal year primarily due to organic growth of some of its largest customers, increased specialty product sales and overall market\ngrowth.  Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8347b1be9e9085ed62a860fca8df0d7162c9cef11426eff96c35d58b2db4ef0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "153fd63a-b934-4558-a612-eb68bda69e24", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3"}, "hash": "0b0b4409add2cb4a897c1906cbeba8b61fd9d150c3f5030f0b875d0f748fbb90", "class_name": "RelatedNodeInfo"}}, "text": "This increase was primarily due to the performance of\nMWI and World Courier.\n", "start_char_idx": 4065, "end_char_idx": 4142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "153fd63a-b934-4558-a612-eb68bda69e24": {"__data__": {"id_": "153fd63a-b934-4558-a612-eb68bda69e24", "embedding": null, "metadata": {"window": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f789752baf2f12d285fa2514e90d45d707781dbea97617ffc25fc8535b1b1c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "589b0799-606e-44bf-a2a9-5b9d96aedae6", "node_type": "1", "metadata": {"window": "Segment operating income of $563.1 million in the second quarter of fiscal 2020 was up 8.9 percent compared to the same\nperiod in the previous fiscal year, primarily due to the increase in gross profit resulting from the growth in revenue.\n Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "This increase was primarily due to the performance of\nMWI and World Courier.\n", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c452d713d6a2a10914084c68ebec5e7acd15727ad995cd16c6cd8fe9cf118b22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e1e265b-452f-4760-b3e9-c09840c3f36c", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "original_text": "healthy communities. "}, "hash": "b0284ee5cfe0ab06f4ec0dd7e3333f0704953771fe02cf5aff93b2a8e69532f9", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "start_char_idx": 4142, "end_char_idx": 4424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e1e265b-452f-4760-b3e9-c09840c3f36c": {"__data__": {"id_": "8e1e265b-452f-4760-b3e9-c09840c3f36c", "embedding": null, "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "original_text": "healthy communities. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "153fd63a-b934-4558-a612-eb68bda69e24", "node_type": "1", "metadata": {"window": "Other\nRevenue in Other was $1.9 billion in the second quarter of fiscal 2020, an increase of 12.7 percent compared to the same period in\nthe prior fiscal year, due to growth at all three operating segments: MWI, ABCS and World Courier.  Operating income in Other\nincreased 8.4 percent to $108.3 million in the second quarter of fiscal 2020.  This increase was primarily due to the performance of\nMWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen published its 2019 Corporate Citizenship Report, detailing the impact of its robust sustainability and\ncommunity efforts across 150 campuses in 50 countries and its focus on sustainable operations, inspired associates and\n3", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "809d804bd374fa4c7db089a018e7700fba6ab7cb46842ec4543ab56cb152336e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf76669e-72d6-4708-a4b0-a6f73c47ecda", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "original_text": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n"}, "hash": "03120a83007e16114771d70230290829037af8e48ad337306c06da4cce724973", "class_name": "RelatedNodeInfo"}}, "text": "healthy communities. ", "start_char_idx": 0, "end_char_idx": 21, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf76669e-72d6-4708-a4b0-a6f73c47ecda": {"__data__": {"id_": "cf76669e-72d6-4708-a4b0-a6f73c47ecda", "embedding": null, "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "original_text": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e1e265b-452f-4760-b3e9-c09840c3f36c", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "original_text": "healthy communities. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "748c39a38c7ae66672eda2eca5c5349ee15bb110f34432c0910bf4524532c68f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "589fa43d-5f9e-4652-9e61-c6a4928f80ba", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "original_text": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n"}, "hash": "8edd14be38ec5df64c9f8943926f59190f5fe506062bdd56ed8b24e4324a7095", "class_name": "RelatedNodeInfo"}}, "text": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n", "start_char_idx": 21, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "589fa43d-5f9e-4652-9e61-c6a4928f80ba": {"__data__": {"id_": "589fa43d-5f9e-4652-9e61-c6a4928f80ba", "embedding": null, "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "original_text": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf76669e-72d6-4708-a4b0-a6f73c47ecda", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "original_text": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66b431da77c7355364e9a023edd397901fe0bbcae8bfedfe209c563c8ba70fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26730318-4d85-41ea-8782-ec1ca378c0c7", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "original_text": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n"}, "hash": "56d63cf725371b1b04c3c0385ea2b36a00be28597c2bd9605388229933619fa3", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n", "start_char_idx": 155, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26730318-4d85-41ea-8782-ec1ca378c0c7": {"__data__": {"id_": "26730318-4d85-41ea-8782-ec1ca378c0c7", "embedding": null, "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "original_text": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "589fa43d-5f9e-4652-9e61-c6a4928f80ba", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "original_text": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd9aa999b3162a09cf6e9bd836f8c476c132be6c8d1bb2b21e25d4bd3186021e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bff07f59-55de-4347-a113-dfccbd5f41e8", "node_type": "1", "metadata": {"window": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "original_text": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. "}, "hash": "1a082502b9983509bb5886d5683aae61748cceb079500593698bf87726758c24", "class_name": "RelatedNodeInfo"}}, "text": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "start_char_idx": 390, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bff07f59-55de-4347-a113-dfccbd5f41e8": {"__data__": {"id_": "bff07f59-55de-4347-a113-dfccbd5f41e8", "embedding": null, "metadata": {"window": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "original_text": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26730318-4d85-41ea-8782-ec1ca378c0c7", "node_type": "1", "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "original_text": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25f5caf242ac96b0c362c1eef307637b5f954a9e991a5b01708a281d6fc907a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "918ca7c4-b19c-48c7-9596-5ce888cd737c", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n"}, "hash": "b016ec0b78526298ad18f7fa65cf4ac2b967ff9e9cab431bce60fd986925c1d5", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "start_char_idx": 595, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "918ca7c4-b19c-48c7-9596-5ce888cd737c": {"__data__": {"id_": "918ca7c4-b19c-48c7-9596-5ce888cd737c", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bff07f59-55de-4347-a113-dfccbd5f41e8", "node_type": "1", "metadata": {"window": "For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "original_text": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a21245bc8095f0baf430f72a39cbdced81e3f00cae0fbf07c99e5d31e3c2d5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62d4ae64-ad71-4fe6-908b-09a543135f6d", "node_type": "1", "metadata": {"window": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. "}, "hash": "85bb8a6939234d01d84f949041a4466330a3b31cb5eaf56c58caa7456beb8f43", "class_name": "RelatedNodeInfo"}}, "text": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "start_char_idx": 699, "end_char_idx": 955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62d4ae64-ad71-4fe6-908b-09a543135f6d": {"__data__": {"id_": "62d4ae64-ad71-4fe6-908b-09a543135f6d", "embedding": null, "metadata": {"window": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "918ca7c4-b19c-48c7-9596-5ce888cd737c", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40e43dbf0bee198ab7bf6d9bae51773077eb0593f0ca2957942cbfe5c790374b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4fc4104-7e43-4ca3-a183-756fea2af828", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "original_text": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n"}, "hash": "47150bc90509f8b804223df240af96f303917cc28fb6b376288f90d0bd7acd80", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "start_char_idx": 955, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4fc4104-7e43-4ca3-a183-756fea2af828": {"__data__": {"id_": "d4fc4104-7e43-4ca3-a183-756fea2af828", "embedding": null, "metadata": {"window": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "original_text": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62d4ae64-ad71-4fe6-908b-09a543135f6d", "node_type": "1", "metadata": {"window": "MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0d651345ea9187c30c4ef1868ede80741ad15806a6a9ebe15d828adb12cde80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39469e2e-80e7-4eea-b989-192f19597712", "node_type": "1", "metadata": {"window": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "5c12badb8b01e8ff46716a0157fc0b393f7e227adfc90d99d3f9167ca25efb4a", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "start_char_idx": 1221, "end_char_idx": 1377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39469e2e-80e7-4eea-b989-192f19597712": {"__data__": {"id_": "39469e2e-80e7-4eea-b989-192f19597712", "embedding": null, "metadata": {"window": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4fc4104-7e43-4ca3-a183-756fea2af828", "node_type": "1", "metadata": {"window": "AmerisourceBergen launched additional offerings to specialty physician practices through IPN Solutions.  Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "original_text": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a877cab48df5384e45d8ef59824621d20ba709e939279279bcbd32905bb6e6e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "61adfc58294813cab65fb09135a14e1a47f3268bbb0bd3a116cd559d9105c8a3", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1377, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7": {"__data__": {"id_": "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7", "embedding": null, "metadata": {"window": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39469e2e-80e7-4eea-b989-192f19597712", "node_type": "1", "metadata": {"window": "Now, practices will\nhave access to an expanded suite of solutions, which include enhanced business insights, revenue cycle management services,\nvaluable clinical research opportunities and more offerings that integrate with existing practice technologies.\n AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "original_text": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d0735f7afa951e60d643672a1e8d122efe6b3352118e91483d256fb3088cb93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf77a9b2-4f0b-4615-89b6-f313ea830f0e", "node_type": "1", "metadata": {"window": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. "}, "hash": "8a6756cd04588969f9bbfde1aff3a1484bacca63369de360d345a449b39e0401", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1621, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf77a9b2-4f0b-4615-89b6-f313ea830f0e": {"__data__": {"id_": "cf77a9b2-4f0b-4615-89b6-f313ea830f0e", "embedding": null, "metadata": {"window": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced that it is continuing its strategic relationship with the American Oncology Network, LLC\n(AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in\ncommunity-based settings.  AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1eaa12b3577173c8d29d2fe7a7f5dd1bd357c7c956e48e8c99be199edcdb69f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdbc257f-cb45-4b12-8145-1e66cfde1d7d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n"}, "hash": "15adcd3abc9d832d28f66842a62d8a33dcd7d6286e0fb0d86027162e2838347b", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "start_char_idx": 1753, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdbc257f-cb45-4b12-8145-1e66cfde1d7d": {"__data__": {"id_": "cdbc257f-cb45-4b12-8145-1e66cfde1d7d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf77a9b2-4f0b-4615-89b6-f313ea830f0e", "node_type": "1", "metadata": {"window": "AmerisourceBergen will support AON in its effort to accelerate key strategic priorities to scale its\nintegrated value-based care delivery model nationwide.\n Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "original_text": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6eb66d5e9a6943a5d6196261177b07bac73094d9d4ec18cb06d6de700b625801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "760040c5-5767-4052-b2e9-ee1191ee2aca", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n"}, "hash": "1951d1fdb61d1be6c1b0be176defcdb4f9ff74d0d0d74ea9b49f1565ce35daf9", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "start_char_idx": 2084, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "760040c5-5767-4052-b2e9-ee1191ee2aca": {"__data__": {"id_": "760040c5-5767-4052-b2e9-ee1191ee2aca", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdbc257f-cb45-4b12-8145-1e66cfde1d7d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "original_text": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "366863e529ddfbd04a899a39c7578e1ca5689a80a0ce6a92002b111385df1453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe08964-7afe-4216-b949-35049273e89d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n"}, "hash": "f115b0cda6fef5bd12c21d42c70e4632bbc510311170592782533d23b45987ce", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "start_char_idx": 2338, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efe08964-7afe-4216-b949-35049273e89d": {"__data__": {"id_": "efe08964-7afe-4216-b949-35049273e89d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "760040c5-5767-4052-b2e9-ee1191ee2aca", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b75b242357f472e0bde44951d161ab477ce4e58a74360106a3fb9959ad88b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n"}, "hash": "196338e8a2c095ac0c80b914302be77ddc3b2f2b669e06a8d4ae5309a55b4d6b", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "start_char_idx": 3196, "end_char_idx": 3324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e": {"__data__": {"id_": "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e", "embedding": null, "metadata": {"window": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe08964-7afe-4216-b949-35049273e89d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2020 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has updated its fiscal year 2020 financial guidance to reflect the Company\u2019s continued strong performance and\nopportunistic share repurchases in the second quarter and incorporate potential impacts of COVID-19 in the second half of the fiscal\nyear.  The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8300a4bf8ade6b49dc247b1ef8cddc5c58ffb680368a7d76d316f1cad7298d55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2f2d897-1dab-4e67-a6b5-b0030af20f86", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4"}, "hash": "9c068853b85fa06e708973d92958d0d73e0056a9efb29bd9b08271194c87fb37", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "start_char_idx": 3324, "end_char_idx": 3530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2f2d897-1dab-4e67-a6b5-b0030af20f86": {"__data__": {"id_": "e2f2d897-1dab-4e67-a6b5-b0030af20f86", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50be3750df8517d81fdd2b0f163273273f11b0031133043ef62341a61dc031f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e", "node_type": "1", "metadata": {"window": "The Company now expects:\nRevenue growth in the low- to mid-single digit percent range, down from the mid- to high- single digit percent range; and\nAdjusted Diluted EPS to be in the range of $7.35 to $7.65, down from the previous range of $7.55 to $7.80.\n Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da5f29a74b987f1afcfadfdcfb5c77f3c1c9b23f93bdf6892c6cc89a74a7a5ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c91b7fb-8541-45a9-826f-045152fbd18d", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020. ", "original_text": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. "}, "hash": "cc761519920e761becfa18fcce1f90cdd4e8b9b62a7fb37aaf3a6b805d29d211", "class_name": "RelatedNodeInfo"}}, "text": "New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "start_char_idx": 3530, "end_char_idx": 3686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c91b7fb-8541-45a9-826f-045152fbd18d": {"__data__": {"id_": "8c91b7fb-8541-45a9-826f-045152fbd18d", "embedding": null, "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020. ", "original_text": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2f2d897-1dab-4e67-a6b5-b0030af20f86", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating expenses to increase in the low-single digit percent range, down from the mid-single digit percent range;\nAdjusted operating income growth in the low- to mid-single digit percent range, widened from the mid-single digit percent\nrange;\nPharmaceutical Distribution Services segment operating income growth in the low- to mid-single digit percent range,\nwidened from mid-single digit percent range;\nOther, which is comprised of businesses focused on Global Commercialization Services & Animal Health, operating\nincome decline in the low-single digit percent range, revised from growth in the high-single digit percent range; and\nWeighted average diluted shares are now expected to be between 206 million to 207 million, down from the previous\nexpectation of approximately 208 million for the fiscal year.\n All other previously communicated aspects of the Company's fiscal year 2020 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.42 per common share, payable June 1, 2020, to\nstockholders of record at the close of business on May 18, 2020.\n New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "original_text": "New Shar e Repur chase Authorization\nIn May 2020, AmerisourceBergen's Board of Directors authorized a new share repurchase program allowing the Company to\n4", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3a5f57fbe18d6cae10ab95d997617b0fed150ee5f1cb590d3821cf262dde2eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21d55bce-ca4a-487f-a470-837e41220929", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n"}, "hash": "e638306997e389cc316002486ee566d7eddd9da41698d1c2da169312c0539b45", "class_name": "RelatedNodeInfo"}}, "text": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. ", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21d55bce-ca4a-487f-a470-837e41220929": {"__data__": {"id_": "21d55bce-ca4a-487f-a470-837e41220929", "embedding": null, "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c91b7fb-8541-45a9-826f-045152fbd18d", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020. ", "original_text": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0698db6d6058b3a81e5ae391299355c5b1e2fbdff6a35064a26a5044e67d0ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91a308eb-47bb-4ccc-a47c-3c614666b732", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "caf3ce84de3b8b3ada7ed37396371a28349300e3f442a4b30f926ff6c260fe8e", "class_name": "RelatedNodeInfo"}}, "text": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n", "start_char_idx": 101, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91a308eb-47bb-4ccc-a47c-3c614666b732": {"__data__": {"id_": "91a308eb-47bb-4ccc-a47c-3c614666b732", "embedding": null, "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21d55bce-ca4a-487f-a470-837e41220929", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19508cd5998a23abf305516698667bb8b496f4838b2f3382d91b7581e102eada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8564a7ef-e986-4a30-9590-6a6ad53c95a0", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on May 7, 2020. "}, "hash": "12e38350220add85b80e472b1a8dd936153acabe8361e926e27d18eb0c5538c6", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 226, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8564a7ef-e986-4a30-9590-6a6ad53c95a0": {"__data__": {"id_": "8564a7ef-e986-4a30-9590-6a6ad53c95a0", "embedding": null, "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on May 7, 2020. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91a308eb-47bb-4ccc-a47c-3c614666b732", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b33b0924165c0bd52fe0e16913b604172868aeea15d47edbe71be2602f9da2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d", "node_type": "1", "metadata": {"window": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "5eb90c01cdacccc54ff54b627aee02407dd039486e3955ae3d62ec5f79853c34", "class_name": "RelatedNodeInfo"}}, "text": "ET on May 7, 2020. ", "start_char_idx": 341, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d": {"__data__": {"id_": "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d", "embedding": null, "metadata": {"window": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8564a7ef-e986-4a30-9590-6a6ad53c95a0", "node_type": "1", "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797. ", "original_text": "ET on May 7, 2020. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46274e05b5c0f6b3b8ba5f35070f20a7b798d3ab3f6b7e8de1f92d68f31d86e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce89b46b-9790-4fba-b2de-31fc024afb60", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. "}, "hash": "377aa5e4be47d98efbe885e1a9f5cacfc85c3029cfda790ca5c3439837bc7139", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 360, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce89b46b-9790-4fba-b2de-31fc024afb60": {"__data__": {"id_": "ce89b46b-9790-4fba-b2de-31fc024afb60", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d", "node_type": "1", "metadata": {"window": "As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11673a8d9361eb093fd4b76cb98b5db1e595e96b8d0db104f278f5892489d2fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d", "node_type": "1", "metadata": {"window": "ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. "}, "hash": "ce299a27659fa256b7c51c6ecf6409d4c6749b775037ddae506d013215ae62b2", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "start_char_idx": 477, "end_char_idx": 716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d": {"__data__": {"id_": "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d", "embedding": null, "metadata": {"window": "ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce89b46b-9790-4fba-b2de-31fc024afb60", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09b92e6c018cf18d0005857cedd9669d32cbc1d787284591bde0ee93cd33e711", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c87ca1f-bc05-4210-8293-053819248d1b", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "68de320635f68656e6447dc3d8737614ae35936194bbdc6a4825861a7b5104b7", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial (412) 317-0797. ", "start_char_idx": 716, "end_char_idx": 769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c87ca1f-bc05-4210-8293-053819248d1b": {"__data__": {"id_": "3c87ca1f-bc05-4210-8293-053819248d1b", "embedding": null, "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d", "node_type": "1", "metadata": {"window": "ET on May 7, 2020.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial (412) 317-0797. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3113a4de2d6c06bb007b13c938dd4ae13562a163342f9d8536306de96052d232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a74e4311-e68e-499c-b0ea-fd48b8d9a348", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "6d82bb9a451bf4897bd5d821331e99a989c7d2cbec33e30b22924a7f007a8800", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 769, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a74e4311-e68e-499c-b0ea-fd48b8d9a348": {"__data__": {"id_": "a74e4311-e68e-499c-b0ea-fd48b8d9a348", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c87ca1f-bc05-4210-8293-053819248d1b", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea916b310f06fe6c84f27eafc4cdb1fc3608bb6d32118f8b1e5c9b39a4839d28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c847738b-48e9-4cb8-8ba8-f15da17b3647", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "b309f7f6e425ce1c550fecb1044235c6ddff75f4d76509ac5e75ca6223f4a3e0", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 797, "end_char_idx": 894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c847738b-48e9-4cb8-8ba8-f15da17b3647": {"__data__": {"id_": "c847738b-48e9-4cb8-8ba8-f15da17b3647", "embedding": null, "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a74e4311-e68e-499c-b0ea-fd48b8d9a348", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (866) 270-1533.  From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5658dc84a0f924712b29450cdf7b41878441eb3e22cd379ce5084244081f45a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c04183b4-c5ed-4134-8775-3a6e2948ebc6", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 894, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c04183b4-c5ed-4134-8775-3a6e2948ebc6": {"__data__": {"id_": "c04183b4-c5ed-4134-8775-3a6e2948ebc6", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c847738b-48e9-4cb8-8ba8-f15da17b3647", "node_type": "1", "metadata": {"window": "From outside the United States, dial (412) 317-0797.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "615b16a4c3401d7dc4684078d3a330643428316c18bb432a791624d0e96f5d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f28fe8-572b-401b-8ee4-9f8e03fd6489", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "80b230657dea1b2f679665d2b0aff2710493136c1e1e423ccbded544c67949c2", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1017, "end_char_idx": 1087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8f28fe8-572b-401b-8ee4-9f8e03fd6489": {"__data__": {"id_": "f8f28fe8-572b-401b-8ee4-9f8e03fd6489", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c04183b4-c5ed-4134-8775-3a6e2948ebc6", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cceec3a74c3b521a62add92c54e6dbfaae3a64296f350217feccde2fda6825bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f0d331-90d5-4883-a033-ae6550547776", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "0b885c158d26a5b360f201cea0d8affe463970880a02f11eaf905e31bf97d58c", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 1087, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f0d331-90d5-4883-a033-ae6550547776": {"__data__": {"id_": "50f0d331-90d5-4883-a033-ae6550547776", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8f28fe8-572b-401b-8ee4-9f8e03fd6489", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d49c179af2bcd3c3cdc026a73d89ecb44daca9c095695243f5546c6ebb9c4f6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "395007a1-70cb-4048-b12c-2a1b0785f2e8", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "107f4becc6a94b51395c40f4f51ece0128d27b34ff2d79e817524e60a35a1947", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1257, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "395007a1-70cb-4048-b12c-2a1b0785f2e8": {"__data__": {"id_": "395007a1-70cb-4048-b12c-2a1b0785f2e8", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f0d331-90d5-4883-a033-ae6550547776", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5cb4f1f35641908ffafec0e34d9f53559d79dee48a168efe34493c294ea1d7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "original_text": "From Canada, dial (855) 669-9658. "}, "hash": "3f4650c474b2949092646f1766e0f9a8875a3904c4a0df8f91d6755fb89f9c7a", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 1399, "end_char_idx": 1473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631": {"__data__": {"id_": "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "395007a1-70cb-4048-b12c-2a1b0785f2e8", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75847db6b7a3e7d73090771b7754e212c6c34ad8c6426c78dbe72bde3f22cd46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f3f6dc7-5917-4a84-ac7a-36488dfede68", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. "}, "hash": "55895da943070cc5a6bc4aabad997d012af84f6b53d7088cb26c8d5fc803ec12", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial (855) 669-9658. ", "start_char_idx": 1473, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f3f6dc7-5917-4a84-ac7a-36488dfede68": {"__data__": {"id_": "5f3f6dc7-5917-4a84-ac7a-36488dfede68", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "original_text": "From Canada, dial (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3de76f47969c0afeb07ccacc16678795ae296efed6f2a538501ee8ecb7874c19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af1f3b43-ee9f-4311-87e1-ca38740097e4", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10142230.\n"}, "hash": "70b82a5146a7a88affc1419465adf1ea339518141a77f9afeaa7e2aabe5e76f1", "class_name": "RelatedNodeInfo"}}, "text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "start_char_idx": 1507, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af1f3b43-ee9f-4311-87e1-ca38740097e4": {"__data__": {"id_": "af1f3b43-ee9f-4311-87e1-ca38740097e4", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10142230.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f3f6dc7-5917-4a84-ac7a-36488dfede68", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "From outside the\nUnited States and Canada, dial (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e59ea25c774abbea129a4d37aa822962cb4c209afa80d8f9d2ecd7fdc03c0be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf693619-902b-4883-a7ff-fa29660c2864", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n"}, "hash": "71c115a71bf61fe72d3b06726d797048ed613545c0b995986cbd5623ca5b5adf", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10142230.\n", "start_char_idx": 1571, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf693619-902b-4883-a7ff-fa29660c2864": {"__data__": {"id_": "cf693619-902b-4883-a7ff-fa29660c2864", "embedding": null, "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af1f3b43-ee9f-4311-87e1-ca38740097e4", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "original_text": "The access code for the replay is 10142230.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a41d8c7f899a9dd510cf6c39694128f77808e20249d69c52248a3b32ddd34ce7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d69df88f-eb44-4586-a4e8-d16e0734367a", "node_type": "1", "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "fc2a621ed6bbd03c6205a74baa6adebf8e0bd1b8fd8c3407d1070adf441393b8", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "start_char_idx": 1615, "end_char_idx": 1819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d69df88f-eb44-4586-a4e8-d16e0734367a": {"__data__": {"id_": "d69df88f-eb44-4586-a4e8-d16e0734367a", "embedding": null, "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf693619-902b-4883-a7ff-fa29660c2864", "node_type": "1", "metadata": {"window": "From Canada, dial (855) 669-9658.  From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cfb35e61b575130a22ccbc5c23ecc7b35b23eb1c9d858d9375cdeaad235360e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ca38170-6766-4fe5-8b46-9b25ad33561d", "node_type": "1", "metadata": {"window": "The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n"}, "hash": "bebd25185f9a3f16e5cb993d7463c04946f8fc42f28afb48dc58253d75a29d4b", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 1819, "end_char_idx": 1948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ca38170-6766-4fe5-8b46-9b25ad33561d": {"__data__": {"id_": "3ca38170-6766-4fe5-8b46-9b25ad33561d", "embedding": null, "metadata": {"window": "The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d69df88f-eb44-4586-a4e8-d16e0734367a", "node_type": "1", "metadata": {"window": "From outside the\nUnited States and Canada, dial (412) 317-0088.  The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cd2ab1261a952b63f32d3ff40660663723d079e4af57d2528be2aad0f20eb83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "404c6f44-79ba-4fef-8eae-259b276b595a", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. "}, "hash": "56241c9e503ac33ae30e439d4251c2e60ada6b3b67647676ce5293183a60fed5", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "start_char_idx": 1948, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "404c6f44-79ba-4fef-8eae-259b276b595a": {"__data__": {"id_": "404c6f44-79ba-4fef-8eae-259b276b595a", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ca38170-6766-4fe5-8b46-9b25ad33561d", "node_type": "1", "metadata": {"window": "The access code for the replay is 10142230.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cda641cbdd366572960b1ef9af15fa205e6408fd4787f339785da40325e720a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n"}, "hash": "bd586078b4e7769262cab84e00182d725bef235a19cba68de89e066be1d6037e", "class_name": "RelatedNodeInfo"}}, "text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "start_char_idx": 2101, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547": {"__data__": {"id_": "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "404c6f44-79ba-4fef-8eae-259b276b595a", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be participating in the following investor conference in the coming months:\nGoldman Sachs 41st Annual Global Healthcare Conference, June 9-11.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "original_text": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e335fd0a1e0e8b4f9b1fb8b4d600de0150eaf4498a671dd02d5ccd9fc1a5d513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d4315ce-cf28-4723-8379-58c95e268126", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n"}, "hash": "aebc4c2cfb51b28ba3015cd4a38cf53c4b5aeee8a71e16e30724ee8c562851a1", "class_name": "RelatedNodeInfo"}}, "text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "start_char_idx": 2251, "end_char_idx": 2348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d4315ce-cf28-4723-8379-58c95e268126": {"__data__": {"id_": "2d4315ce-cf28-4723-8379-58c95e268126", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa. ", "original_text": "Global manufacturers depend on us for services that drive commercial success for their products.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "890844274f330dcd6d52da3a4d32e2ca42e62652b479bb31bf17b3ec883304e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26272aae-e375-40db-8083-edb11f6070f9", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. "}, "hash": "0dcc30e6190a7f58768b4bc52bcd6f37b4cd49c3fb5dfc0f32a6fb7ecf07d241", "class_name": "RelatedNodeInfo"}}, "text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "start_char_idx": 2348, "end_char_idx": 2473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26272aae-e375-40db-8083-edb11f6070f9": {"__data__": {"id_": "26272aae-e375-40db-8083-edb11f6070f9", "embedding": null, "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d4315ce-cf28-4723-8379-58c95e268126", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care.\n Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries. ", "original_text": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ef5631de71ec0fb6c7c89d76a2c568919c27151d0dacae406390985c894b801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c4f99d2-866b-4388-b7f3-a00897f446ee", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. "}, "hash": "0d32ad6cc2d7e3d2ae932f4ce7188ac7243adfce983c796bde6af64e93dbab33", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "start_char_idx": 2473, "end_char_idx": 2572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c4f99d2-866b-4388-b7f3-a00897f446ee": {"__data__": {"id_": "7c4f99d2-866b-4388-b7f3-a00897f446ee", "embedding": null, "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26272aae-e375-40db-8083-edb11f6070f9", "node_type": "1", "metadata": {"window": "Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the\npharmaceutical supply chain.  Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c90cbbe852c28edb463fbd9b6287e1920224f6e84154eefc1e196096e332bc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "435432df-6eac-4023-b3db-fcff853ea1f6", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. "}, "hash": "2e47e76656207a66e5acd002c225504b043b0143ef1feb5800accf488ac77c88", "class_name": "RelatedNodeInfo"}}, "text": "The company is\nheadquartered in Valley Forge, Pa. ", "start_char_idx": 2572, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "435432df-6eac-4023-b3db-fcff853ea1f6": {"__data__": {"id_": "435432df-6eac-4023-b3db-fcff853ea1f6", "embedding": null, "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c4f99d2-866b-4388-b7f3-a00897f446ee", "node_type": "1", "metadata": {"window": "Global manufacturers depend on us for services that drive commercial success for their products.\n Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "original_text": "The company is\nheadquartered in Valley Forge, Pa. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cae99df7b1fd8b9016de0785d3b1ff84ea201af19afd65a19723238c805b7f71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d8f67d-178a-4bec-a6de-3257570d391e", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "5631b8bab61118657afb6e07902ca1591f73e0cdb475904445649b1a2286c3cf", "class_name": "RelatedNodeInfo"}}, "text": "and has a presence in 50+ countries. ", "start_char_idx": 2622, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d8f67d-178a-4bec-a6de-3257570d391e": {"__data__": {"id_": "c6d8f67d-178a-4bec-a6de-3257570d391e", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "435432df-6eac-4023-b3db-fcff853ea1f6", "node_type": "1", "metadata": {"window": "Through our daily work\u2014and powered by our 22,000 associates\u2014we are united in our responsibility to create healthier futures.\n AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "original_text": "and has a presence in 50+ countries. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ae5493b478c853c0208aac1487a69040a65c169e186f80bfe9346cffa64d803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92cbaa00-d5af-4895-9486-0bb27f5ca468", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. "}, "hash": "fe71244f6b2c67e469ddd315eaac25f556f330c506ea28300e3eb2f7e15e93ac", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 2659, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92cbaa00-d5af-4895-9486-0bb27f5ca468": {"__data__": {"id_": "92cbaa00-d5af-4895-9486-0bb27f5ca468", "embedding": null, "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6d8f67d-178a-4bec-a6de-3257570d391e", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500, with more than $175 billion in annual revenue.  The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e17053383d9e117be24525bdde446ed0108b2e68d3e7002cec5cfbcaf6cc84b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92f4ed50-5104-46e5-be8f-31ed285e1c02", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. "}, "hash": "4a562fa855271f17929e5bca5536a6812fbe595f1b6b7ae3424a0f7588067dcb", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "start_char_idx": 2706, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92f4ed50-5104-46e5-be8f-31ed285e1c02": {"__data__": {"id_": "92f4ed50-5104-46e5-be8f-31ed285e1c02", "embedding": null, "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92cbaa00-d5af-4895-9486-0bb27f5ca468", "node_type": "1", "metadata": {"window": "The company is\nheadquartered in Valley Forge, Pa.  and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c8936c90c61016a51d50be52d1b0b3e095e52c1049af68593720c09b4bb0b4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4d79965-0f4a-41aa-bf6d-70d401306879", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. "}, "hash": "d4bf863f94c686054a5ecd9db136e9f80066a69e48cfe05bb7093267bb9f0492", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "start_char_idx": 2996, "end_char_idx": 3346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4d79965-0f4a-41aa-bf6d-70d401306879": {"__data__": {"id_": "e4d79965-0f4a-41aa-bf6d-70d401306879", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92f4ed50-5104-46e5-be8f-31ed285e1c02", "node_type": "1", "metadata": {"window": "and has a presence in 50+ countries.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f7efe7ac1861f7ee944661e5c656af6ae9a7bf0bd365290b7c16a6f518f4bc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e64b71cc-9d84-4033-a580-e636b5d9f0a9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. "}, "hash": "549cac63c2f37ccdf081c3cf17ff071900b7c7c71956fab3acd656166d11db01", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "start_char_idx": 3346, "end_char_idx": 3508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e64b71cc-9d84-4033-a580-e636b5d9f0a9": {"__data__": {"id_": "e64b71cc-9d84-4033-a580-e636b5d9f0a9", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4d79965-0f4a-41aa-bf6d-70d401306879", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f04ac1ecfb8342eced77ebe8ae3a3757d61202c3102690b86fda78c2e71fa43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb5a9d3d-ce05-479e-b7f8-62c705b12309", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5"}, "hash": "cae9901775d1e69af01130e3cf9366fafe0ec691c72c7c0c877d1853e8181d8a", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 3508, "end_char_idx": 3707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb5a9d3d-ce05-479e-b7f8-62c705b12309": {"__data__": {"id_": "eb5a9d3d-ce05-479e-b7f8-62c705b12309", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be43bdb15179fa62169556628f2a17a44ce21cfc7a290705c5a5f4c5eb4cc6fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e64b71cc-9d84-4033-a580-e636b5d9f0a9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7851dceaca1be7f0522455190c863d4a2b949236882e4b1838069a991560ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c616a0b-a300-43f2-b895-5229a2fc045a", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. "}, "hash": "f1407f4d997b11c38fa10f4ac534b28d66eff68c9fa6a244f64c3900fa5a1113", "class_name": "RelatedNodeInfo"}}, "text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "start_char_idx": 3707, "end_char_idx": 4354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c616a0b-a300-43f2-b895-5229a2fc045a": {"__data__": {"id_": "1c616a0b-a300-43f2-b895-5229a2fc045a", "embedding": null, "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb5a9d3d-ce05-479e-b7f8-62c705b12309", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\"\n\"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\"\n\"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions are intended to identify such forward-\nlooking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes\nin circumstances and speak only as of the date hereof.  These statements are not guarantees of future performance and are based on\nassumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated.  Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "original_text": "Among\nthe factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following:\nunfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation;\ncompetition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our\nproducts and services; changes in the United States healthcare and regulatory environment, including changes that could impact\nprescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical\n5", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d17691bff3e57d82a2c6837cee9b9f9a8383c50c82d2236667bd0392065ac3df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e32102-c445-4a22-a86e-a5b96c2a6fcb", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. "}, "hash": "c50be5d7d996185fbf1949ebd0edf583f1dac3cc32f6a0d786ca32914f3c8ad5", "class_name": "RelatedNodeInfo"}}, "text": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e32102-c445-4a22-a86e-a5b96c2a6fcb": {"__data__": {"id_": "24e32102-c445-4a22-a86e-a5b96c2a6fcb", "embedding": null, "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c616a0b-a300-43f2-b895-5229a2fc045a", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "510829e763f367ff6ce125e287a6e0e46a0a6a7a385857fbc1660335724fabee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "077e1eb0-c2b7-4bbb-b161-03ad02684407", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. "}, "hash": "5d10af9b2f6432441aec936dc6f7d2ff2c4e85ab8fd7e7bb57e86fbb6f2fce74", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "start_char_idx": 1394, "end_char_idx": 1966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "077e1eb0-c2b7-4bbb-b161-03ad02684407": {"__data__": {"id_": "077e1eb0-c2b7-4bbb-b161-03ad02684407", "embedding": null, "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e32102-c445-4a22-a86e-a5b96c2a6fcb", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "original_text": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f56730a969374f6c16930d7239f50c12646afc965f1b02961c6055fb053831cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fa7c41c-1c1d-4e24-acfe-c56127418b41", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. "}, "hash": "a880e7000c6f8c7b75b1b85df0c2ddbe212d645a47344b289c90437be7812afb", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "start_char_idx": 1966, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa7c41c-1c1d-4e24-acfe-c56127418b41": {"__data__": {"id_": "5fa7c41c-1c1d-4e24-acfe-c56127418b41", "embedding": null, "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "077e1eb0-c2b7-4bbb-b161-03ad02684407", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61393fbb36f6e5876ee37c96ed68bdbd9c27a48e6bec5423fd46862e9cff942e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "780e0580-72a5-4d08-b082-adf9dcbdf4ad", "node_type": "1", "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n"}, "hash": "d999cd4f1edd286180ea4bf5e8a279057081173b69f9004e339c4a36f3d3d092", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "start_char_idx": 3643, "end_char_idx": 4058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "780e0580-72a5-4d08-b082-adf9dcbdf4ad": {"__data__": {"id_": "780e0580-72a5-4d08-b082-adf9dcbdf4ad", "embedding": null, "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa7c41c-1c1d-4e24-acfe-c56127418b41", "node_type": "1", "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aa8211f5183db17f5c57fa9cba2f064c569371d55c1c12f4bbf9ab6a9844ad7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd08ac6-3ef6-43a5-815d-d41bf72be804", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "cfa542ee5fbd70af5a6fa9c5e859fcfb409042db181ce3ef8f0888a3f825b623", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "start_char_idx": 4058, "end_char_idx": 4207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd08ac6-3ef6-43a5-815d-d41bf72be804": {"__data__": {"id_": "fcd08ac6-3ef6-43a5-815d-d41bf72be804", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70ddf015-0316-4e15-87cb-48211c55f4dc", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddc98f1e4f1810e7a8295f1de00dc25392c97c97948d13de217c82d82f2b64e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "780e0580-72a5-4d08-b082-adf9dcbdf4ad", "node_type": "1", "metadata": {"window": "and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8849291952446355f0313033a53ce313dc9b98a09060c17ab6ba879b9abb5b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "897852c7-bd18-4903-af8c-b40892ce7216", "node_type": "1", "metadata": {"window": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7"}, "hash": "7906686d5ad3eb9c09297685c7d75c585eff1bfa8d733d69044fe737141c2270", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 4207, "end_char_idx": 4497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "897852c7-bd18-4903-af8c-b40892ce7216": {"__data__": {"id_": "897852c7-bd18-4903-af8c-b40892ce7216", "embedding": null, "metadata": {"window": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "57c8931b-62cc-430f-9f04-ded5e11d1438", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8652dc61196bfc6b1492b4927ce0f4591ea94c9dd9fa6574621ae5f7573afd61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd08ac6-3ef6-43a5-815d-d41bf72be804", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the\nfederal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Three \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$47,417,639 \u00a0\u00a0\u00a0 \u00a0$43,319,602 \u00a0\u00a0\u00a0 \u00a09.5%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d7d8e4103a7138b870eaaef712c4cd88f70f2ad60f5204b7b7a3b52221c60a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaf428c5-9d04-4510-9db1-1ccd407fe254", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "original_text": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020. "}, "hash": "7f0105fe66f8d3d94bb2c58885700c189c007fde8d2ef6b45acdda5f90db0ed2", "class_name": "RelatedNodeInfo"}}, "text": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "start_char_idx": 0, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaf428c5-9d04-4510-9db1-1ccd407fe254": {"__data__": {"id_": "eaf428c5-9d04-4510-9db1-1ccd407fe254", "embedding": null, "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "original_text": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020. ", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "897852c7-bd18-4903-af8c-b40892ce7216", "node_type": "1", "metadata": {"window": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e9f7e2228640f84d31b373c800024ec89b0201565f43b0eac08b1e678cbda9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ecd681c-2da9-431b-8778-567f364b554a", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n"}, "hash": "1c98d60a71fae0ab6d69c1a1c664553575963916b59f25750f5a08a328afbdcb", "class_name": "RelatedNodeInfo"}}, "text": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020. ", "start_char_idx": 0, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ecd681c-2da9-431b-8778-567f364b554a": {"__data__": {"id_": "4ecd681c-2da9-431b-8778-567f364b554a", "embedding": null, "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaf428c5-9d04-4510-9db1-1ccd407fe254", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "original_text": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020. ", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5674d05236f0e1a0f7d95807a7c8d23b55038dd094ff1160ebe27c67b77c776e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d584f730-37ec-49c1-a2cf-9f50054b51d0", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n"}, "hash": "d658549f53d2a88c64d6f166b04ec45a0d309389f8f50786c868e26b5cc4dbf0", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n", "start_char_idx": 465, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d584f730-37ec-49c1-a2cf-9f50054b51d0": {"__data__": {"id_": "d584f730-37ec-49c1-a2cf-9f50054b51d0", "embedding": null, "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ecd681c-2da9-431b-8778-567f364b554a", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae0c648d56360282a228186ef9dc7d7577a24dc5a9529ac66da32e82d5ed1931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd17174-5221-410e-a6c3-f1cff44d8db3", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. "}, "hash": "d0ef880e5e3490437ffc53eddfc8453aee23a24fa9642e8f358c9b513308cfea", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n", "start_char_idx": 657, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd17174-5221-410e-a6c3-f1cff44d8db3": {"__data__": {"id_": "6bd17174-5221-410e-a6c3-f1cff44d8db3", "embedding": null, "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d584f730-37ec-49c1-a2cf-9f50054b51d0", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c86939cd454faf88cc9456e8bf53f5ec80916b152206a6586c1a67ababc957f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75647e0f-6c7c-4a95-8a94-3f0d45318d70", "node_type": "1", "metadata": {"window": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n"}, "hash": "e23f2b4a3485b49d839bbec94fc7cc64aa0e45e4d61e603decb306306bdf8e05", "class_name": "RelatedNodeInfo"}}, "text": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "start_char_idx": 909, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75647e0f-6c7c-4a95-8a94-3f0d45318d70": {"__data__": {"id_": "75647e0f-6c7c-4a95-8a94-3f0d45318d70", "embedding": null, "metadata": {"window": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd17174-5221-410e-a6c3-f1cff44d8db3", "node_type": "1", "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dac6fa8cd9af59d69faebe8a14cf935fa8fd4bf7283c0ea1fa2345134802c27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cda3905-f139-47c3-aaaf-9e45faa8740f", "node_type": "1", "metadata": {"window": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n"}, "hash": "e5952474b932390ad26d896e4de0a5ca5cb0c7add390589076ed1a07ca9ff926", "class_name": "RelatedNodeInfo"}}, "text": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "start_char_idx": 1279, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cda3905-f139-47c3-aaaf-9e45faa8740f": {"__data__": {"id_": "1cda3905-f139-47c3-aaaf-9e45faa8740f", "embedding": null, "metadata": {"window": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75647e0f-6c7c-4a95-8a94-3f0d45318d70", "node_type": "1", "metadata": {"window": "Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1111f46855568d27e0fb6288f8649be718fd4af238b5084abe1d5c1efa61c234", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c22879-4c2f-4765-97a9-305cd3292f4f", "node_type": "1", "metadata": {"window": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n"}, "hash": "51ea0990abcc0078ccd47a4159b7d2a75d7aaa16673bae69d69364651dd72a91", "class_name": "RelatedNodeInfo"}}, "text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "start_char_idx": 1649, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c22879-4c2f-4765-97a9-305cd3292f4f": {"__data__": {"id_": "d7c22879-4c2f-4765-97a9-305cd3292f4f", "embedding": null, "metadata": {"window": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cda3905-f139-47c3-aaaf-9e45faa8740f", "node_type": "1", "metadata": {"window": "2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e523c887073c4aacfb61b425b5061c88870713e32c01f183f4f8d73c9593b3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75d5bdee-f242-4849-9132-4d652ad4917b", "node_type": "1", "metadata": {"window": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8"}, "hash": "553a49cc8fb16720dd348db427998672ddd70741faf703912450fe08bf541ce1", "class_name": "RelatedNodeInfo"}}, "text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "start_char_idx": 1761, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75d5bdee-f242-4849-9132-4d652ad4917b": {"__data__": {"id_": "75d5bdee-f242-4849-9132-4d652ad4917b", "embedding": null, "metadata": {"window": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b0552dc49f4eb99207db857245baa0c409304cfb8d2f9d755f37b1e42e34f41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c22879-4c2f-4765-97a9-305cd3292f4f", "node_type": "1", "metadata": {"window": "3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020.  Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e04f83c9e7fa1418fd5163122d8a1bddcf2b40180ce4fad6f2170ac8f451376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbfb531-ecf3-42f7-aaad-3dc8199a09d2", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9"}, "hash": "868199ea57335987e3c34c43d3cd929c7750d2d2bd96ae4a7edab42273e2baf5", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "start_char_idx": 1961, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbfb531-ecf3-42f7-aaad-3dc8199a09d2": {"__data__": {"id_": "7fbfb531-ecf3-42f7-aaad-3dc8199a09d2", "embedding": null, "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb8794e3-2a5a-4f55-a8f7-bc4aad4532ed", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86f30f0838b2feb433a8727a09250c59ec0ae4c8892eded8997f9095e7ddcbad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75d5bdee-f242-4849-9132-4d652ad4917b", "node_type": "1", "metadata": {"window": "Includes\n$14.0 million of employee severance, $13.8 million of litigation costs related to legal fees in connection with opioid lawsuits\nand investigations, and $27.5 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the three months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the three months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the three months ended March 31, 2020.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n8", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8585c43ef8b3876fc1421a5c95f521edf2db2a77d12d89b49e03c2be1ee504b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2c1992e-aff5-4ecb-bdce-b434c1a5dd55", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "original_text": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020. "}, "hash": "7c58d8706dfd43c6fb2c965c90455b1f430b94533710a24e83937bc8a46f504b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "start_char_idx": 0, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2c1992e-aff5-4ecb-bdce-b434c1a5dd55": {"__data__": {"id_": "f2c1992e-aff5-4ecb-bdce-b434c1a5dd55", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "original_text": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020. ", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbfb531-ecf3-42f7-aaad-3dc8199a09d2", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59c857a247af623738526d09445ef6df65c659bb7fa6ffc99cb9b1b211ecb29f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0035fddb-63ca-42ce-bbcd-94c6c6c84107", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n"}, "hash": "e1e8b7e7401f8bcc44cdba209128fcfd0a7927101e3e86a33e22b3c1b105b4c0", "class_name": "RelatedNodeInfo"}}, "text": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020. ", "start_char_idx": 0, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0035fddb-63ca-42ce-bbcd-94c6c6c84107": {"__data__": {"id_": "0035fddb-63ca-42ce-bbcd-94c6c6c84107", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2c1992e-aff5-4ecb-bdce-b434c1a5dd55", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "original_text": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020. ", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2dd07aa730672f18e749c163bf1603e8af7b56da002ae0c3ee101ee47c89b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c46279-3c54-4570-828d-4f108272a838", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n"}, "hash": "d91df71c45c75b4614b09ddfec1b724ca452936ccf496b3228b224f55689a9d0", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n", "start_char_idx": 731, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36c46279-3c54-4570-828d-4f108272a838": {"__data__": {"id_": "36c46279-3c54-4570-828d-4f108272a838", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0035fddb-63ca-42ce-bbcd-94c6c6c84107", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d24e365b2c6d19904aca51e7ec8d4b53e1ef1bc50cb785a7c151cc3b136e7753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af6ea5b7-a339-40ca-9848-5a0169c1307e", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. "}, "hash": "92b617aaebc5d29b64efc1e4346d9d761d15f56de87d1eeb0579823c6766f787", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n", "start_char_idx": 1031, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af6ea5b7-a339-40ca-9848-5a0169c1307e": {"__data__": {"id_": "af6ea5b7-a339-40ca-9848-5a0169c1307e", "embedding": null, "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c46279-3c54-4570-828d-4f108272a838", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "original_text": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6359f9d600347d7fe0c73a73dd73da2e0c44048b1abcc7dd331a339876a7c627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d428454-6ec0-41e9-8467-f8f16a8f59c2", "node_type": "1", "metadata": {"window": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n"}, "hash": "abb184ecc536f53a39380e41e8680b8b5b697d56b3796836b59e09fd46e4f7e1", "class_name": "RelatedNodeInfo"}}, "text": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "start_char_idx": 1297, "end_char_idx": 1665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d428454-6ec0-41e9-8467-f8f16a8f59c2": {"__data__": {"id_": "3d428454-6ec0-41e9-8467-f8f16a8f59c2", "embedding": null, "metadata": {"window": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af6ea5b7-a339-40ca-9848-5a0169c1307e", "node_type": "1", "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "original_text": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13a9da0d9d2b6942e24d830e3b57a01a6264ec7c72929c5f3351efdb0e54de07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5285eb77-2226-42e0-88fc-e64072d51a42", "node_type": "1", "metadata": {"window": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n"}, "hash": "d8767770f768762e832a705e504ab511aa7bba14d390b0acb92a4aacd3a20427", "class_name": "RelatedNodeInfo"}}, "text": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "start_char_idx": 1665, "end_char_idx": 2033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5285eb77-2226-42e0-88fc-e64072d51a42": {"__data__": {"id_": "5285eb77-2226-42e0-88fc-e64072d51a42", "embedding": null, "metadata": {"window": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d428454-6ec0-41e9-8467-f8f16a8f59c2", "node_type": "1", "metadata": {"window": "Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d2b6eaa5739ad813b4337a52f4828b12d08762cba896593019faf99bb26def0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac3fcb4e-5606-4a32-8531-e59a36c1a60c", "node_type": "1", "metadata": {"window": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n"}, "hash": "6dd3108a3c85586bf6c50fded5b54c615068cbc92f1daff5b45fe9793613733a", "class_name": "RelatedNodeInfo"}}, "text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "start_char_idx": 2033, "end_char_idx": 2143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac3fcb4e-5606-4a32-8531-e59a36c1a60c": {"__data__": {"id_": "ac3fcb4e-5606-4a32-8531-e59a36c1a60c", "embedding": null, "metadata": {"window": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5285eb77-2226-42e0-88fc-e64072d51a42", "node_type": "1", "metadata": {"window": "2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79464c8e79f25985477ac4e09657c9485a400b7ceffbca32cd0be175fa6bdb9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32e80f0a-83e0-4f0e-9b63-b396b493742a", "node_type": "1", "metadata": {"window": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "10"}, "hash": "e2889cec6ae973c05ba96eb1bb5b9c154d56de4ccfad42a87f45137f3179bafd", "class_name": "RelatedNodeInfo"}}, "text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "start_char_idx": 2143, "end_char_idx": 2341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32e80f0a-83e0-4f0e-9b63-b396b493742a": {"__data__": {"id_": "32e80f0a-83e0-4f0e-9b63-b396b493742a", "embedding": null, "metadata": {"window": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "10", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dc48b99d7140e4e3e5f3779156f56c186d082f8f4413a55e37f49232cd45641", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac3fcb4e-5606-4a32-8531-e59a36c1a60c", "node_type": "1", "metadata": {"window": "3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020.  Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f225d8575f1352c8105c5929e2d7c14b8ff5fcc08077ca0e41b19c89c4c5a0f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0714c505-ec74-4f5e-b8d2-4c78370df48a", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11"}, "hash": "4f3b6f314e9969e4a0115336fa0ab40c172a583e1737604f1fc9b91839955894", "class_name": "RelatedNodeInfo"}}, "text": "10", "start_char_idx": 2341, "end_char_idx": 2343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0714c505-ec74-4f5e-b8d2-4c78370df48a": {"__data__": {"id_": "0714c505-ec74-4f5e-b8d2-4c78370df48a", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c93b6dc3-9a96-4996-9db3-9c2aac96aa23", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bd9a27e1f2f4f18115f514159b7a6445b32892bc649036021e7674ef2015777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32e80f0a-83e0-4f0e-9b63-b396b493742a", "node_type": "1", "metadata": {"window": "Includes\n$18.8 million of employee severance, $28.4 million of litigation costs related to legal fees in connection with opioid lawsuits and\ninvestigations, and $48.9 million of other costs in connection with acquisition-related deal and integration costs, business\ntransformation efforts, and other restructuring initiatives in the six months ended March 31, 2019.\n\u00a0\n 4\u00a0Includes a $13.7 million gain on the sale of an equity investment in the six months ended March 31, 2019.\n\u00a0\n 5\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business in the six months ended March 31, 2020.\n 10", "original_text": "10", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66c231c33cfa54514cd728394af42a30254780bfe17ba52e99365e4e78acbc2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a208cfe-8e3f-4716-a744-8b5e0850c3cf", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "bf3afaf0d1d07a7f7d1c901c85b958957dbcfce41bfe0c87f4ce485d8cdd3299", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "start_char_idx": 0, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a208cfe-8e3f-4716-a744-8b5e0850c3cf": {"__data__": {"id_": "3a208cfe-8e3f-4716-a744-8b5e0850c3cf", "embedding": null, "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e771eff-38f7-4804-b9a4-708eb49f069d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37b0c8a38b81ec0579fc70553a0c09928509d8b75b183442e613df0346bc301", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0714c505-ec74-4f5e-b8d2-4c78370df48a", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5a4b009b0bf8280976d42463480631c34619423d0ebff7b50de58f0a9c124ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4830f8-7410-4ab3-964f-41db9e09d0a9", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n"}, "hash": "37ebf944f3d9425b8f49bc3f0445046d3d5a33b3037ea5587b48e49660b99cbe", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4830f8-7410-4ab3-964f-41db9e09d0a9": {"__data__": {"id_": "ed4830f8-7410-4ab3-964f-41db9e09d0a9", "embedding": null, "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e771eff-38f7-4804-b9a4-708eb49f069d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37b0c8a38b81ec0579fc70553a0c09928509d8b75b183442e613df0346bc301", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a208cfe-8e3f-4716-a744-8b5e0850c3cf", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c2531aa7b02ba74183370de7628f85862379a35114ee4544f051796e55866f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c267ac1-40dc-4563-8b3e-d33c4834aad9", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "c02812df7e5fafdb6bf3a912b418cb451f0c0a4130cdf78523c2ed0bee07ea21", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "start_char_idx": 515, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c267ac1-40dc-4563-8b3e-d33c4834aad9": {"__data__": {"id_": "1c267ac1-40dc-4563-8b3e-d33c4834aad9", "embedding": null, "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e771eff-38f7-4804-b9a4-708eb49f069d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37b0c8a38b81ec0579fc70553a0c09928509d8b75b183442e613df0346bc301", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4830f8-7410-4ab3-964f-41db9e09d0a9", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54bf3d8d07542192f724e1d3c2a4aa22347b2b2d95f367dcddf81830298cce58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e18e2681-a87b-4759-94cc-45bc8a9169da", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c24ad7402caa451858a8756c554ff33792a0592e95e613766c65d098f794395e", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 931, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e18e2681-a87b-4759-94cc-45bc8a9169da": {"__data__": {"id_": "e18e2681-a87b-4759-94cc-45bc8a9169da", "embedding": null, "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e771eff-38f7-4804-b9a4-708eb49f069d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37b0c8a38b81ec0579fc70553a0c09928509d8b75b183442e613df0346bc301", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c267ac1-40dc-4563-8b3e-d33c4834aad9", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65378dd61b1b84e4c15af1a30dcc34b2369ebe71399c4aeb998b76cde113687a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dab5b807-83d7-42e9-bbd3-3807851d39f4", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12"}, "hash": "7419eb4c3c5380794dafbe05499c62fb4606eca78ff494a305d56a8c91d3dec3", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 1003, "end_char_idx": 1180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dab5b807-83d7-42e9-bbd3-3807851d39f4": {"__data__": {"id_": "dab5b807-83d7-42e9-bbd3-3807851d39f4", "embedding": null, "metadata": {"window": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6e771eff-38f7-4804-b9a4-708eb49f069d", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37b0c8a38b81ec0579fc70553a0c09928509d8b75b183442e613df0346bc301", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e18e2681-a87b-4759-94cc-45bc8a9169da", "node_type": "1", "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10513fbd43a91e9b265c85b7dbf8cb6a9a54db35696d967cd304ceec2e6c4812", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "230c6c61-aefe-47d4-9745-c445c52ffd35", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13"}, "hash": "f1df35b82747edb694b6641a66422669820cace7a0ea628d4777e6248dcba36d", "class_name": "RelatedNodeInfo"}}, "text": "12", "start_char_idx": 147, "end_char_idx": 149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "230c6c61-aefe-47d4-9745-c445c52ffd35": {"__data__": {"id_": "230c6c61-aefe-47d4-9745-c445c52ffd35", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87673ae1-375e-445b-a42d-c72fa3c8f97b", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bb88bcd678485d1e4ed3a2f4c40de5029417772609214db52c6bf05f58d6e57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dab5b807-83d7-42e9-bbd3-3807851d39f4", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 12", "original_text": "12", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95bbc37d8101ef929461859686b118a7720c7e3d137f4db11c5646214b496b80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a09d952e-5019-4e41-a1bb-d3f2b78a94b3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "d8e7d286c2b54270bb77da69aa1a44ac6b393efd64f0aa208fd03efe546bb5f8", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "start_char_idx": 0, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a09d952e-5019-4e41-a1bb-d3f2b78a94b3": {"__data__": {"id_": "a09d952e-5019-4e41-a1bb-d3f2b78a94b3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c492767e-4cd8-4f88-9119-1967513f7983", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf40a98f8a80fabb2c1033c12b16825879ae59661ce38a26b87e9b1817fbea5e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "230c6c61-aefe-47d4-9745-c445c52ffd35", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3f8812e1b6278e347f18c3d26d567107c172eb43fe61faba44be316c244ca4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db8d00ed-6700-4010-8eba-ab5154df3bf8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "cadb96135a0aad3e252a2004924c97dda5c8037f688bc7f10bee89c95563646d", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db8d00ed-6700-4010-8eba-ab5154df3bf8": {"__data__": {"id_": "db8d00ed-6700-4010-8eba-ab5154df3bf8", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c492767e-4cd8-4f88-9119-1967513f7983", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf40a98f8a80fabb2c1033c12b16825879ae59661ce38a26b87e9b1817fbea5e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a09d952e-5019-4e41-a1bb-d3f2b78a94b3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdbb418f4efe51c2b804854c73b99e717f302510a758b9a72d1a09122a938641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c604e02d-5247-4aae-b19b-aeaa74430976", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14"}, "hash": "0b09bab0e511949d3c7ca85e652425d37e7b8ca5d6bd62b67f4cc5abecf52b6a", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 640, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c604e02d-5247-4aae-b19b-aeaa74430976": {"__data__": {"id_": "c604e02d-5247-4aae-b19b-aeaa74430976", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c492767e-4cd8-4f88-9119-1967513f7983", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf40a98f8a80fabb2c1033c12b16825879ae59661ce38a26b87e9b1817fbea5e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db8d00ed-6700-4010-8eba-ab5154df3bf8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b7a7f9870886b5d1a745d7bd1738bb06b79ceb600898237b68ad0177ff9e4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae7284e6-1765-438a-9097-a434f757372e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15"}, "hash": "9ba06d4e8a70b7a5762fddca8be593f7ea051d3b87bcbde0253dd86837e5cac2", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "start_char_idx": 817, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae7284e6-1765-438a-9097-a434f757372e": {"__data__": {"id_": "ae7284e6-1765-438a-9097-a434f757372e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ccd4f98-6c7d-411d-b175-39f2575e525c", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ae17e306a75ccef08541ac3dfd775329f8abd64cb7746d572f2d00027bf2946", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c604e02d-5247-4aae-b19b-aeaa74430976", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba11b518c5b16a249483de97754af2dc57c7882df45061214d03d09602f4f7fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "199195a7-e439-4254-b606-3d04783ce826", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n"}, "hash": "fe4e534348be4f3e0aec9275e498dc0750d2188395c95c54adcaf5e96de8c2ec", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "start_char_idx": 0, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "199195a7-e439-4254-b606-3d04783ce826": {"__data__": {"id_": "199195a7-e439-4254-b606-3d04783ce826", "embedding": null, "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fabb3688-92c6-43a0-aff7-369674f3a247", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887cd0740039efa5d932f02ad1550b20dfeb4e33a771c029180579e8f52d2aa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae7284e6-1765-438a-9097-a434f757372e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99083363fd629165ed087e8f0ac0222bd956748d9fb3b20062130496305ed1f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n"}, "hash": "fbac72078e32624f04e93acbfffff393de22eeb984bd86596c301fc93a2f14df", "class_name": "RelatedNodeInfo"}}, "text": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd": {"__data__": {"id_": "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd", "embedding": null, "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fabb3688-92c6-43a0-aff7-369674f3a247", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887cd0740039efa5d932f02ad1550b20dfeb4e33a771c029180579e8f52d2aa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "199195a7-e439-4254-b606-3d04783ce826", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2488075f2cb65f45781b1b0a12f5eaa57e0c08a76c7b673bda001694bc1dba7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88c00538-4f27-4f49-8bd8-1b8a2caf4700", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "3196245b73d00bf4135689afc0f78df3e4da9d02623a489676a8749bbb163853", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "start_char_idx": 255, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88c00538-4f27-4f49-8bd8-1b8a2caf4700": {"__data__": {"id_": "88c00538-4f27-4f49-8bd8-1b8a2caf4700", "embedding": null, "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fabb3688-92c6-43a0-aff7-369674f3a247", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887cd0740039efa5d932f02ad1550b20dfeb4e33a771c029180579e8f52d2aa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2ee4cc77d440dc31cb6d0e0990ee43759ef6bac5e4fa3e24908010277f6caa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb894ba0-692d-41be-b9e9-dc25127f2c17", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "f98005ab0c97a652e03bde8e889fb7f3aca1ef745b6731fe8273151dfef15ac0", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 668, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb894ba0-692d-41be-b9e9-dc25127f2c17": {"__data__": {"id_": "eb894ba0-692d-41be-b9e9-dc25127f2c17", "embedding": null, "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fabb3688-92c6-43a0-aff7-369674f3a247", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887cd0740039efa5d932f02ad1550b20dfeb4e33a771c029180579e8f52d2aa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88c00538-4f27-4f49-8bd8-1b8a2caf4700", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad725fe09e024366f93408fa098d7fc94fd30a580548bc14805ebbdeeb9455e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b504fd4-79a2-4e6c-80c4-152126b3432e", "node_type": "1", "metadata": {"window": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16"}, "hash": "18acdcbec163bcfd9616df498979b4c9894bb6f348dff68a89058f4a1742baf9", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 740, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b504fd4-79a2-4e6c-80c4-152126b3432e": {"__data__": {"id_": "5b504fd4-79a2-4e6c-80c4-152126b3432e", "embedding": null, "metadata": {"window": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fabb3688-92c6-43a0-aff7-369674f3a247", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "887cd0740039efa5d932f02ad1550b20dfeb4e33a771c029180579e8f52d2aa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb894ba0-692d-41be-b9e9-dc25127f2c17", "node_type": "1", "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3343d675b12f96f446b6d20c00217bdcf14ab8ef11b34c95cd350039587d7981", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "113f33f6-cd50-4321-aacb-3cdffe07483e", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "original_text": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17"}, "hash": "1eadab21b5792e76d14dbbbe315b33a58cdd4f5d5a01fe120eb2ff7e6c68f5f8", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "start_char_idx": 917, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "113f33f6-cd50-4321-aacb-3cdffe07483e": {"__data__": {"id_": "113f33f6-cd50-4321-aacb-3cdffe07483e", "embedding": null, "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "original_text": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "page_label": "17", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ba372c5-508f-45d2-87a6-176747186adf", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1673f4b4353a4d36ab5547fdc52343063aff220302cc8c588f84b2a70064cc54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b504fd4-79a2-4e6c-80c4-152126b3432e", "node_type": "1", "metadata": {"window": "prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n16", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "008e48201e5876f3f9b3e1e96dadcd95aed4115d00d403ca86ef2dd3297ded38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0e7e1f-f8b9-47ef-b198-b5074df71827", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n"}, "hash": "e90834f4fd71b3c18cf54b811d34b8b91a731e537d3e79e125f9b61d4c2af973", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "start_char_idx": 0, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0e7e1f-f8b9-47ef-b198-b5074df71827": {"__data__": {"id_": "da0e7e1f-f8b9-47ef-b198-b5074df71827", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3907ddf9a8cc2fc70a4e7e975d817e375aa15f2e8e6fab177fecdbc1db822f74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "113f33f6-cd50-4321-aacb-3cdffe07483e", "node_type": "1", "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "original_text": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "page_label": "17", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3b43a7f2c3230a4dc30e4adaaa009aceb00d9c42dc84472684179377650c3d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07e35197-99f2-43e0-95d0-282cfa9e7db3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "a08ac3d04c0d66a1d4faefee644063d6eb3097cc1f3f36d4a00922cbfaa0b549", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07e35197-99f2-43e0-95d0-282cfa9e7db3": {"__data__": {"id_": "07e35197-99f2-43e0-95d0-282cfa9e7db3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3907ddf9a8cc2fc70a4e7e975d817e375aa15f2e8e6fab177fecdbc1db822f74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0e7e1f-f8b9-47ef-b198-b5074df71827", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b43f2bc2ce247d20287beaca5ca55fdb841b761d667560686e96865cf479bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ebb51d2-90fe-42ef-aaac-948633c93a52", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18"}, "hash": "67fd8c5e9cc542801010ef6b63199d65494bac547106c43635a9aa45b84b1c06", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 551, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ebb51d2-90fe-42ef-aaac-948633c93a52": {"__data__": {"id_": "5ebb51d2-90fe-42ef-aaac-948633c93a52", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3907ddf9a8cc2fc70a4e7e975d817e375aa15f2e8e6fab177fecdbc1db822f74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07e35197-99f2-43e0-95d0-282cfa9e7db3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11dc47d89773a0e10e9fa14406657d7b26b594e8eeb88ea4f24a451f6ac695ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43ec5730-1884-4f72-af03-848bbae84902", "node_type": "1", "metadata": {"window": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "original_text": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19"}, "hash": "6e6c5981d884ae64ef6bbe50cdfcf9d8717ee0da751c9b752ac2f415e55f3163", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "start_char_idx": 728, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43ec5730-1884-4f72-af03-848bbae84902": {"__data__": {"id_": "43ec5730-1884-4f72-af03-848bbae84902", "embedding": null, "metadata": {"window": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "original_text": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5eb4e149-434d-445a-b350-30d38b695ac2", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0cdb22b9f2adb2c6130bd4962360d3ac05289883a12f523a47e3b5c0e4ec001", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ebb51d2-90fe-42ef-aaac-948633c93a52", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c824c0bdb8f356cac149743f597d0a4659b396860bc000abba38f12c15711cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1c29696-5455-43f5-8d9f-17b358865b25", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "50de4cf1e1b81bcf3c963acb046dfe9150ff9501c48566c03f1a2e05a611a2aa", "class_name": "RelatedNodeInfo"}}, "text": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "start_char_idx": 0, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1c29696-5455-43f5-8d9f-17b358865b25": {"__data__": {"id_": "c1c29696-5455-43f5-8d9f-17b358865b25", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c1bdebf7-4513-4868-b7b9-9c94fd4323db", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a164adee4537dd7d9a052e0c332b2a40d188ee1aaaca436b135549a04606b70f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43ec5730-1884-4f72-af03-848bbae84902", "node_type": "1", "metadata": {"window": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "original_text": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cdc1446bb6b42176003d32b148010793012a7d8d769177e5d16ca89e34aa422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96461443-f6b5-4d68-a5aa-01a73e65d399", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20"}, "hash": "b070bf431b830768b6f229d363e622cf22569f5775da91f001d9c84fbcb7a077", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96461443-f6b5-4d68-a5aa-01a73e65d399": {"__data__": {"id_": "96461443-f6b5-4d68-a5aa-01a73e65d399", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c1bdebf7-4513-4868-b7b9-9c94fd4323db", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a164adee4537dd7d9a052e0c332b2a40d188ee1aaaca436b135549a04606b70f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1c29696-5455-43f5-8d9f-17b358865b25", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5637354585bc5dba731530944d5f57e5ecf50df5b3c27da436871e6165ef7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a9267e-7b1a-408a-953a-3c46c91d9cee", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "original_text": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21"}, "hash": "712bb92cb6da6848981fa76de2e01e054a863168d1b4e3ea173b61ad1d303e69", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "start_char_idx": 652, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a9267e-7b1a-408a-953a-3c46c91d9cee": {"__data__": {"id_": "33a9267e-7b1a-408a-953a-3c46c91d9cee", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "original_text": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7431cefc-7d20-4da7-a04d-0eba392a6763", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb10022b1604a55f47b07b33cab845d063f457300bb6109bd54eaad2fa75e80a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96461443-f6b5-4d68-a5aa-01a73e65d399", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69f6321cafa29c8c63cf19eec294bc691e714dfdf3148974c193da0d83f951f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e3e9cd-47f3-4482-9128-76b064de39fe", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "13625f51632232926cdc5aa6b42ca2c478a9f027ee73bcc1b26a22bfb17a34d0", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "start_char_idx": 0, "end_char_idx": 1139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e3e9cd-47f3-4482-9128-76b064de39fe": {"__data__": {"id_": "24e3e9cd-47f3-4482-9128-76b064de39fe", "embedding": null, "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d56fa770-2e81-4234-be90-9a776b41125b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f610c32a156d9a69e0bfa7188828efd149d322328ee1d99366b548e10347aad0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a9267e-7b1a-408a-953a-3c46c91d9cee", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "original_text": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebe9cc5499b7e82a910d34ce641ebf4c01dcd038c04ec7a2e75b0d2b8c3cbff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8154a2fe-71de-4201-9a5a-748ae7a9808e", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22"}, "hash": "6b2dcda67b1d609ac006bfa5e058e129a72d4fd900f6230276c657b16d9d48d8", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8154a2fe-71de-4201-9a5a-748ae7a9808e": {"__data__": {"id_": "8154a2fe-71de-4201-9a5a-748ae7a9808e", "embedding": null, "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d56fa770-2e81-4234-be90-9a776b41125b", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f610c32a156d9a69e0bfa7188828efd149d322328ee1d99366b548e10347aad0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e3e9cd-47f3-4482-9128-76b064de39fe", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8de99685f71ab5985aa88e6c37b3f66c4385939a79be47a953c57a3f699206df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c347b52-e085-4bca-be47-30902a5f7710", "node_type": "1", "metadata": {"window": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23"}, "hash": "5059eba3043600b4ad7b5b7dcaedde6cdab1341f078f4eac10c6a2a15caae477", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "start_char_idx": 722, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c347b52-e085-4bca-be47-30902a5f7710": {"__data__": {"id_": "2c347b52-e085-4bca-be47-30902a5f7710", "embedding": null, "metadata": {"window": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7fb5b92-4df5-4cb9-b691-72340ec31ceb", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df89489c0ee07283a961586aece0e4323f5c0f7dfdda0fc2bf007e28a64f04d1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8154a2fe-71de-4201-9a5a-748ae7a9808e", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19fec85570b8c9ce77ce212225c152782b8c931bf981c739248bc4a3668eccfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "853b1cd2-6817-4179-91f8-a2790d741941", "node_type": "1", "metadata": {"window": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "original_text": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24"}, "hash": "c3014fc75d4a04d893120ca35646c15a44a9475aef32e9798709bfe61fc1b740", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "start_char_idx": 0, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "853b1cd2-6817-4179-91f8-a2790d741941": {"__data__": {"id_": "853b1cd2-6817-4179-91f8-a2790d741941", "embedding": null, "metadata": {"window": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "original_text": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "page_label": "24", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7ad5fac5-6870-41f2-8187-a3d41f4e8137", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cfe69c96b59b5123f5a7012fb1242229b8c03ef154e103dd8130b6c211b8b03", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c347b52-e085-4bca-be47-30902a5f7710", "node_type": "1", "metadata": {"window": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cd05d428cbce667f70b6998fd604d76f8d97713c115e434146c81fd2fb9ffc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2833c69-f4ba-45ae-a82e-b3193f1be0f3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020. "}, "hash": "93a74eb740512ebdf1699ae2f5b10bbc3e567543bf957b8d59a14d0d9594d8bd", "class_name": "RelatedNodeInfo"}}, "text": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "start_char_idx": 0, "end_char_idx": 905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2833c69-f4ba-45ae-a82e-b3193f1be0f3": {"__data__": {"id_": "f2833c69-f4ba-45ae-a82e-b3193f1be0f3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020. ", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b536028f6623e370f85cd45b1077c19693305999d821d526c81a5e18b0ea6a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "853b1cd2-6817-4179-91f8-a2790d741941", "node_type": "1", "metadata": {"window": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "original_text": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "page_label": "24", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a15388e25c2ea51470c393b87ad2398613c0847d8d7ccd9371ee53b327a166bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fb3da70-63ea-4b01-87d9-0f442e911cbc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n"}, "hash": "5125be39e7ddc145377b998bd255f103d3178f505fa83fbcce69e2350b4a766b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020. ", "start_char_idx": 0, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fb3da70-63ea-4b01-87d9-0f442e911cbc": {"__data__": {"id_": "5fb3da70-63ea-4b01-87d9-0f442e911cbc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b536028f6623e370f85cd45b1077c19693305999d821d526c81a5e18b0ea6a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2833c69-f4ba-45ae-a82e-b3193f1be0f3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020. ", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6a87f89e03aa708270ff7473524db0968c5da7037e02f0c0d2d747bfc408bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba550b8e-37d8-4330-9f11-3cde37d94d05", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n"}, "hash": "00a644473d014f1cd4f8d08470d4c12668292e607cac9b216adf660f4971f805", "class_name": "RelatedNodeInfo"}}, "text": "Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n", "start_char_idx": 965, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba550b8e-37d8-4330-9f11-3cde37d94d05": {"__data__": {"id_": "ba550b8e-37d8-4330-9f11-3cde37d94d05", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b536028f6623e370f85cd45b1077c19693305999d821d526c81a5e18b0ea6a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fb3da70-63ea-4b01-87d9-0f442e911cbc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d86b85a8fc49c9b1ebba99ecca8f713feed9be4c69343716cc924c6f36e8d757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "25"}, "hash": "b996e7e1dae40f9ca9b08f5e64319457cc78a94465da01d74aad4c17de69130e", "class_name": "RelatedNodeInfo"}}, "text": "2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "start_char_idx": 1104, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c": {"__data__": {"id_": "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "25", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b536028f6623e370f85cd45b1077c19693305999d821d526c81a5e18b0ea6a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba550b8e-37d8-4330-9f11-3cde37d94d05", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "653f1035907062bbe661b513086d3962d92881669c1a93ca62b6a99f64301e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f685e8f-09ec-4d06-9bc8-032ca1fbf336", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. "}, "hash": "27346b03d4fccf7527267c96212c4831c98b2289e4a4c7497ae15fe7b48df5bb", "class_name": "RelatedNodeInfo"}}, "text": "25", "start_char_idx": 1274, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f685e8f-09ec-4d06-9bc8-032ca1fbf336": {"__data__": {"id_": "9f685e8f-09ec-4d06-9bc8-032ca1fbf336", "embedding": null, "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "25", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce308626e11290aa02aed977f2df555f0c141cce3c998d147f3147838e6543aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce1b0717-2bd9-41a4-b993-d23da906694a", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n"}, "hash": "8ab2b1f6cbde6f0b1af56f7666de1f83f5febafc393729349f7ced9cd155e283", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "start_char_idx": 0, "end_char_idx": 155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce1b0717-2bd9-41a4-b993-d23da906694a": {"__data__": {"id_": "ce1b0717-2bd9-41a4-b993-d23da906694a", "embedding": null, "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f685e8f-09ec-4d06-9bc8-032ca1fbf336", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c77a7d48218e03644db3738f499ce55d9395ea4023eeb68cb8aa84228519b4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab0b696b-4747-4a98-b481-041f265241a5", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "4da8f54666c04dd3f76be8300eb010b3ad8b115359f12d9747237ce04db17198", "class_name": "RelatedNodeInfo"}}, "text": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n", "start_char_idx": 155, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab0b696b-4747-4a98-b481-041f265241a5": {"__data__": {"id_": "ab0b696b-4747-4a98-b481-041f265241a5", "embedding": null, "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce1b0717-2bd9-41a4-b993-d23da906694a", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4986c2f73e02a67bf70074d8ea10f5e3dd73911f1c85bd8407c026302aab7630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cce78eb-9135-41a2-bb37-f640800ad7ff", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "f8471f9df506a1c543324619a88253064c092bdd9ca631ff4e674d61c9753825", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 306, "end_char_idx": 444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cce78eb-9135-41a2-bb37-f640800ad7ff": {"__data__": {"id_": "7cce78eb-9135-41a2-bb37-f640800ad7ff", "embedding": null, "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab0b696b-4747-4a98-b481-041f265241a5", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9b10d30b09cdd275c670d2c60f9ab9c37ad9ea7f8952f059ef34d87d4d25faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a35e6562-7239-405a-bcee-77a239c9858c", "node_type": "1", "metadata": {"window": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "4387d22b4ffe3ca0bd6cfc51b3dc259311fea3777a06d73e289f4d50fb0d4c21", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 444, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a35e6562-7239-405a-bcee-77a239c9858c": {"__data__": {"id_": "a35e6562-7239-405a-bcee-77a239c9858c", "embedding": null, "metadata": {"window": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cce78eb-9135-41a2-bb37-f640800ad7ff", "node_type": "1", "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af5bb30924ece16d126b7eb6c08cd78111613ffb46536acc784b8fc121c0bc37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75f4e486-c1db-44f6-9e9a-fdf0f83c5485", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d7f41ea6e423d600cac2fbc4858ef319d95447153d4c26be00f5ad76552c02d8", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 559, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75f4e486-c1db-44f6-9e9a-fdf0f83c5485": {"__data__": {"id_": "75f4e486-c1db-44f6-9e9a-fdf0f83c5485", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a35e6562-7239-405a-bcee-77a239c9858c", "node_type": "1", "metadata": {"window": "Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a9cdf49ed65e34073da1b52600af19ca519987c912017bb786ca0d7cd44efe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faf0068c-750a-4543-9d45-c747c5e2867c", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "5fbd7a9bc52b9ebcdbb866683a179146ede8607428bf2ec9ce7c15d54e19b2df", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 699, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faf0068c-750a-4543-9d45-c747c5e2867c": {"__data__": {"id_": "faf0068c-750a-4543-9d45-c747c5e2867c", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75f4e486-c1db-44f6-9e9a-fdf0f83c5485", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f16eb0d1c59d88abd7b767f0228a2bf40847373a58bb78af375b1e014e0be357", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25284fea-64a6-4701-889d-e4f68f62e65d", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "966e68cb33ff5a7e802919072ba2d9bd3610a4db87f80c6ac53a21a9bb57831b", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 818, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25284fea-64a6-4701-889d-e4f68f62e65d": {"__data__": {"id_": "25284fea-64a6-4701-889d-e4f68f62e65d", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faf0068c-750a-4543-9d45-c747c5e2867c", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e97e2d4fa5fc0fa82e2efe1946983ff3085a289b0e66737e96770e37d08c594", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da12fb34-8c93-41c8-84ce-3100dde2b14c", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "10b8cb83a9ea4093f80d960fc2230de203d330cbb023d3bc8c17a901168687ec", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1037, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da12fb34-8c93-41c8-84ce-3100dde2b14c": {"__data__": {"id_": "da12fb34-8c93-41c8-84ce-3100dde2b14c", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25284fea-64a6-4701-889d-e4f68f62e65d", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6747f1a0fbb9c4cfd0395d46799d814ca20012ec4fffa79c809ec92a99366e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). "}, "hash": "d48206520e13d6caf9cb6321e2b934378735bf2e209ac0f603a8a99dfd259395", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1219, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c": {"__data__": {"id_": "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da12fb34-8c93-41c8-84ce-3100dde2b14c", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fac8366dfe10a6cf000f9904062de073bada4e0b6284888e88af481225a45ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bbeab8b-eca3-4d44-b502-1481e47ac7fc", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. "}, "hash": "620afde49e54ce483dc587a51c6b123f4daeb71797562b559365ae3080c87bf5", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "start_char_idx": 1500, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bbeab8b-eca3-4d44-b502-1481e47ac7fc": {"__data__": {"id_": "9bbeab8b-eca3-4d44-b502-1481e47ac7fc", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95270bbe20d3319a2fe9ed1ede55c09ea90b6413b1c569775d542136f90b6fb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "061b0423-3d3c-467b-9127-faf21786651d", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n"}, "hash": "1c795e3ecbf8d988525f9c864c1c00487f7263a63ca60cfd7fd2a93915881e7d", "class_name": "RelatedNodeInfo"}}, "text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "start_char_idx": 1956, "end_char_idx": 2122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "061b0423-3d3c-467b-9127-faf21786651d": {"__data__": {"id_": "061b0423-3d3c-467b-9127-faf21786651d", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bbeab8b-eca3-4d44-b502-1481e47ac7fc", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "original_text": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a54a4c5b658e98b71a2591971c940b3f8e8eb9729f728c3cdf61a50ca72f7b96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0baf085-c428-4b19-b366-6c5bdc931a73", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. "}, "hash": "bedfa803b8076e924a7a2e779cd616edd27779107e09f82108d52bae57e0c074", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "start_char_idx": 2122, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0baf085-c428-4b19-b366-6c5bdc931a73": {"__data__": {"id_": "a0baf085-c428-4b19-b366-6c5bdc931a73", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "061b0423-3d3c-467b-9127-faf21786651d", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e0b6a4903d709bbc05fa952e99d01dee660afca2c2ab6ba45f376c61c532f21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db021644-6a1a-4f9b-8896-783bf6bf078b", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. "}, "hash": "0dc4695f9d267e063df8b3363881d1caa11c63be1eb4b11e35745e0b81d76637", "class_name": "RelatedNodeInfo"}}, "text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "start_char_idx": 2205, "end_char_idx": 2390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db021644-6a1a-4f9b-8896-783bf6bf078b": {"__data__": {"id_": "db021644-6a1a-4f9b-8896-783bf6bf078b", "embedding": null, "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0baf085-c428-4b19-b366-6c5bdc931a73", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium remediation costs, certain PharMEDium\nshutdown costs, and the (credit) related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "original_text": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b89ab54a6a42bb3e451bd493cb1d000a8b91ded56978cb500d73306c2a1bef9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c40bd46b-3da8-4b32-bf75-153d032b101f", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "3ed25a7c41624faab46770ce27ce38b6997812a242b4704a240aa333d84caa3e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "start_char_idx": 2390, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c40bd46b-3da8-4b32-bf75-153d032b101f": {"__data__": {"id_": "c40bd46b-3da8-4b32-bf75-153d032b101f", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db021644-6a1a-4f9b-8896-783bf6bf078b", "node_type": "1", "metadata": {"window": "Gain from\nantitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the amounts\nrecognized or timing of these items.  PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34edaa15a17509dc57ddf71559b0c2ba7a1b70ca55fe6071420f99afbc8bd42d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad", "node_type": "1", "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. "}, "hash": "2dae74fc8a36fac852162d17c6b733309958ffa1df5b27a049cea6e5c9974825", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 2475, "end_char_idx": 2632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad": {"__data__": {"id_": "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad", "embedding": null, "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c40bd46b-3da8-4b32-bf75-153d032b101f", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they are unpredictable expenses.\n The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections. ", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4928bc696cab32edafe612fd3045706e3015a3ea5c09b4eb07da9da05e741ba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. "}, "hash": "e21f93b9f4535f2b18220e6a0a7d12f36ac137e6e44c165abb6569fdb8d5e14a", "class_name": "RelatedNodeInfo"}}, "text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "start_char_idx": 2632, "end_char_idx": 2932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb": {"__data__": {"id_": "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad", "node_type": "1", "metadata": {"window": "The (credit) related to the NYS Opioid Act and PharMEDium shutdown costs are excluded because they are unusual and non-\nrecurring and, in the case of the NYS Opioid Act, also non-cash.  Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "original_text": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95e04b887fbc0a3724088247fc1d0031aefd70e69279202c595e02cc057235a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdbffe04-c084-4edb-937c-18a18c77b3fa", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "84a173650f93cc66efb7463ced2cd2f72ceebc02bfda6682e3685874e77b1071", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "start_char_idx": 2932, "end_char_idx": 3056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdbffe04-c084-4edb-937c-18a18c77b3fa": {"__data__": {"id_": "cdbffe04-c084-4edb-937c-18a18c77b3fa", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross\nprofit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c514464c4208d9ccece85e294bb106f6a9bf0ca038201fb9d5ee18f75e694111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32fc84b-951e-471b-bac6-528ce5df4403", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. "}, "hash": "d4b3c7f30e91adc27722ab12a00d9536099bd6d8d9883bec95153d1d0d52da27", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 3056, "end_char_idx": 3098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32fc84b-951e-471b-bac6-528ce5df4403": {"__data__": {"id_": "e32fc84b-951e-471b-bac6-528ce5df4403", "embedding": null, "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdbffe04-c084-4edb-937c-18a18c77b3fa", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34324b74ed233444cf195d29e38c9c6c7d552603493ca4b32190a1c51e22c7b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9530ff9c-d5fd-45f6-a8be-e7186e468528", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. "}, "hash": "11b1137a205fd7c5733f054b56e1c5a067830adf846478b8f8793f59e911c7c1", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "start_char_idx": 3098, "end_char_idx": 3213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9530ff9c-d5fd-45f6-a8be-e7186e468528": {"__data__": {"id_": "9530ff9c-d5fd-45f6-a8be-e7186e468528", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32fc84b-951e-471b-bac6-528ce5df4403", "node_type": "1", "metadata": {"window": "The gain from antitrust litigation settlements\nrelates to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the\nmanufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the\nmarket.  The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "original_text": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "432967402edf39c77752dd9df4cfd58ff591b1e030e8d63a0997df14db9ec127", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6821bdfe-9e21-4d0d-8d6b-857683d731a1", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. "}, "hash": "65236cf518e62e31a36d9bbda10bbcfb65935ebce8c125df9d2247d045333ad5", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "start_char_idx": 3213, "end_char_idx": 3395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6821bdfe-9e21-4d0d-8d6b-857683d731a1": {"__data__": {"id_": "6821bdfe-9e21-4d0d-8d6b-857683d731a1", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9530ff9c-d5fd-45f6-a8be-e7186e468528", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended production activities\nfollowing U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ed02c2942844c246e629787f0675bac6e4da75a348656728bef6d4645dfbfdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e20ef56-df89-40fb-841e-66859deb4f96", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. "}, "hash": "ef2af6e4e22c36dfd88faf2a232c93818035e2d6c012056dc419491ea9731784", "class_name": "RelatedNodeInfo"}}, "text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "start_char_idx": 3395, "end_char_idx": 3651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e20ef56-df89-40fb-841e-66859deb4f96": {"__data__": {"id_": "1e20ef56-df89-40fb-841e-66859deb4f96", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6821bdfe-9e21-4d0d-8d6b-857683d731a1", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "original_text": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d7e11fb72f97cd691e0774508b98de03b03769fa7297754c7ec7daddbdcd1e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd483feb-fc24-4210-a058-c12c6b6a92a6", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n"}, "hash": "a61186f8c6a89a8b450473b7642e9e2fca82636f7d8dbb51daa8c345dd17ed1a", "class_name": "RelatedNodeInfo"}}, "text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "start_char_idx": 3651, "end_char_idx": 3727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd483feb-fc24-4210-a058-c12c6b6a92a6": {"__data__": {"id_": "bd483feb-fc24-4210-a058-c12c6b6a92a6", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e20ef56-df89-40fb-841e-66859deb4f96", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are costs incurred in connection with\nthe permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b15d5d5950a6d5d2c6fe2c5004a59f9df89a45d1659fde793f34d1f305ae5a06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4626de9f-e431-48ee-95b6-e054cd8bb2ac", "node_type": "1", "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. "}, "hash": "059aa6a0c1b0171a1a8c55947f5404c67f8df331073eb2e0ad759febbcb0d16b", "class_name": "RelatedNodeInfo"}}, "text": "District Court for the Southern District of\nNew York.\n", "start_char_idx": 3727, "end_char_idx": 3781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4626de9f-e431-48ee-95b6-e054cd8bb2ac": {"__data__": {"id_": "4626de9f-e431-48ee-95b6-e054cd8bb2ac", "embedding": null, "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd483feb-fc24-4210-a058-c12c6b6a92a6", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.  The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "District Court for the Southern District of\nNew York.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f86ffd43bf5db1fa24c3a858a201605281ad70f91ac1dd5e0e828dec327bc653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb3451aa-4399-47e4-8316-56ab90dd403b", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n"}, "hash": "dcb024158d0965e9227b3cb5a9abdc6c5f532f3e5d4f686dbc13905d196f0e28", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "start_char_idx": 3781, "end_char_idx": 4162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb3451aa-4399-47e4-8316-56ab90dd403b": {"__data__": {"id_": "fb3451aa-4399-47e4-8316-56ab90dd403b", "embedding": null, "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4626de9f-e431-48ee-95b6-e054cd8bb2ac", "node_type": "1", "metadata": {"window": "The NYS\nOpioid Act, which went into effect on July 1, 2018, established an annual $100 million fund and requires manufacturers,\ndistributors, and importers to ratably share the assessment based upon opioids sold or distributed to or within New York\nstate.  In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dba4ae7c1091f88111e482f236145b4bfa680ccd380c351279ec4117ef6956ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a16770da-56f5-4e0c-8201-76f39cefbf9c", "node_type": "1", "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. "}, "hash": "2e653e09e73243014dfe2bf47b9f48ce0198fab74305fb55faf88c447ae337cf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "start_char_idx": 4162, "end_char_idx": 4258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a16770da-56f5-4e0c-8201-76f39cefbf9c": {"__data__": {"id_": "a16770da-56f5-4e0c-8201-76f39cefbf9c", "embedding": null, "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb3451aa-4399-47e4-8316-56ab90dd403b", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by the U.S.  District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb47f941be2f42c6cde6b0a0b804aeb0f3f673f9bfb34b9fabe8d35cd0b94ffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a06b4f-5a15-446c-96c1-b27315bc5225", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. "}, "hash": "ecccc4312fa5b76667a3bec78140bfa399a9eea23703f8f66bec88404494c939", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "start_char_idx": 4258, "end_char_idx": 4419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a06b4f-5a15-446c-96c1-b27315bc5225": {"__data__": {"id_": "f5a06b4f-5a15-446c-96c1-b27315bc5225", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a16770da-56f5-4e0c-8201-76f39cefbf9c", "node_type": "1", "metadata": {"window": "District Court for the Southern District of\nNew York.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f91fac41e59bf0839702f01f52254fd4b9be62da0f8687df3ca1a8a9798d531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b5dbe26-e4fd-4387-8d23-5fa74642c55c", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. "}, "hash": "b0e3bc1f66151bd99ad952694d44cfd7fe5574d8a600edcf16ffd215d6050718", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "start_char_idx": 4419, "end_char_idx": 4532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b5dbe26-e4fd-4387-8d23-5fa74642c55c": {"__data__": {"id_": "3b5dbe26-e4fd-4387-8d23-5fa74642c55c", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a06b4f-5a15-446c-96c1-b27315bc5225", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium remediation costs, certain PharMEDium shutdown costs, impairment of PharMEDium's assets, and a contingent\nconsideration adjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4b268fc415cf207e7a069ca7fa72c4c740560cb172223b508cfe28399d98c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3da6806d-8944-4334-b0ac-9e9adaa243c4", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26"}, "hash": "dacf284a43b6a376ffc1facee20597b4a89f764d6eb927ba7abb9c8d772e66af", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "start_char_idx": 4532, "end_char_idx": 4933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3da6806d-8944-4334-b0ac-9e9adaa243c4": {"__data__": {"id_": "3da6806d-8944-4334-b0ac-9e9adaa243c4", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64920aad9690d09ad05ccbb36b8524c2391e40cec84d933ab9de9efe3f392c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b5dbe26-e4fd-4387-8d23-5fa74642c55c", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c378cb865c0356e28eaef89678041b124166890948e2dc2c694fd8848575b66f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c812afd-1eaa-4012-a97e-8ba86b4e0b7a", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "business acquisition.\n"}, "hash": "6614f78d76ecc659962dda235a43ca8c3823560d472cc0758d2ee625a37ea592", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "start_char_idx": 4933, "end_char_idx": 5207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c812afd-1eaa-4012-a97e-8ba86b4e0b7a": {"__data__": {"id_": "8c812afd-1eaa-4012-a97e-8ba86b4e0b7a", "embedding": null, "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "business acquisition.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3da6806d-8944-4334-b0ac-9e9adaa243c4", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nremediation costs, PharMEDium shutdown costs, a contingent consideration adjustment and the impairment of\nPharMEDium's assets, that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we\nbelieve these exclusions facilitate the analysis of our ongoing operational performance.  The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "original_text": "The contingent consideration\nadjustment reflects an adjustment made by one of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de\nProdutos Farmac\u00eauticos S.A., of its previous estimate of contingent consideration related to the purchase price of a prior\n26", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2c0799bc80025aa3204d1211614be47addd4b6d7dab82af1a46a29913be11d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa75ade-8517-43f0-af09-ccc3f0edc146", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "0e75ead8dade8491f803c868bc5ee1a6afbd0331f6e6eca1ad6c67ddf45b819b", "class_name": "RelatedNodeInfo"}}, "text": "business acquisition.\n", "start_char_idx": 0, "end_char_idx": 22, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa75ade-8517-43f0-af09-ccc3f0edc146": {"__data__": {"id_": "8aa75ade-8517-43f0-af09-ccc3f0edc146", "embedding": null, "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c812afd-1eaa-4012-a97e-8ba86b4e0b7a", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "business acquisition.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cc9fa6e90142fec27037a2e47ef1b5fbd78ae12d64330eb5f21215a63f4ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e241428-1a42-4141-b6be-23a8d363ac8b", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "f36303a170eed46bd3deda2ac68c6f72e9aaf08f64d30abb1ba8082e34e06931", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 22, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e241428-1a42-4141-b6be-23a8d363ac8b": {"__data__": {"id_": "8e241428-1a42-4141-b6be-23a8d363ac8b", "embedding": null, "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa75ade-8517-43f0-af09-ccc3f0edc146", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45bc635ce1c905d85201c469346140180404b947cecd206ef734fc73cc47985c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "a07a5b96636469ad48c7330fb2cfa4936a3f0417e09df176b090169b998e92b6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 271, "end_char_idx": 364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c": {"__data__": {"id_": "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c", "embedding": null, "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e241428-1a42-4141-b6be-23a8d363ac8b", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee34e28a67a805ca2da7517deb23a7ba1af7834081c779938aa1396679fde85a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062a5c65-683d-4d45-ac1c-83ee53fe29ce", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "8e44da107a1c12c151c05baf68ff50dde1ed63c4dd3792bd0541cfcc1b870d87", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 364, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062a5c65-683d-4d45-ac1c-83ee53fe29ce": {"__data__": {"id_": "062a5c65-683d-4d45-ac1c-83ee53fe29ce", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c", "node_type": "1", "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fb00565ab5237903f07f12210e055b76a7dcb606388c22eb4b7af573b172bf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. "}, "hash": "568bccbc8e0f86995221303a315fc99d04afaa5fc1a12d808fe66ddc87e05673", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 611, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4": {"__data__": {"id_": "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062a5c65-683d-4d45-ac1c-83ee53fe29ce", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14d0dd509be3ecedb81f2b10789c5afae3affaf8fbfe7995a8f485cbb775bca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b8ad773-fb60-4b8f-af89-14e0006062d5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "55affe47d97dc5193e88c641e9f89ae4c5aa9bd638732196a158075052dee41c", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "start_char_idx": 816, "end_char_idx": 997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b8ad773-fb60-4b8f-af89-14e0006062d5": {"__data__": {"id_": "9b8ad773-fb60-4b8f-af89-14e0006062d5", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590b57a130dec1a7affb13525a20b824facc87ae7ff8025595fd93b8fc087acc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "caa15845faf2e1edba8e85aaa67dc3a293414b37c1d2edd1e5e5b56af50b95d0", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 997, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481": {"__data__": {"id_": "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b8ad773-fb60-4b8f-af89-14e0006062d5", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3d4fc32d9402ccab23cb605757b496ff19403990c35813b658688f186d753bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6eaa803-a08c-4469-94f2-2a1ba292b7cf", "node_type": "1", "metadata": {"window": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "5b3f668e890008dcf4e785f431fad48be1710bbc55b46868050a5fd5332533af", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 1162, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6eaa803-a08c-4469-94f2-2a1ba292b7cf": {"__data__": {"id_": "d6eaa803-a08c-4469-94f2-2a1ba292b7cf", "embedding": null, "metadata": {"window": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c341f6bd03737d606ca371e8b7068f54f0f8c649db6528e6a290247e21eb1f79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "905b41fb-9598-4900-a7d6-97fbca4b1f50", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "25a979cdfd700e6f060edcfca1a054350daaf0f4aeeb948e071916a6dae36adf", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 1359, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "905b41fb-9598-4900-a7d6-97fbca4b1f50": {"__data__": {"id_": "905b41fb-9598-4900-a7d6-97fbca4b1f50", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6eaa803-a08c-4469-94f2-2a1ba292b7cf", "node_type": "1", "metadata": {"window": "In addition, the gain on sale of an\nequity investment in fiscal 2019 is excluded from adjusted income before income taxes because it was unusual, non-\noperating, and non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a73e2e688eb422776d474ef28ebc43ac4072f1db4033bf6bb8b1a232c2ad539", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66802f4c-093e-4c9b-a80a-3d824cf5bd7d", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. "}, "hash": "8c2a2f4118928b641779c691ad4951ffc62b660a49122ea2ae0b5f3e159b1810", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 1631, "end_char_idx": 1869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66802f4c-093e-4c9b-a80a-3d824cf5bd7d": {"__data__": {"id_": "66802f4c-093e-4c9b-a80a-3d824cf5bd7d", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "905b41fb-9598-4900-a7d6-97fbca4b1f50", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4972e1534bc5ef1fc55512bdae5444dafe0db14074f8f3c5ccb0d2cb75a38e29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d556cfb-ae2a-4f14-892c-374f20253a0a", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. "}, "hash": "db1469d9ba19cde99a33f3ac228225408e1543d2133569fecbe86282880cd342", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "start_char_idx": 1869, "end_char_idx": 2202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d556cfb-ae2a-4f14-892c-374f20253a0a": {"__data__": {"id_": "1d556cfb-ae2a-4f14-892c-374f20253a0a", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66802f4c-093e-4c9b-a80a-3d824cf5bd7d", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e329637509182a851ec58a9a456c1e2525393364e448bee7546c794603041c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a130933-3196-450e-8d4a-f99ba0263526", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. "}, "hash": "cef0605c311d7753f1014b56b4699253574bf846cbd533a4158174b5b7cb5661", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the final U.S. ", "start_char_idx": 2202, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a130933-3196-450e-8d4a-f99ba0263526": {"__data__": {"id_": "3a130933-3196-450e-8d4a-f99ba0263526", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d556cfb-ae2a-4f14-892c-374f20253a0a", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "In addition, the final U.S. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90f39f3ba3021a2708c7981b9719e357300b72af902ba95ee0c5b73f2a64b5a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9081016-2221-4dd5-a2db-9553027a815d", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n"}, "hash": "944641d215b69a85b1d1ee6868ed17ca6943a2cb2285fae3d55a415c2f9c4605", "class_name": "RelatedNodeInfo"}}, "text": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "start_char_idx": 2230, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9081016-2221-4dd5-a2db-9553027a815d": {"__data__": {"id_": "d9081016-2221-4dd5-a2db-9553027a815d", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a130933-3196-450e-8d4a-f99ba0263526", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a1a914640a3c9775d265509c37bc75343b77104f7661c80c3a2a61f84594b57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "982029c8-46b0-4feb-801c-8541d0a3a3b2", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "4c29bbb92f8cc92d31e47a8686518220a70e6fb8195cad8f43dd2ef10f2e4af8", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "start_char_idx": 2482, "end_char_idx": 2726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "982029c8-46b0-4feb-801c-8541d0a3a3b2": {"__data__": {"id_": "982029c8-46b0-4feb-801c-8541d0a3a3b2", "embedding": null, "metadata": {"window": "In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9081016-2221-4dd5-a2db-9553027a815d", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and six months ended March 31, 2020.  In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "160fdeca5b9528db817a48055e1fa25e82326b74470eb14c3bef3a043fb67d8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9405e8b9-a845-40d8-814e-77f705856dc4", "node_type": "1", "metadata": {"window": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "aa8c5b1952530d6f2c894621483290032375dcc7f844d5b385dc40d85783c4a6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 2726, "end_char_idx": 2994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9405e8b9-a845-40d8-814e-77f705856dc4": {"__data__": {"id_": "9405e8b9-a845-40d8-814e-77f705856dc4", "embedding": null, "metadata": {"window": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "982029c8-46b0-4feb-801c-8541d0a3a3b2", "node_type": "1", "metadata": {"window": "In addition, the final U.S.  tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bba9f67f1d668baadc722983390a412844bf6496ce6d07351b5e3662c3fe4a80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd7ab5ff-dad8-4b27-bdab-1bd54613da64", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "2553a1dcd5dc305bbfe481bc98e72f12c82c20256a607e1bb6389b16515311bd", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 2994, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd7ab5ff-dad8-4b27-bdab-1bd54613da64": {"__data__": {"id_": "bd7ab5ff-dad8-4b27-bdab-1bd54613da64", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9405e8b9-a845-40d8-814e-77f705856dc4", "node_type": "1", "metadata": {"window": "tax\nreform measurement period adjustment to the one-time transition tax liability on historical foreign earnings and profits\nthrough December 31, 2017 (\"Tax Reform\") is excluded from adjusted income tax expense for the six months ended March\n31, 2019.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fdadcca0de90eb1c9aec0a15d3a7f3966f04971b1c7ac9cdcbfaa41eabaa391", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "513ddf2e69126a045c36f169db80bd0151b5dd20391277c6fdfe79afdc852289", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 3157, "end_char_idx": 3326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a": {"__data__": {"id_": "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd7ab5ff-dad8-4b27-bdab-1bd54613da64", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "531a6c6bae088ef3636c87a5c7777c47fe4f51323a21e6e4122ebf0cd44d3ede", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41c6791d-17fb-4505-80b2-3245b573301c", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "2023079e54a6c1cc87461b7872928d2e51939f7e2a7e2128f0e887b99dab216c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 3326, "end_char_idx": 3571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41c6791d-17fb-4505-80b2-3245b573301c": {"__data__": {"id_": "41c6791d-17fb-4505-80b2-3245b573301c", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a2439255c1e7e7546e5f87795554fe880457d0d5f30958420844d0fb2c95a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. "}, "hash": "b7ba741ea29b001bac07331864f4e7c57772a37273d99bbb4302c02eba67b775", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 3571, "end_char_idx": 4175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed": {"__data__": {"id_": "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41c6791d-17fb-4505-80b2-3245b573301c", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04223bc8d25ed0ff94b3a4bf01e3be9629d43a3b66e0e42df94188ebcf7d9991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a62d70f1-dd29-4850-b281-b42b0991e54f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "5eb1131f2950949b406c28a32c23cd9d6ffc7e1255016b504384313d6ac5351f", "class_name": "RelatedNodeInfo"}}, "text": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "start_char_idx": 4175, "end_char_idx": 4627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a62d70f1-dd29-4850-b281-b42b0991e54f": {"__data__": {"id_": "a62d70f1-dd29-4850-b281-b42b0991e54f", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "original_text": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31cbcafe22bda8622c5be440c6fb87f02c36b848897fc3ff1d5c7a597ad40d72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "c5188c7ffd364e772c64d1a6d4d2784ee8ed248cd15d4797206709c2e45fab15", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 4627, "end_char_idx": 4982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb": {"__data__": {"id_": "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a62d70f1-dd29-4850-b281-b42b0991e54f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "264ae5c2bc04d6dfc330c60e7aa9fdd9fe9ba7161f06100939fae9e1dd4371ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. "}, "hash": "d6e6a8519feeb09517b7494815e5701710107161cf75b988d22e242e66226f61", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 4982, "end_char_idx": 5433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3": {"__data__": {"id_": "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3", "embedding": null, "metadata": {"window": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium remediation costs; PharMEDium\nshutdown costs; the (credit) related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance,\nlitigation, and other; a contingent consideration adjustment; gain on sale of an equity investment; and impairment of\nPharMEDium's assets; in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa91758b34a7b9d73890cd5de7b4aefca1a339c5242d56498b6071951d80a46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2", "node_type": "1", "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. "}, "hash": "1c4798f26cc505b8bf38738237a9ab476f5f7c90330e3c0d07edde4dab034afb", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "start_char_idx": 5433, "end_char_idx": 5513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2": {"__data__": {"id_": "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2", "embedding": null, "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share for the six months ended\nMarch 31, 2019 and the per share impact of certain discrete tax benefits primarily attributable to the income tax deduction\nrecognized in connection with the permanent shutdown of PharMEDium as well as the CARES Act are also excluded from\nadjusted diluted earnings per share for the three and six months ended March 31, 2020.  Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311f2ca003d900f53d8c52db75cf00b8789aca6cb283aff2eb4f05941e8ff2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fceab10d-f25c-4357-9535-a82a7ae71f30", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27"}, "hash": "29e1c16bbe1bf69c614ee4c7c37cc7f2dbf6ae20727d26f510d191ace76e78d3", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "start_char_idx": 5513, "end_char_idx": 5799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fceab10d-f25c-4357-9535-a82a7ae71f30": {"__data__": {"id_": "fceab10d-f25c-4357-9535-a82a7ae71f30", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e82d079-e988-42b9-9f63-fe3f2080a397", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b63ed438677e4f3d2a46ecb2e05073c0470cedb598c34de8e22026380dce9af8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2", "node_type": "1", "metadata": {"window": "Management believes that this non-\nGAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the\ncontrol of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent\nunusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures. ", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d2369a56fdc92e25361b56231d39e43f12aa4ce0ea1929de845fa285878c57b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e669354b-5a41-46d2-8d57-0cef1b6ffbe8", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million. "}, "hash": "d7f266604c0d094bb0172dbb1ba8c709c18bdab34451f80cb2ba87e9e1095fc5", "class_name": "RelatedNodeInfo"}}, "text": "For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "start_char_idx": 5799, "end_char_idx": 5883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e669354b-5a41-46d2-8d57-0cef1b6ffbe8": {"__data__": {"id_": "e669354b-5a41-46d2-8d57-0cef1b6ffbe8", "embedding": null, "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dff6d12034808460af056e7c4808652d7ad18996b05ba98b43b28e6f274de374", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fceab10d-f25c-4357-9535-a82a7ae71f30", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2020 guidance for diluted earnings per share, operating expense,\noperating income, and effective income tax rate that excludes the same or similar items as those that are excluded from the\nhistorical non-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2020 adjusted\nfree cash flow guidance.  For fiscal year 2020, we have defined the non-GAAP financial measure of adjusted free cash flow as net\ncash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating\nto legal settlements, minus capital expenditures.  For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "original_text": "For the six months ended March 31, 2020 adjusted free cash flow of $909.4 million\n27", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fb54b0d07c6a35d7bfc27e408e6e9716e230d4a0837090538aa27fa897e03d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e208a950-42e9-404e-b14c-d4dab6264a60", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. "}, "hash": "b6d5e5c7024dd8aec5f2b0dd25eb8181dcde3929548d6499ca40007a645e72e6", "class_name": "RelatedNodeInfo"}}, "text": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million. ", "start_char_idx": 0, "end_char_idx": 293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e208a950-42e9-404e-b14c-d4dab6264a60": {"__data__": {"id_": "e208a950-42e9-404e-b14c-d4dab6264a60", "embedding": null, "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dff6d12034808460af056e7c4808652d7ad18996b05ba98b43b28e6f274de374", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e669354b-5a41-46d2-8d57-0cef1b6ffbe8", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e3d98d264d395a6ac7dd816d11828bc1d61223c03b82859943db26313f7ef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dad56c0-1b53-4c92-97c1-ca3584501636", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "9bb543b175edd4ce674141b57b4d8b83c6c7e64c38a52068f74f6f5819ea3e83", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "start_char_idx": 293, "end_char_idx": 529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dad56c0-1b53-4c92-97c1-ca3584501636": {"__data__": {"id_": "6dad56c0-1b53-4c92-97c1-ca3584501636", "embedding": null, "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dff6d12034808460af056e7c4808652d7ad18996b05ba98b43b28e6f274de374", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e208a950-42e9-404e-b14c-d4dab6264a60", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1bf3824898f8db7d71c8cc1550b1bf779b3001cbcc648f233008642ecca3c71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69f2a5c-bd6d-4571-ad78-54dac0b47f43", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n"}, "hash": "e5c6db2013479e826793f3583e9cac5f6114804ca71863afb5f290f108dd61e0", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 529, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69f2a5c-bd6d-4571-ad78-54dac0b47f43": {"__data__": {"id_": "b69f2a5c-bd6d-4571-ad78-54dac0b47f43", "embedding": null, "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dff6d12034808460af056e7c4808652d7ad18996b05ba98b43b28e6f274de374", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dad56c0-1b53-4c92-97c1-ca3584501636", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35a4764f824b8cdd5a5cbfe7ddb4bc2384c389a33066f51dcc309bae1d836ca6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0af943c-0055-4cd3-a0dd-865e1d212823", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28"}, "hash": "39338f17a096672ec15f4cbd3a7db9b54b11784af6e6315231304e31bb763141", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "start_char_idx": 845, "end_char_idx": 940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0af943c-0055-4cd3-a0dd-865e1d212823": {"__data__": {"id_": "c0af943c-0055-4cd3-a0dd-865e1d212823", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dff6d12034808460af056e7c4808652d7ad18996b05ba98b43b28e6f274de374", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69f2a5c-bd6d-4571-ad78-54dac0b47f43", "node_type": "1", "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "original_text": "Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b617669801e6ad548ff89d155a647b1f0882c73f76610d834fb17f2d42eb94cd", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20200507005132/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-209-5691 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n28", "start_char_idx": 940, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"9e1448a7-40c0-439a-b715-fb5e0626a7ed": {"doc_hash": "6f6f6503cc6b6cc972f2ea0283691224d0987d5b5b60af32295d2ce123b061f9", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "4e4caecd-0c8d-434e-b1cc-67d7fa008bca": {"doc_hash": "1a64114eaf9303d2eda40a42d15eda69998842be524bd99891c5c61d7300db82", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "753aa288-fa05-4a7e-84f6-daa6697c6ae2": {"doc_hash": "69b46a49640449a4785adee5b4fc8673885ddca64394018f4322a452e73841cf", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "b3fc6c82-927f-4bd1-841b-c7da2fa2333d": {"doc_hash": "337bf452ed6a67c2ab65a3ce0446b36ab7af444f9f77a8db22257154450ead31", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "fd85bdce-4434-42b7-92c2-94d1d55ce57b": {"doc_hash": "aac8cca3c499b7975555a57d05f9bce758f609e0e657aee5a14012058ed1ec96", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "42c0cd43-72e8-417f-be3b-aec5602f3643": {"doc_hash": "2c5b8e6bd4d7ceda27bed038b27fd8ee9bdef47992690a2700b522dff07e6f60", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "e0332363-ae4c-4167-ace6-f9b47de977e5": {"doc_hash": "b2af841ecc34359b29b495581579ce14ad93e72813ad2db9ea44be4979e6feb5", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "8012f630-7aaf-4bbf-b3b7-d9b154fd085c": {"doc_hash": "d7a70f2e00990050eafa075ba2df47fcf9e807dfb8c724e8879c26fbe276f027", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "bd8f9f0b-7e43-4599-b02a-c223f7065690": {"doc_hash": "63fcf0abf7c64c21e4d9b7b0966cf9922befb3968a0365ebbe849a4222242aae", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "3d6a6350-4de4-46ec-ac4f-61a38b354ed9": {"doc_hash": "2e2a1cfc1f641f871fd77f734ef9870a1becd4ddae2afafd62a36e2c0b6dae07", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd": {"doc_hash": "a8c5458d4aa932cf7b6bedb0a0ac27b560263c1dcb34357494d8f9782a90cfae", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "8ca4bd51-7540-4db7-9ac5-d7b29d24c287": {"doc_hash": "e5f9c121c89e8c7f5f253575c2683e7f0432dc8744579222881d41e1fc541fe8", "ref_doc_id": "2f0b870b-482e-4ab8-917a-46f750ffef65"}, "1178edf3-42ca-48cd-b615-e81837651457": {"doc_hash": "dcab8f998ed91ff6e2fb7dca56f6f52f67c989d5e18d722c7ec832ced7212d5a", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "a920da31-fb34-414c-b9e1-44e4704d7b5c": {"doc_hash": "f575e7a86e43d3af50c0e2bd4a97a2f0ea3dfb7f1fdf97386011d394c96c516e", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "c9af51a1-862c-4d58-a236-54e792d5fa58": {"doc_hash": "9f7e03e7c496892ab2cf67ebc5cb445adaeebbf6c4826ab495f38e189662afc3", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "09771bcc-4962-4a1e-9c49-8b70f26269d1": {"doc_hash": "134aee5f557061b0398a1495254b31059a659be011d21c9de4a7cb5bb23a1ad6", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "1c72f756-f67d-438b-8e91-2451b8a7b2ae": {"doc_hash": "55fca2850d0523b66fcb9ec16fa2c3ed1a3dbf613fe19c2665e57982c39da9c1", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "36703ad5-4147-49ad-a4ad-2004b9014cfe": {"doc_hash": "c5e95ab83aa9f533e700d4bb46bfefdb6b8be839afbbb2b273d4c94d483bfaee", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a": {"doc_hash": "9d8549354a5ba6ecb5fc786365f27a5da002048ef1a68df829f4e887309c86f2", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "71a8571c-e76f-43ef-a14b-b7d7d56db1a2": {"doc_hash": "8e1cbd559d2d800e68664402bb8ee07b44f17bacdf7358138748f35f9f4f30e0", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "78329396-c816-4716-a1a8-caf1fe82ce78": {"doc_hash": "f87f63c2b970801634a00f40af8ab3813f0b9ed87cdcddae59fe114de358d2f5", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "f9c45057-640d-484b-9682-947d80462202": {"doc_hash": "5f5d34bff6d879a28bf87ed63ff522ca03a0260c91ef4fa28cb7a77f008a1785", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "787a3382-e992-4bcf-8773-c8ebf2a33123": {"doc_hash": "67bd8694ee57d6da43d37ee51ac363d6a18bc902cd287eedf29f16fa0e1114f1", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "6e39ecdd-2c12-4d95-987e-9da4e5c9237e": {"doc_hash": "3e731c55878d469a920adc5b88175b128a52792dd56117ab21fda4765c1229a5", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "16a6f58c-9cd7-44da-8cca-ba4af112ec04": {"doc_hash": "2615d0b15d7d28dd23b1ce5312b275cb4f4482eb2d9fc4fae238ee79319b7e53", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "9f0554ce-7b3c-4bee-aa16-a04d31f44412": {"doc_hash": "7f6069014196dfc783214af74d21455660bf3c69fa79b6bb2d9427257c5a29ab", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "2a3fb84d-3c8d-45b5-b655-27e17409e162": {"doc_hash": "84e297ba5918db02a295e780abcad09a9490e4cfe36b93e3bec758bf256a5fba", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "77f912a3-ef78-4315-aaa1-7e0b2f84223f": {"doc_hash": "b17cfeb0d99bd670325c561ac10f2c68cde8924ffa49f4e94072c05569441b57", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "4547c220-68dc-4f99-9ea6-6d87537d2d3d": {"doc_hash": "abfe86377da82527f231a5ad27aab0817fc1546047dd0f48802ea3050eb4b66f", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9": {"doc_hash": "b0ddc064c2dc1f8bc49e3b3dd63f28236b250734f7e979877a84f6366c9d8103", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "32ec9f13-1442-4638-b7ee-429d2efb33c9": {"doc_hash": "6f1a83f4bc3418451c8f5804e018dddf555e8487ff48313e9986407fbd1b9278", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "0b291c37-1dd5-4941-85b5-a2e1d75c0f80": {"doc_hash": "71b8a57d933a2ca642541edc627697233246a07e818908886e8fa5d912ae2f06", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "08297ad3-8f60-40d5-b3ca-c4426de1517a": {"doc_hash": "4deeecd2c5d4dd98dbb1b1389866900b862aae36e53fc33826b61bea8ce82ab3", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "200fc712-b8a8-4317-a029-4c2335a22cc1": {"doc_hash": "c26e16a34d3e8485fe23279b245ec77e437dea5e6d89fb15574d3db87ac7b094", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "961af97c-cb15-40e4-9e11-72ca23f7975f": {"doc_hash": "ee30d475a5f6c7c4ee629707e864d9546768b0143a8d8d68c28191e82678d67d", "ref_doc_id": "f27a7f03-afa3-4dd8-87a7-757bd6116b9d"}, "2de0f251-9ad8-448e-8920-4b16a374bf29": {"doc_hash": "c21f36947e4d13f9768ddca3b07844e87f897e2d49f50dbb58c2b8ed196c2384", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "dea4e833-0c56-4c6e-ba76-91a365333ea1": {"doc_hash": "e0e3a03cee0e892d262be3b608a02e5a573024dd4a9432def0c1d1fc6d336041", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "ce2062ea-a77c-4fad-a192-878793f3bc40": {"doc_hash": "80ae12344407bb2cc006290661ab30593247d6f5078ea985b64f9886ae4a8d0f", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "952fda2f-edc8-43e6-8ca2-ad5554f0c7df": {"doc_hash": "a43bd05ecc6677543a5bc4c02d2cea7136e66e420874f498c8b0885e5e6439ea", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be": {"doc_hash": "f9b261fb829bfb394dd93ea34ee3292150bb2aeb51351c2acc984f14099eb0e1", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "3b4fbe22-c161-4c59-a452-c2cec8136a71": {"doc_hash": "bbbe98b1f1c7e2ad640b078ebb11a22ef656e61fdd44b866d9827ed1523b8feb", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "260645d6-7ba2-481e-a109-4ee5c3093afc": {"doc_hash": "15420b012b55bb63a31b1bd32ede0dca6ac731f6b55359adbfb85c2dcd09f537", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "0037409a-ea96-415d-9771-2f0f0a80e866": {"doc_hash": "b12d18c66ed131e50091388c31ef972d6203a5df11009c65b8cf340fffcd5116", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "1d9ff01e-9059-43ae-ad6c-bbca1cc56176": {"doc_hash": "1639f6a50893ff790cb15d951d81f1552a755a1b4afce77b6b8666dcce5fcfb5", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "4f9de117-d441-4540-bf27-3cc57e308eed": {"doc_hash": "4acf24b8fa3e76bea4de463f3b0d1277be11dea253ff3513440ba85fa116cfdd", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "c6050150-248b-4f43-9dae-c94771ce27f9": {"doc_hash": "de303c1910356903642c3302577dd11bc0b1796c8e945a0d646aceb88f095987", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "1917b774-682c-4b68-9581-74bbf7b1aa86": {"doc_hash": "bbb279de07da1949a4bec87bbac380f1083e5e774a05baaf7faa69d0e4823d73", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "4e8a05ee-9314-4b30-bf4a-b0f66a5172af": {"doc_hash": "6456674460a5d887194524e91b5e7762d43711be79eeca110db8e83bce4a07e9", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "80707ad6-1962-4234-a7b3-77a76044307a": {"doc_hash": "16afe108723a3dfaa95c3d00c3fa86e020fcb7210f91ad6b825510a1a0e09d00", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "8c1754c0-c4c2-4500-a068-9fab2bf9bc67": {"doc_hash": "8a39914bccc17430dffb4b2899242a7112e4565425a5b1997d3753fad1eb78dc", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1": {"doc_hash": "361c3301cc30b09edd8d7adfabd6485d0e156c67a6f33834dd51b91a78bb8e18", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "3fc3b9f9-0c41-4f58-9922-2234d4979296": {"doc_hash": "4ba0efabd00ee514213832f794cbf1d8c198c5d9b66c927615fe874405f10aea", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "138bd8a6-4659-4709-9912-f3b6e9c8305c": {"doc_hash": "8347b1be9e9085ed62a860fca8df0d7162c9cef11426eff96c35d58b2db4ef0d", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "589b0799-606e-44bf-a2a9-5b9d96aedae6": {"doc_hash": "c452d713d6a2a10914084c68ebec5e7acd15727ad995cd16c6cd8fe9cf118b22", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "153fd63a-b934-4558-a612-eb68bda69e24": {"doc_hash": "809d804bd374fa4c7db089a018e7700fba6ab7cb46842ec4543ab56cb152336e", "ref_doc_id": "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077"}, "8e1e265b-452f-4760-b3e9-c09840c3f36c": {"doc_hash": "748c39a38c7ae66672eda2eca5c5349ee15bb110f34432c0910bf4524532c68f", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "cf76669e-72d6-4708-a4b0-a6f73c47ecda": {"doc_hash": "66b431da77c7355364e9a023edd397901fe0bbcae8bfedfe209c563c8ba70fe7", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "589fa43d-5f9e-4652-9e61-c6a4928f80ba": {"doc_hash": "fd9aa999b3162a09cf6e9bd836f8c476c132be6c8d1bb2b21e25d4bd3186021e", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "26730318-4d85-41ea-8782-ec1ca378c0c7": {"doc_hash": "25f5caf242ac96b0c362c1eef307637b5f954a9e991a5b01708a281d6fc907a8", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "bff07f59-55de-4347-a113-dfccbd5f41e8": {"doc_hash": "0a21245bc8095f0baf430f72a39cbdced81e3f00cae0fbf07c99e5d31e3c2d5b", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "918ca7c4-b19c-48c7-9596-5ce888cd737c": {"doc_hash": "40e43dbf0bee198ab7bf6d9bae51773077eb0593f0ca2957942cbfe5c790374b", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "62d4ae64-ad71-4fe6-908b-09a543135f6d": {"doc_hash": "c0d651345ea9187c30c4ef1868ede80741ad15806a6a9ebe15d828adb12cde80", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "d4fc4104-7e43-4ca3-a183-756fea2af828": {"doc_hash": "a877cab48df5384e45d8ef59824621d20ba709e939279279bcbd32905bb6e6e8", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "39469e2e-80e7-4eea-b989-192f19597712": {"doc_hash": "9d0735f7afa951e60d643672a1e8d122efe6b3352118e91483d256fb3088cb93", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7": {"doc_hash": "1eaa12b3577173c8d29d2fe7a7f5dd1bd357c7c956e48e8c99be199edcdb69f7", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "cf77a9b2-4f0b-4615-89b6-f313ea830f0e": {"doc_hash": "6eb66d5e9a6943a5d6196261177b07bac73094d9d4ec18cb06d6de700b625801", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "cdbc257f-cb45-4b12-8145-1e66cfde1d7d": {"doc_hash": "366863e529ddfbd04a899a39c7578e1ca5689a80a0ce6a92002b111385df1453", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "760040c5-5767-4052-b2e9-ee1191ee2aca": {"doc_hash": "1b75b242357f472e0bde44951d161ab477ce4e58a74360106a3fb9959ad88b26", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "efe08964-7afe-4216-b949-35049273e89d": {"doc_hash": "8300a4bf8ade6b49dc247b1ef8cddc5c58ffb680368a7d76d316f1cad7298d55", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e": {"doc_hash": "da5f29a74b987f1afcfadfdcfb5c77f3c1c9b23f93bdf6892c6cc89a74a7a5ea", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "e2f2d897-1dab-4e67-a6b5-b0030af20f86": {"doc_hash": "f3a5f57fbe18d6cae10ab95d997617b0fed150ee5f1cb590d3821cf262dde2eb", "ref_doc_id": "a6d63677-1b07-4b67-87aa-7d6a40f9f39e"}, "8c91b7fb-8541-45a9-826f-045152fbd18d": {"doc_hash": "0698db6d6058b3a81e5ae391299355c5b1e2fbdff6a35064a26a5044e67d0ad3", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "21d55bce-ca4a-487f-a470-837e41220929": {"doc_hash": "19508cd5998a23abf305516698667bb8b496f4838b2f3382d91b7581e102eada", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "91a308eb-47bb-4ccc-a47c-3c614666b732": {"doc_hash": "8b33b0924165c0bd52fe0e16913b604172868aeea15d47edbe71be2602f9da2e", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "8564a7ef-e986-4a30-9590-6a6ad53c95a0": {"doc_hash": "46274e05b5c0f6b3b8ba5f35070f20a7b798d3ab3f6b7e8de1f92d68f31d86e6", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d": {"doc_hash": "11673a8d9361eb093fd4b76cb98b5db1e595e96b8d0db104f278f5892489d2fd", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "ce89b46b-9790-4fba-b2de-31fc024afb60": {"doc_hash": "09b92e6c018cf18d0005857cedd9669d32cbc1d787284591bde0ee93cd33e711", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d": {"doc_hash": "3113a4de2d6c06bb007b13c938dd4ae13562a163342f9d8536306de96052d232", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "3c87ca1f-bc05-4210-8293-053819248d1b": {"doc_hash": "ea916b310f06fe6c84f27eafc4cdb1fc3608bb6d32118f8b1e5c9b39a4839d28", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "a74e4311-e68e-499c-b0ea-fd48b8d9a348": {"doc_hash": "5658dc84a0f924712b29450cdf7b41878441eb3e22cd379ce5084244081f45a0", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "c847738b-48e9-4cb8-8ba8-f15da17b3647": {"doc_hash": "615b16a4c3401d7dc4684078d3a330643428316c18bb432a791624d0e96f5d9c", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "c04183b4-c5ed-4134-8775-3a6e2948ebc6": {"doc_hash": "cceec3a74c3b521a62add92c54e6dbfaae3a64296f350217feccde2fda6825bf", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "f8f28fe8-572b-401b-8ee4-9f8e03fd6489": {"doc_hash": "d49c179af2bcd3c3cdc026a73d89ecb44daca9c095695243f5546c6ebb9c4f6b", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "50f0d331-90d5-4883-a033-ae6550547776": {"doc_hash": "e5cb4f1f35641908ffafec0e34d9f53559d79dee48a168efe34493c294ea1d7d", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "395007a1-70cb-4048-b12c-2a1b0785f2e8": {"doc_hash": "75847db6b7a3e7d73090771b7754e212c6c34ad8c6426c78dbe72bde3f22cd46", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631": {"doc_hash": "3de76f47969c0afeb07ccacc16678795ae296efed6f2a538501ee8ecb7874c19", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "5f3f6dc7-5917-4a84-ac7a-36488dfede68": {"doc_hash": "e59ea25c774abbea129a4d37aa822962cb4c209afa80d8f9d2ecd7fdc03c0be1", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "af1f3b43-ee9f-4311-87e1-ca38740097e4": {"doc_hash": "a41d8c7f899a9dd510cf6c39694128f77808e20249d69c52248a3b32ddd34ce7", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "cf693619-902b-4883-a7ff-fa29660c2864": {"doc_hash": "0cfb35e61b575130a22ccbc5c23ecc7b35b23eb1c9d858d9375cdeaad235360e", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "d69df88f-eb44-4586-a4e8-d16e0734367a": {"doc_hash": "9cd2ab1261a952b63f32d3ff40660663723d079e4af57d2528be2aad0f20eb83", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "3ca38170-6766-4fe5-8b46-9b25ad33561d": {"doc_hash": "1cda641cbdd366572960b1ef9af15fa205e6408fd4787f339785da40325e720a", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "404c6f44-79ba-4fef-8eae-259b276b595a": {"doc_hash": "e335fd0a1e0e8b4f9b1fb8b4d600de0150eaf4498a671dd02d5ccd9fc1a5d513", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547": {"doc_hash": "890844274f330dcd6d52da3a4d32e2ca42e62652b479bb31bf17b3ec883304e5", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "2d4315ce-cf28-4723-8379-58c95e268126": {"doc_hash": "5ef5631de71ec0fb6c7c89d76a2c568919c27151d0dacae406390985c894b801", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "26272aae-e375-40db-8083-edb11f6070f9": {"doc_hash": "6c90cbbe852c28edb463fbd9b6287e1920224f6e84154eefc1e196096e332bc7", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "7c4f99d2-866b-4388-b7f3-a00897f446ee": {"doc_hash": "cae99df7b1fd8b9016de0785d3b1ff84ea201af19afd65a19723238c805b7f71", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "435432df-6eac-4023-b3db-fcff853ea1f6": {"doc_hash": "5ae5493b478c853c0208aac1487a69040a65c169e186f80bfe9346cffa64d803", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "c6d8f67d-178a-4bec-a6de-3257570d391e": {"doc_hash": "e17053383d9e117be24525bdde446ed0108b2e68d3e7002cec5cfbcaf6cc84b0", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "92cbaa00-d5af-4895-9486-0bb27f5ca468": {"doc_hash": "0c8936c90c61016a51d50be52d1b0b3e095e52c1049af68593720c09b4bb0b4f", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "92f4ed50-5104-46e5-be8f-31ed285e1c02": {"doc_hash": "0f7efe7ac1861f7ee944661e5c656af6ae9a7bf0bd365290b7c16a6f518f4bc3", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "e4d79965-0f4a-41aa-bf6d-70d401306879": {"doc_hash": "8f04ac1ecfb8342eced77ebe8ae3a3757d61202c3102690b86fda78c2e71fa43", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "e64b71cc-9d84-4033-a580-e636b5d9f0a9": {"doc_hash": "f7851dceaca1be7f0522455190c863d4a2b949236882e4b1838069a991560ffa", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "eb5a9d3d-ce05-479e-b7f8-62c705b12309": {"doc_hash": "d17691bff3e57d82a2c6837cee9b9f9a8383c50c82d2236667bd0392065ac3df", "ref_doc_id": "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b"}, "1c616a0b-a300-43f2-b895-5229a2fc045a": {"doc_hash": "510829e763f367ff6ce125e287a6e0e46a0a6a7a385857fbc1660335724fabee", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "24e32102-c445-4a22-a86e-a5b96c2a6fcb": {"doc_hash": "f56730a969374f6c16930d7239f50c12646afc965f1b02961c6055fb053831cc", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "077e1eb0-c2b7-4bbb-b161-03ad02684407": {"doc_hash": "61393fbb36f6e5876ee37c96ed68bdbd9c27a48e6bec5423fd46862e9cff942e", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "5fa7c41c-1c1d-4e24-acfe-c56127418b41": {"doc_hash": "5aa8211f5183db17f5c57fa9cba2f064c569371d55c1c12f4bbf9ab6a9844ad7", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "780e0580-72a5-4d08-b082-adf9dcbdf4ad": {"doc_hash": "8849291952446355f0313033a53ce313dc9b98a09060c17ab6ba879b9abb5b26", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "fcd08ac6-3ef6-43a5-815d-d41bf72be804": {"doc_hash": "5d7d8e4103a7138b870eaaef712c4cd88f70f2ad60f5204b7b7a3b52221c60a5", "ref_doc_id": "70ddf015-0316-4e15-87cb-48211c55f4dc"}, "897852c7-bd18-4903-af8c-b40892ce7216": {"doc_hash": "63e9f7e2228640f84d31b373c800024ec89b0201565f43b0eac08b1e678cbda9", "ref_doc_id": "57c8931b-62cc-430f-9f04-ded5e11d1438"}, "eaf428c5-9d04-4510-9db1-1ccd407fe254": {"doc_hash": "5674d05236f0e1a0f7d95807a7c8d23b55038dd094ff1160ebe27c67b77c776e", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "4ecd681c-2da9-431b-8778-567f364b554a": {"doc_hash": "ae0c648d56360282a228186ef9dc7d7577a24dc5a9529ac66da32e82d5ed1931", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "d584f730-37ec-49c1-a2cf-9f50054b51d0": {"doc_hash": "c86939cd454faf88cc9456e8bf53f5ec80916b152206a6586c1a67ababc957f3", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "6bd17174-5221-410e-a6c3-f1cff44d8db3": {"doc_hash": "8dac6fa8cd9af59d69faebe8a14cf935fa8fd4bf7283c0ea1fa2345134802c27", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "75647e0f-6c7c-4a95-8a94-3f0d45318d70": {"doc_hash": "1111f46855568d27e0fb6288f8649be718fd4af238b5084abe1d5c1efa61c234", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "1cda3905-f139-47c3-aaaf-9e45faa8740f": {"doc_hash": "e523c887073c4aacfb61b425b5061c88870713e32c01f183f4f8d73c9593b3a0", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "d7c22879-4c2f-4765-97a9-305cd3292f4f": {"doc_hash": "7e04f83c9e7fa1418fd5163122d8a1bddcf2b40180ce4fad6f2170ac8f451376", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "75d5bdee-f242-4849-9132-4d652ad4917b": {"doc_hash": "8585c43ef8b3876fc1421a5c95f521edf2db2a77d12d89b49e03c2be1ee504b7", "ref_doc_id": "a56fff47-37c4-4d7c-b25c-414b67aba1b3"}, "7fbfb531-ecf3-42f7-aaad-3dc8199a09d2": {"doc_hash": "59c857a247af623738526d09445ef6df65c659bb7fa6ffc99cb9b1b211ecb29f", "ref_doc_id": "cb8794e3-2a5a-4f55-a8f7-bc4aad4532ed"}, "f2c1992e-aff5-4ecb-bdce-b434c1a5dd55": {"doc_hash": "d2dd07aa730672f18e749c163bf1603e8af7b56da002ae0c3ee101ee47c89b7a", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "0035fddb-63ca-42ce-bbcd-94c6c6c84107": {"doc_hash": "d24e365b2c6d19904aca51e7ec8d4b53e1ef1bc50cb785a7c151cc3b136e7753", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "36c46279-3c54-4570-828d-4f108272a838": {"doc_hash": "6359f9d600347d7fe0c73a73dd73da2e0c44048b1abcc7dd331a339876a7c627", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "af6ea5b7-a339-40ca-9848-5a0169c1307e": {"doc_hash": "13a9da0d9d2b6942e24d830e3b57a01a6264ec7c72929c5f3351efdb0e54de07", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "3d428454-6ec0-41e9-8467-f8f16a8f59c2": {"doc_hash": "6d2b6eaa5739ad813b4337a52f4828b12d08762cba896593019faf99bb26def0", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "5285eb77-2226-42e0-88fc-e64072d51a42": {"doc_hash": "79464c8e79f25985477ac4e09657c9485a400b7ceffbca32cd0be175fa6bdb9c", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "ac3fcb4e-5606-4a32-8531-e59a36c1a60c": {"doc_hash": "f225d8575f1352c8105c5929e2d7c14b8ff5fcc08077ca0e41b19c89c4c5a0f3", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "32e80f0a-83e0-4f0e-9b63-b396b493742a": {"doc_hash": "66c231c33cfa54514cd728394af42a30254780bfe17ba52e99365e4e78acbc2d", "ref_doc_id": "5356b78c-90c6-4c1d-af32-df1a1bd66ccd"}, "0714c505-ec74-4f5e-b8d2-4c78370df48a": {"doc_hash": "a5a4b009b0bf8280976d42463480631c34619423d0ebff7b50de58f0a9c124ed", "ref_doc_id": "c93b6dc3-9a96-4996-9db3-9c2aac96aa23"}, "3a208cfe-8e3f-4716-a744-8b5e0850c3cf": {"doc_hash": "4c2531aa7b02ba74183370de7628f85862379a35114ee4544f051796e55866f8", "ref_doc_id": "6e771eff-38f7-4804-b9a4-708eb49f069d"}, "ed4830f8-7410-4ab3-964f-41db9e09d0a9": {"doc_hash": "54bf3d8d07542192f724e1d3c2a4aa22347b2b2d95f367dcddf81830298cce58", "ref_doc_id": "6e771eff-38f7-4804-b9a4-708eb49f069d"}, "1c267ac1-40dc-4563-8b3e-d33c4834aad9": {"doc_hash": "65378dd61b1b84e4c15af1a30dcc34b2369ebe71399c4aeb998b76cde113687a", "ref_doc_id": "6e771eff-38f7-4804-b9a4-708eb49f069d"}, "e18e2681-a87b-4759-94cc-45bc8a9169da": {"doc_hash": "10513fbd43a91e9b265c85b7dbf8cb6a9a54db35696d967cd304ceec2e6c4812", "ref_doc_id": "6e771eff-38f7-4804-b9a4-708eb49f069d"}, "dab5b807-83d7-42e9-bbd3-3807851d39f4": {"doc_hash": "95bbc37d8101ef929461859686b118a7720c7e3d137f4db11c5646214b496b80", "ref_doc_id": "6e771eff-38f7-4804-b9a4-708eb49f069d"}, "230c6c61-aefe-47d4-9745-c445c52ffd35": {"doc_hash": "b3f8812e1b6278e347f18c3d26d567107c172eb43fe61faba44be316c244ca4b", "ref_doc_id": "87673ae1-375e-445b-a42d-c72fa3c8f97b"}, "a09d952e-5019-4e41-a1bb-d3f2b78a94b3": {"doc_hash": "fdbb418f4efe51c2b804854c73b99e717f302510a758b9a72d1a09122a938641", "ref_doc_id": "c492767e-4cd8-4f88-9119-1967513f7983"}, "db8d00ed-6700-4010-8eba-ab5154df3bf8": {"doc_hash": "e7b7a7f9870886b5d1a745d7bd1738bb06b79ceb600898237b68ad0177ff9e4b", "ref_doc_id": "c492767e-4cd8-4f88-9119-1967513f7983"}, "c604e02d-5247-4aae-b19b-aeaa74430976": {"doc_hash": "ba11b518c5b16a249483de97754af2dc57c7882df45061214d03d09602f4f7fa", "ref_doc_id": "c492767e-4cd8-4f88-9119-1967513f7983"}, "ae7284e6-1765-438a-9097-a434f757372e": {"doc_hash": "99083363fd629165ed087e8f0ac0222bd956748d9fb3b20062130496305ed1f8", "ref_doc_id": "0ccd4f98-6c7d-411d-b175-39f2575e525c"}, "199195a7-e439-4254-b606-3d04783ce826": {"doc_hash": "2488075f2cb65f45781b1b0a12f5eaa57e0c08a76c7b673bda001694bc1dba7f", "ref_doc_id": "fabb3688-92c6-43a0-aff7-369674f3a247"}, "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd": {"doc_hash": "ad2ee4cc77d440dc31cb6d0e0990ee43759ef6bac5e4fa3e24908010277f6caa", "ref_doc_id": "fabb3688-92c6-43a0-aff7-369674f3a247"}, "88c00538-4f27-4f49-8bd8-1b8a2caf4700": {"doc_hash": "ad725fe09e024366f93408fa098d7fc94fd30a580548bc14805ebbdeeb9455e2", "ref_doc_id": "fabb3688-92c6-43a0-aff7-369674f3a247"}, "eb894ba0-692d-41be-b9e9-dc25127f2c17": {"doc_hash": "3343d675b12f96f446b6d20c00217bdcf14ab8ef11b34c95cd350039587d7981", "ref_doc_id": "fabb3688-92c6-43a0-aff7-369674f3a247"}, "5b504fd4-79a2-4e6c-80c4-152126b3432e": {"doc_hash": "008e48201e5876f3f9b3e1e96dadcd95aed4115d00d403ca86ef2dd3297ded38", "ref_doc_id": "fabb3688-92c6-43a0-aff7-369674f3a247"}, "113f33f6-cd50-4321-aacb-3cdffe07483e": {"doc_hash": "b3b43a7f2c3230a4dc30e4adaaa009aceb00d9c42dc84472684179377650c3d6", "ref_doc_id": "4ba372c5-508f-45d2-87a6-176747186adf"}, "da0e7e1f-f8b9-47ef-b198-b5074df71827": {"doc_hash": "4b43f2bc2ce247d20287beaca5ca55fdb841b761d667560686e96865cf479bef", "ref_doc_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77"}, "07e35197-99f2-43e0-95d0-282cfa9e7db3": {"doc_hash": "11dc47d89773a0e10e9fa14406657d7b26b594e8eeb88ea4f24a451f6ac695ce", "ref_doc_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77"}, "5ebb51d2-90fe-42ef-aaac-948633c93a52": {"doc_hash": "8c824c0bdb8f356cac149743f597d0a4659b396860bc000abba38f12c15711cf", "ref_doc_id": "545df202-e6e8-4bdc-ab36-29a297e2dc77"}, "43ec5730-1884-4f72-af03-848bbae84902": {"doc_hash": "6cdc1446bb6b42176003d32b148010793012a7d8d769177e5d16ca89e34aa422", "ref_doc_id": "5eb4e149-434d-445a-b350-30d38b695ac2"}, "c1c29696-5455-43f5-8d9f-17b358865b25": {"doc_hash": "8dd5637354585bc5dba731530944d5f57e5ecf50df5b3c27da436871e6165ef7", "ref_doc_id": "c1bdebf7-4513-4868-b7b9-9c94fd4323db"}, "96461443-f6b5-4d68-a5aa-01a73e65d399": {"doc_hash": "69f6321cafa29c8c63cf19eec294bc691e714dfdf3148974c193da0d83f951f5", "ref_doc_id": "c1bdebf7-4513-4868-b7b9-9c94fd4323db"}, "33a9267e-7b1a-408a-953a-3c46c91d9cee": {"doc_hash": "ebe9cc5499b7e82a910d34ce641ebf4c01dcd038c04ec7a2e75b0d2b8c3cbff2", "ref_doc_id": "7431cefc-7d20-4da7-a04d-0eba392a6763"}, "24e3e9cd-47f3-4482-9128-76b064de39fe": {"doc_hash": "8de99685f71ab5985aa88e6c37b3f66c4385939a79be47a953c57a3f699206df", "ref_doc_id": "d56fa770-2e81-4234-be90-9a776b41125b"}, "8154a2fe-71de-4201-9a5a-748ae7a9808e": {"doc_hash": "19fec85570b8c9ce77ce212225c152782b8c931bf981c739248bc4a3668eccfc", "ref_doc_id": "d56fa770-2e81-4234-be90-9a776b41125b"}, "2c347b52-e085-4bca-be47-30902a5f7710": {"doc_hash": "6cd05d428cbce667f70b6998fd604d76f8d97713c115e434146c81fd2fb9ffc9", "ref_doc_id": "c7fb5b92-4df5-4cb9-b691-72340ec31ceb"}, "853b1cd2-6817-4179-91f8-a2790d741941": {"doc_hash": "a15388e25c2ea51470c393b87ad2398613c0847d8d7ccd9371ee53b327a166bc", "ref_doc_id": "7ad5fac5-6870-41f2-8187-a3d41f4e8137"}, "f2833c69-f4ba-45ae-a82e-b3193f1be0f3": {"doc_hash": "e6a87f89e03aa708270ff7473524db0968c5da7037e02f0c0d2d747bfc408bf6", "ref_doc_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3"}, "5fb3da70-63ea-4b01-87d9-0f442e911cbc": {"doc_hash": "d86b85a8fc49c9b1ebba99ecca8f713feed9be4c69343716cc924c6f36e8d757", "ref_doc_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3"}, "ba550b8e-37d8-4330-9f11-3cde37d94d05": {"doc_hash": "653f1035907062bbe661b513086d3962d92881669c1a93ca62b6a99f64301e80", "ref_doc_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3"}, "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c": {"doc_hash": "ce308626e11290aa02aed977f2df555f0c141cce3c998d147f3147838e6543aa", "ref_doc_id": "1c70e909-f342-4ed8-88dc-fce6e0d450c3"}, "9f685e8f-09ec-4d06-9bc8-032ca1fbf336": {"doc_hash": "0c77a7d48218e03644db3738f499ce55d9395ea4023eeb68cb8aa84228519b4f", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "ce1b0717-2bd9-41a4-b993-d23da906694a": {"doc_hash": "4986c2f73e02a67bf70074d8ea10f5e3dd73911f1c85bd8407c026302aab7630", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "ab0b696b-4747-4a98-b481-041f265241a5": {"doc_hash": "b9b10d30b09cdd275c670d2c60f9ab9c37ad9ea7f8952f059ef34d87d4d25faf", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "7cce78eb-9135-41a2-bb37-f640800ad7ff": {"doc_hash": "af5bb30924ece16d126b7eb6c08cd78111613ffb46536acc784b8fc121c0bc37", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "a35e6562-7239-405a-bcee-77a239c9858c": {"doc_hash": "3a9cdf49ed65e34073da1b52600af19ca519987c912017bb786ca0d7cd44efe5", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "75f4e486-c1db-44f6-9e9a-fdf0f83c5485": {"doc_hash": "f16eb0d1c59d88abd7b767f0228a2bf40847373a58bb78af375b1e014e0be357", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "faf0068c-750a-4543-9d45-c747c5e2867c": {"doc_hash": "4e97e2d4fa5fc0fa82e2efe1946983ff3085a289b0e66737e96770e37d08c594", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "25284fea-64a6-4701-889d-e4f68f62e65d": {"doc_hash": "6747f1a0fbb9c4cfd0395d46799d814ca20012ec4fffa79c809ec92a99366e15", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "da12fb34-8c93-41c8-84ce-3100dde2b14c": {"doc_hash": "7fac8366dfe10a6cf000f9904062de073bada4e0b6284888e88af481225a45ff", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c": {"doc_hash": "95270bbe20d3319a2fe9ed1ede55c09ea90b6413b1c569775d542136f90b6fb1", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "9bbeab8b-eca3-4d44-b502-1481e47ac7fc": {"doc_hash": "a54a4c5b658e98b71a2591971c940b3f8e8eb9729f728c3cdf61a50ca72f7b96", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "061b0423-3d3c-467b-9127-faf21786651d": {"doc_hash": "3e0b6a4903d709bbc05fa952e99d01dee660afca2c2ab6ba45f376c61c532f21", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "a0baf085-c428-4b19-b366-6c5bdc931a73": {"doc_hash": "b89ab54a6a42bb3e451bd493cb1d000a8b91ded56978cb500d73306c2a1bef9b", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "db021644-6a1a-4f9b-8896-783bf6bf078b": {"doc_hash": "34edaa15a17509dc57ddf71559b0c2ba7a1b70ca55fe6071420f99afbc8bd42d", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "c40bd46b-3da8-4b32-bf75-153d032b101f": {"doc_hash": "4928bc696cab32edafe612fd3045706e3015a3ea5c09b4eb07da9da05e741ba8", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad": {"doc_hash": "95e04b887fbc0a3724088247fc1d0031aefd70e69279202c595e02cc057235a9", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb": {"doc_hash": "c514464c4208d9ccece85e294bb106f6a9bf0ca038201fb9d5ee18f75e694111", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "cdbffe04-c084-4edb-937c-18a18c77b3fa": {"doc_hash": "34324b74ed233444cf195d29e38c9c6c7d552603493ca4b32190a1c51e22c7b5", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "e32fc84b-951e-471b-bac6-528ce5df4403": {"doc_hash": "432967402edf39c77752dd9df4cfd58ff591b1e030e8d63a0997df14db9ec127", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "9530ff9c-d5fd-45f6-a8be-e7186e468528": {"doc_hash": "3ed02c2942844c246e629787f0675bac6e4da75a348656728bef6d4645dfbfdb", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "6821bdfe-9e21-4d0d-8d6b-857683d731a1": {"doc_hash": "4d7e11fb72f97cd691e0774508b98de03b03769fa7297754c7ec7daddbdcd1e0", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "1e20ef56-df89-40fb-841e-66859deb4f96": {"doc_hash": "b15d5d5950a6d5d2c6fe2c5004a59f9df89a45d1659fde793f34d1f305ae5a06", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "bd483feb-fc24-4210-a058-c12c6b6a92a6": {"doc_hash": "f86ffd43bf5db1fa24c3a858a201605281ad70f91ac1dd5e0e828dec327bc653", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "4626de9f-e431-48ee-95b6-e054cd8bb2ac": {"doc_hash": "dba4ae7c1091f88111e482f236145b4bfa680ccd380c351279ec4117ef6956ef", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "fb3451aa-4399-47e4-8316-56ab90dd403b": {"doc_hash": "eb47f941be2f42c6cde6b0a0b804aeb0f3f673f9bfb34b9fabe8d35cd0b94ffc", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "a16770da-56f5-4e0c-8201-76f39cefbf9c": {"doc_hash": "4f91fac41e59bf0839702f01f52254fd4b9be62da0f8687df3ca1a8a9798d531", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "f5a06b4f-5a15-446c-96c1-b27315bc5225": {"doc_hash": "e4b268fc415cf207e7a069ca7fa72c4c740560cb172223b508cfe28399d98c51", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "3b5dbe26-e4fd-4387-8d23-5fa74642c55c": {"doc_hash": "c378cb865c0356e28eaef89678041b124166890948e2dc2c694fd8848575b66f", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "3da6806d-8944-4334-b0ac-9e9adaa243c4": {"doc_hash": "e2c0799bc80025aa3204d1211614be47addd4b6d7dab82af1a46a29913be11d1", "ref_doc_id": "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d"}, "8c812afd-1eaa-4012-a97e-8ba86b4e0b7a": {"doc_hash": "13cc9fa6e90142fec27037a2e47ef1b5fbd78ae12d64330eb5f21215a63f4ae4", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "8aa75ade-8517-43f0-af09-ccc3f0edc146": {"doc_hash": "45bc635ce1c905d85201c469346140180404b947cecd206ef734fc73cc47985c", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "8e241428-1a42-4141-b6be-23a8d363ac8b": {"doc_hash": "ee34e28a67a805ca2da7517deb23a7ba1af7834081c779938aa1396679fde85a", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c": {"doc_hash": "8fb00565ab5237903f07f12210e055b76a7dcb606388c22eb4b7af573b172bf0", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "062a5c65-683d-4d45-ac1c-83ee53fe29ce": {"doc_hash": "14d0dd509be3ecedb81f2b10789c5afae3affaf8fbfe7995a8f485cbb775bca8", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4": {"doc_hash": "590b57a130dec1a7affb13525a20b824facc87ae7ff8025595fd93b8fc087acc", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "9b8ad773-fb60-4b8f-af89-14e0006062d5": {"doc_hash": "b3d4fc32d9402ccab23cb605757b496ff19403990c35813b658688f186d753bd", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481": {"doc_hash": "c341f6bd03737d606ca371e8b7068f54f0f8c649db6528e6a290247e21eb1f79", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "d6eaa803-a08c-4469-94f2-2a1ba292b7cf": {"doc_hash": "2a73e2e688eb422776d474ef28ebc43ac4072f1db4033bf6bb8b1a232c2ad539", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "905b41fb-9598-4900-a7d6-97fbca4b1f50": {"doc_hash": "4972e1534bc5ef1fc55512bdae5444dafe0db14074f8f3c5ccb0d2cb75a38e29", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "66802f4c-093e-4c9b-a80a-3d824cf5bd7d": {"doc_hash": "e329637509182a851ec58a9a456c1e2525393364e448bee7546c794603041c22", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "1d556cfb-ae2a-4f14-892c-374f20253a0a": {"doc_hash": "90f39f3ba3021a2708c7981b9719e357300b72af902ba95ee0c5b73f2a64b5a6", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "3a130933-3196-450e-8d4a-f99ba0263526": {"doc_hash": "9a1a914640a3c9775d265509c37bc75343b77104f7661c80c3a2a61f84594b57", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "d9081016-2221-4dd5-a2db-9553027a815d": {"doc_hash": "160fdeca5b9528db817a48055e1fa25e82326b74470eb14c3bef3a043fb67d8e", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "982029c8-46b0-4feb-801c-8541d0a3a3b2": {"doc_hash": "bba9f67f1d668baadc722983390a412844bf6496ce6d07351b5e3662c3fe4a80", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "9405e8b9-a845-40d8-814e-77f705856dc4": {"doc_hash": "5fdadcca0de90eb1c9aec0a15d3a7f3966f04971b1c7ac9cdcbfaa41eabaa391", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "bd7ab5ff-dad8-4b27-bdab-1bd54613da64": {"doc_hash": "531a6c6bae088ef3636c87a5c7777c47fe4f51323a21e6e4122ebf0cd44d3ede", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a": {"doc_hash": "2a2439255c1e7e7546e5f87795554fe880457d0d5f30958420844d0fb2c95a92", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "41c6791d-17fb-4505-80b2-3245b573301c": {"doc_hash": "04223bc8d25ed0ff94b3a4bf01e3be9629d43a3b66e0e42df94188ebcf7d9991", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed": {"doc_hash": "31cbcafe22bda8622c5be440c6fb87f02c36b848897fc3ff1d5c7a597ad40d72", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "a62d70f1-dd29-4850-b281-b42b0991e54f": {"doc_hash": "264ae5c2bc04d6dfc330c60e7aa9fdd9fe9ba7161f06100939fae9e1dd4371ff", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb": {"doc_hash": "aa91758b34a7b9d73890cd5de7b4aefca1a339c5242d56498b6071951d80a46a", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3": {"doc_hash": "311f2ca003d900f53d8c52db75cf00b8789aca6cb283aff2eb4f05941e8ff2d6", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2": {"doc_hash": "9d2369a56fdc92e25361b56231d39e43f12aa4ce0ea1929de845fa285878c57b", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "fceab10d-f25c-4357-9535-a82a7ae71f30": {"doc_hash": "7fb54b0d07c6a35d7bfc27e408e6e9716e230d4a0837090538aa27fa897e03d2", "ref_doc_id": "8e82d079-e988-42b9-9f63-fe3f2080a397"}, "e669354b-5a41-46d2-8d57-0cef1b6ffbe8": {"doc_hash": "63e3d98d264d395a6ac7dd816d11828bc1d61223c03b82859943db26313f7ef1", "ref_doc_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee"}, "e208a950-42e9-404e-b14c-d4dab6264a60": {"doc_hash": "b1bf3824898f8db7d71c8cc1550b1bf779b3001cbcc648f233008642ecca3c71", "ref_doc_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee"}, "6dad56c0-1b53-4c92-97c1-ca3584501636": {"doc_hash": "35a4764f824b8cdd5a5cbfe7ddb4bc2384c389a33066f51dcc309bae1d836ca6", "ref_doc_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee"}, "b69f2a5c-bd6d-4571-ad78-54dac0b47f43": {"doc_hash": "b617669801e6ad548ff89d155a647b1f0882c73f76610d834fb17f2d42eb94cd", "ref_doc_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee"}, "c0af943c-0055-4cd3-a0dd-865e1d212823": {"doc_hash": "8130a564c0856cc2d5233da243ba2f51a8de03ae4e8a7e3f49c68418a92af61f", "ref_doc_id": "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee"}}, "docstore/ref_doc_info": {"2f0b870b-482e-4ab8-917a-46f750ffef65": {"node_ids": ["9e1448a7-40c0-439a-b715-fb5e0626a7ed", "4e4caecd-0c8d-434e-b1cc-67d7fa008bca", "753aa288-fa05-4a7e-84f6-daa6697c6ae2", "b3fc6c82-927f-4bd1-841b-c7da2fa2333d", "fd85bdce-4434-42b7-92c2-94d1d55ce57b", "42c0cd43-72e8-417f-be3b-aec5602f3643", "e0332363-ae4c-4167-ace6-f9b47de977e5", "8012f630-7aaf-4bbf-b3b7-d9b154fd085c", "bd8f9f0b-7e43-4599-b02a-c223f7065690", "3d6a6350-4de4-46ec-ac4f-61a38b354ed9", "78f22839-01ae-4c5a-a00f-bd02bb3e3dbd", "8ca4bd51-7540-4db7-9ac5-d7b29d24c287"], "metadata": {"window": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion.  On the basis of U.S.  generally accepted\naccounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in\nthe prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7\npercent to $2.40 in the fiscal second quarter.\n", "original_text": "Amerisourcebergen Corporation Logo\nAmerisour ceBer gen R epor ts Fiscal 2020 Second Quar ter Results\n5/7/2020\nRevenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year \n Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Diluted EPS of $2.40 \n Adjusted Diluted EPS Guidance Range Revised to $7.35 to $7.65 for Fiscal 2020\nVALLEY FORGE, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020\nsecond quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f27a7f03-afa3-4dd8-87a7-757bd6116b9d": {"node_ids": ["1178edf3-42ca-48cd-b615-e81837651457", "a920da31-fb34-414c-b9e1-44e4704d7b5c", "c9af51a1-862c-4d58-a236-54e792d5fa58", "09771bcc-4962-4a1e-9c49-8b70f26269d1", "1c72f756-f67d-438b-8e91-2451b8a7b2ae", "36703ad5-4147-49ad-a4ad-2004b9014cfe", "67c0e5c4-2c13-4e7d-83c3-0f6957a72d3a", "71a8571c-e76f-43ef-a14b-b7d7d56db1a2", "78329396-c816-4716-a1a8-caf1fe82ce78", "f9c45057-640d-484b-9682-947d80462202", "787a3382-e992-4bcf-8773-c8ebf2a33123", "6e39ecdd-2c12-4d95-987e-9da4e5c9237e", "16a6f58c-9cd7-44da-8cca-ba4af112ec04", "9f0554ce-7b3c-4bee-aa16-a04d31f44412", "2a3fb84d-3c8d-45b5-b655-27e17409e162", "77f912a3-ef78-4315-aaa1-7e0b2f84223f", "4547c220-68dc-4f99-9ea6-6d87537d2d3d", "1b1592a2-dfb0-4d1c-84fe-e0386e6f0ec9", "32ec9f13-1442-4638-b7ee-429d2efb33c9", "0b291c37-1dd5-4941-85b5-a2e1d75c0f80", "08297ad3-8f60-40d5-b3ca-c4426de1517a", "200fc712-b8a8-4317-a029-4c2335a22cc1", "961af97c-cb15-40e4-9e11-72ca23f7975f"], "metadata": {"window": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental Information\nRegarding non-GAAP Financial Measures following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2020, revenue was $47.4 billion, up 9.5 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 9.3 percent increase in Pharmaceutical Distribution Services revenue and a 12.7 percent\nincrease in revenue within Other.\n", "original_text": "Net Income A ttributable t o ABC $960M $497M\nDilut ed Earnings P er Shar e $4.64 $2.40\nDilut ed Shar es Outstanding 207M 207M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "19cf4676-f1ed-4a0b-9008-ecbd5a4b1077": {"node_ids": ["2de0f251-9ad8-448e-8920-4b16a374bf29", "dea4e833-0c56-4c6e-ba76-91a365333ea1", "ce2062ea-a77c-4fad-a192-878793f3bc40", "952fda2f-edc8-43e6-8ca2-ad5554f0c7df", "e30a6a47-f3ce-4bad-ba96-8dfc59bcf8be", "3b4fbe22-c161-4c59-a452-c2cec8136a71", "260645d6-7ba2-481e-a109-4ee5c3093afc", "0037409a-ea96-415d-9771-2f0f0a80e866", "1d9ff01e-9059-43ae-ad6c-bbca1cc56176", "4f9de117-d441-4540-bf27-3cc57e308eed", "c6050150-248b-4f43-9dae-c94771ce27f9", "1917b774-682c-4b68-9581-74bbf7b1aa86", "4e8a05ee-9314-4b30-bf4a-b0f66a5172af", "80707ad6-1962-4234-a7b3-77a76044307a", "8c1754c0-c4c2-4500-a068-9fab2bf9bc67", "f8c1ee82-8a43-4c0c-a164-f6c993dbdec1", "3fc3b9f9-0c41-4f58-9922-2234d4979296", "138bd8a6-4659-4709-9912-f3b6e9c8305c", "589b0799-606e-44bf-a2a9-5b9d96aedae6", "153fd63a-b934-4558-a612-eb68bda69e24"], "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other.  Adjusted gross profit as a percentage of revenue was 2.99 percent in the fiscal 2020 second quarter, a decrease of\n5 basis points from the prior year quarter.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2020, adjusted operating expenses were $745.2 million, an\nincrease of 6.2 percent compared to the same period in the previous fiscal year primarily due to an increase in costs to\nsupport revenue growth primarily in Other, offset in part by lower depreciation due to the completion of the integration of H.\nD. Smith.  Adjusted operating expenses as a percentage of revenue in the fiscal 2020 second quarter was 1.57 percent,\ncompared to 1.62 percent for the same period in the previous fiscal year.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2020 second quarter was $1.4 billion, which was up 7.5 percent\ncompared to the same period in the previous year, due to the increases in gross profit in Pharmaceutical Distribution Services\nand Other. ", "page_label": "3", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a6d63677-1b07-4b67-87aa-7d6a40f9f39e": {"node_ids": ["8e1e265b-452f-4760-b3e9-c09840c3f36c", "cf76669e-72d6-4708-a4b0-a6f73c47ecda", "589fa43d-5f9e-4652-9e61-c6a4928f80ba", "26730318-4d85-41ea-8782-ec1ca378c0c7", "bff07f59-55de-4347-a113-dfccbd5f41e8", "918ca7c4-b19c-48c7-9596-5ce888cd737c", "62d4ae64-ad71-4fe6-908b-09a543135f6d", "d4fc4104-7e43-4ca3-a183-756fea2af828", "39469e2e-80e7-4eea-b989-192f19597712", "25ff1e3d-3e48-4122-bf02-8b9c7feba3e7", "cf77a9b2-4f0b-4615-89b6-f313ea830f0e", "cdbc257f-cb45-4b12-8145-1e66cfde1d7d", "760040c5-5767-4052-b2e9-ee1191ee2aca", "efe08964-7afe-4216-b949-35049273e89d", "bfef28c7-d14b-48a2-b3a3-95fa9bd5b69e", "e2f2d897-1dab-4e67-a6b5-b0030af20f86"], "metadata": {"window": "healthy communities.  For the second year in a row, selected information within the 2019 Report was assured by ERM\nCertification and Verification Services.\n The AmerisourceBergen Foundation has made grant donations that will be deployed to regional, national and global\norganizations focused on combating the economic, psychosocial and health challenges resulting from the COVID-19\npandemic.\n MWI Animal Health announced a series of technology tools that will enable veterinarian practices to virtually engage with\ntheir clients, which has become critically important during the COVID-19 pandemic.\n", "original_text": "healthy communities. ", "page_label": "4", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6fe629ab-40a5-475f-a41b-b3d8d4c4f34b": {"node_ids": ["8c91b7fb-8541-45a9-826f-045152fbd18d", "21d55bce-ca4a-487f-a470-837e41220929", "91a308eb-47bb-4ccc-a47c-3c614666b732", "8564a7ef-e986-4a30-9590-6a6ad53c95a0", "8b180c6b-fe26-4c5d-8f61-54f2ad32de6d", "ce89b46b-9790-4fba-b2de-31fc024afb60", "e0dd723d-17f0-4aa7-9112-1cb4cb2dd91d", "3c87ca1f-bc05-4210-8293-053819248d1b", "a74e4311-e68e-499c-b0ea-fd48b8d9a348", "c847738b-48e9-4cb8-8ba8-f15da17b3647", "c04183b4-c5ed-4134-8775-3a6e2948ebc6", "f8f28fe8-572b-401b-8ee4-9f8e03fd6489", "50f0d331-90d5-4883-a033-ae6550547776", "395007a1-70cb-4048-b12c-2a1b0785f2e8", "c9c9bc5b-d0b9-4b4d-abdd-472f5ed93631", "5f3f6dc7-5917-4a84-ac7a-36488dfede68", "af1f3b43-ee9f-4311-87e1-ca38740097e4", "cf693619-902b-4883-a7ff-fa29660c2864", "d69df88f-eb44-4586-a4e8-d16e0734367a", "3ca38170-6766-4fe5-8b46-9b25ad33561d", "404c6f44-79ba-4fef-8eae-259b276b595a", "8379c1c4-a0e1-49cd-b4e4-ac9187a0a547", "2d4315ce-cf28-4723-8379-58c95e268126", "26272aae-e375-40db-8083-edb11f6070f9", "7c4f99d2-866b-4388-b7f3-a00897f446ee", "435432df-6eac-4023-b3db-fcff853ea1f6", "c6d8f67d-178a-4bec-a6de-3257570d391e", "92cbaa00-d5af-4895-9486-0bb27f5ca468", "92f4ed50-5104-46e5-be8f-31ed285e1c02", "e4d79965-0f4a-41aa-bf6d-70d401306879", "e64b71cc-9d84-4033-a580-e636b5d9f0a9", "eb5a9d3d-ce05-479e-b7f8-62c705b12309"], "metadata": {"window": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions.  As of March 31, 2020, the\nCompany had $68.8 million remaining under the share repurchase program authorized in October 2018.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 7, 2020. ", "original_text": "purchase up to $500 million of its outstanding shares of common stock, subject to market conditions. ", "page_label": "5", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "70ddf015-0316-4e15-87cb-48211c55f4dc": {"node_ids": ["1c616a0b-a300-43f2-b895-5229a2fc045a", "24e32102-c445-4a22-a86e-a5b96c2a6fcb", "077e1eb0-c2b7-4bbb-b161-03ad02684407", "5fa7c41c-1c1d-4e24-acfe-c56127418b41", "780e0580-72a5-4d08-b082-adf9dcbdf4ad", "fcd08ac6-3ef6-43a5-815d-d41bf72be804"], "metadata": {"window": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc.  and the Company, including\nprincipally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement;\nchanges in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax\nliabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with\nour former compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including\nnon-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations;\nfinancial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19;\nsubstantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer,\nincluding as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the\ncustomer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally\nassociated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events\nthat affect the Company\u2019s operations; the impairment of goodwill or other intangible assets (including any additional impairments\nwith respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected,\nor that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the\nanticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of\nthe Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business,\ncompetitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors\nthat management believes could cause actual outcomes and results to differ materially from those described in forward-looking\nstatements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\nSeptember 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange\nAct. ", "original_text": "supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state\ngovernment enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled\nsubstances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and\nregulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid\nlitigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased\nfederal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing,\nsale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with\nthe Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or\nsupplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or\nsuppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms;\nrisks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "57c8931b-62cc-430f-9f04-ded5e11d1438": {"node_ids": ["897852c7-bd18-4903-af8c-b40892ce7216"], "metadata": {"window": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a046,029,532 \u00a0\u00a0\u00a0 \u00a041,894,846 \u00a0\u00a0\u00a0 \u00a09.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,388,107 \u00a0\u00a02.93% \u00a01,424,756 \u00a0\u00a03.29% \u00a0(2.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0693,413 \u00a0\u00a01.46% \u00a0628,036 \u00a0\u00a01.45% \u00a010.4%\nDepreciation and amortization \u00a093,795 \u00a0\u00a00.20% \u00a0123,766 \u00a0\u00a00.29% \u00a0(24.2)%\nEmployee severance, litigation, and other 3 \u00a067,732 \u00a0\u00a0\u00a0 \u00a055,389 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0223,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,078,592 \u00a0\u00a02.27% \u00a01,377,191 \u00a0\u00a03.18% \u00a0(21.7)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0309,515 \u00a0\u00a00.65% \u00a047,565 \u00a0\u00a00.11% \u00a0550.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income 4 \u00a0(1,109 )\u00a0\u00a0 \u00a0(14,494 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a034,421 \u00a0\u00a0\u00a0 \u00a043,275 \u00a0\u00a0\u00a0 \u00a0(20.5)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0276,203 \u00a0\u00a00.58% \u00a018,784 \u00a0\u00a00.04% \u00a01,370.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax benefit 5 \u00a0(694,908 )\u00a0\u00a0 \u00a0(9,289 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0971,111 \u00a0\u00a02.05% \u00a028,073 \u00a0\u00a00.06% \u00a03,359.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interest \u00a0(10,834 )\u00a0\u00a0 \u00a0(938 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$960,277 \u00a0\u00a02.03% \u00a0$27,135 \u00a0\u00a00.06% \u00a03,438.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a56fff47-37c4-4d7c-b25c-414b67aba1b3": {"node_ids": ["eaf428c5-9d04-4510-9db1-1ccd407fe254", "4ecd681c-2da9-431b-8778-567f364b554a", "d584f730-37ec-49c1-a2cf-9f50054b51d0", "6bd17174-5221-410e-a6c3-f1cff44d8db3", "75647e0f-6c7c-4a95-8a94-3f0d45318d70", "1cda3905-f139-47c3-aaaf-9e45faa8740f", "d7c22879-4c2f-4765-97a9-305cd3292f4f", "75d5bdee-f242-4849-9132-4d652ad4917b"], "metadata": {"window": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020.  Includes a $66.8 million LIFO credit, a $52.0 million gain from\nantitrust litigation settlements, and $12.3 million of PharMEDium remediation costs in the three months ended March 31, 2019.\n\u00a0\n 2\u00a0Includes $27.5 million of PharMEDium shutdown costs and a $12.2 million adjustment to Profarma's estimate of contingent\nconsideration related to the purchase price of one of its prior business acquisitions in the three months ended March 31, 2020.\n\u00a0\n 3\u00a0Includes $25.0 million of employee severance, $30.8 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $11.9 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the three months ended March 31, 2020. ", "original_text": "Basic \u00a0$4.68 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,500.0%\nDiluted \u00a0$4.64 \u00a0\u00a0\u00a0 \u00a0$0.13 \u00a0\u00a0\u00a0 \u00a03,469.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,370 \u00a0\u00a0\u00a0 \u00a0210,934 \u00a0\u00a0\u00a0 \u00a0(2.6)%\nDiluted \u00a0207,062 \u00a0\u00a0\u00a0 \u00a0212,563 \u00a0\u00a0\u00a0 \u00a0(2.6)%\n________________________________________\n1\u00a0Includes a $23.9 million LIFO expense, a $0.1 million gain from antitrust litigation settlements, and $5.0 million of PharMEDium\nshutdown costs in the three months ended March 31, 2020. ", "page_label": "8", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cb8794e3-2a5a-4f55-a8f7-bc4aad4532ed": {"node_ids": ["7fbfb531-ecf3-42f7-aaad-3dc8199a09d2"], "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "original_text": "\u00a0\n\u00a0 \u00a0Six \n Months Ended \n March 31, 2020 \u00a0% of \n Revenue \u00a0Six \n Months Ended \n March 31, 2019 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$95,282,381 \u00a0\u00a0\u00a0 \u00a0$88,712,054 \u00a0\u00a0\u00a0 \u00a07.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a092,663,060 \u00a0\u00a0\u00a0 \u00a085,989,718 \u00a0\u00a0\u00a0 \u00a07.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,619,321 \u00a0\u00a02.75% \u00a02,722,336 \u00a0\u00a03.07% \u00a0(3.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,379,366 \u00a0\u00a01.45% \u00a01,284,621 \u00a0\u00a01.45% \u00a07.4%\nDepreciation and amortization \u00a0198,310 \u00a0\u00a00.21% \u00a0246,266 \u00a0\u00a00.28% \u00a0(19.5)%\nEmployee severance, litigation, and other 3 \u00a0107,041 \u00a0\u00a0\u00a0 \u00a096,061 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0570,000 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a02,046,369 \u00a0\u00a02.15% \u00a02,196,948 \u00a0\u00a02.48% \u00a0(6.9)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0572,952 \u00a0\u00a00.60% \u00a0525,388 \u00a0\u00a00.59% \u00a09.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss (income) 4 \u00a01,733 \u00a0\u00a0\u00a0 \u00a0(11,397 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a065,428 \u00a0\u00a0\u00a0 \u00a085,445 \u00a0\u00a0\u00a0 \u00a0(23.4)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0505,791 \u00a0\u00a00.53% \u00a0451,340 \u00a0\u00a00.51% \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax (benefit) expense 5 \u00a0(651,888 )\u00a0\u00a0 \u00a031,514 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,157,679 \u00a0\u00a01.21% \u00a0419,826 \u00a0\u00a00.47% \u00a0175.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n9", "page_label": "9", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5356b78c-90c6-4c1d-af32-df1a1bd66ccd": {"node_ids": ["f2c1992e-aff5-4ecb-bdce-b434c1a5dd55", "0035fddb-63ca-42ce-bbcd-94c6c6c84107", "36c46279-3c54-4570-828d-4f108272a838", "af6ea5b7-a339-40ca-9848-5a0169c1307e", "3d428454-6ec0-41e9-8467-f8f16a8f59c2", "5285eb77-2226-42e0-88fc-e64072d51a42", "ac3fcb4e-5606-4a32-8531-e59a36c1a60c", "32e80f0a-83e0-4f0e-9b63-b396b493742a"], "metadata": {"window": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020.  Includes a $139.3 million gain from\nantitrust litigation settlements, a $69.8 million LIFO credit, $30.2 million of PharMEDium remediation costs, and a $22.0 million\nreversal of a prior period assessment relating to the New York State Opioid Stewardship Act in the six months ended March 31,\n2019.\n\u00a0\n 2\u00a0Includes $36.5 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate\nof contingent consideration related to the purchase price of one of its prior business acquisitions in the six months ended March\n31, 2020.\n\u00a0\n 3\u00a0Includes $25.8 million of employee severance, $55.5 million of litigation costs related to legal fees in connection with opioid\nlawsuits and investigations, and $25.7 million of other costs in connection with business transformation efforts, other\nrestructuring initiatives, and acquisition-related deal and integration costs in the six months ended March 31, 2020. ", "original_text": "Net (income) loss attributable to noncontrolling interest \u00a0(9,762 )\u00a0\u00a0 \u00a0961 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,147,917 \u00a0\u00a01.20% \u00a0$420,787 \u00a0\u00a00.47% \u00a0172.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.58 \u00a0\u00a0\u00a0 \u00a0$1.99 \u00a0\u00a0\u00a0 \u00a0180.4%\nDiluted \u00a0$5.54 \u00a0\u00a0\u00a0 \u00a0$1.97 \u00a0\u00a0\u00a0 \u00a0181.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,693 \u00a0\u00a0\u00a0 \u00a0211,503 \u00a0\u00a0\u00a0 \u00a0(2.7)%\nDiluted \u00a0207,293 \u00a0\u00a0\u00a0 \u00a0213,275 \u00a0\u00a0\u00a0 \u00a0(2.8)%\n________________________________________\n1\u00a0Includes a $37.1 million LIFO expense, an $8.5 million gain from antitrust litigation settlements, and $12.1 million of\nPharMEDium remediation and shutdown costs in the six months ended March 31, 2020. ", "page_label": "10", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c93b6dc3-9a96-4996-9db3-9c2aac96aa23": {"node_ids": ["0714c505-ec74-4f5e-b8d2-4c78370df48a"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,388,107 \u00a0\u00a0$1,078,592 \u00a0\u00a0$309,515 \u00a0\u00a0$276,203 \u00a0\u00a0$(694,908 )\u00a0$(10,834 )\u00a0$960,277 \u00a0\u00a0$4.64 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(54 )\u00a0\u2014\u00a0\n\u00a0(54 )\u00a0(54 )\u00a0(111 )\u00a0\u2014\u00a0\n\u00a057\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a023,853 \u00a0\u00a0\u2014 \u00a0\u00a023,853 \u00a0\u00a023,853 \u00a0\u00a05,972 \u00a0\u00a0\u2014 \u00a0\u00a017,881 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a04,989\u00a0\n\u00a0(27,481 )\u00a032,470\u00a0\n\u00a032,470\u00a0\n\u00a08,107\u00a0\n\u00a0\u2014\u00a0\n\u00a024,363\u00a0\n\u00a00.12\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(26,670 )\u00a026,670\u00a0\n\u00a026,670\u00a0\n\u00a06,894\u00a0\n\u00a0(435 )\u00a019,341\u00a0\n\u00a00.09\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(67,732 )\u00a067,732\u00a0\n\u00a067,732\u00a0\n\u00a016,978\u00a0\n\u00a0\u2014\u00a0\n\u00a050,754\u00a0\n\u00a00.25\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6e771eff-38f7-4804-b9a4-708eb49f069d": {"node_ids": ["3a208cfe-8e3f-4716-a744-8b5e0850c3cf", "ed4830f8-7410-4ab3-964f-41db9e09d0a9", "1c267ac1-40dc-4563-8b3e-d33c4834aad9", "e18e2681-a87b-4759-94cc-45bc8a9169da", "dab5b807-83d7-42e9-bbd3-3807851d39f4"], "metadata": {"window": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nquarter \u00a07.5 %\u00a06.2 %\u00a08.9 %\u00a011.2 %\u00a011.1 %\u00a0\u00a0 \u00a010.7 %\u00a013.7 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.93% \u00a02.99%\nOperating expenses \u00a02.27% \u00a01.57%\nOperating income \u00a00.65% \u00a01.42%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "PharMEDium\nassets \u00a0\u2014 \u00a0(223,652 )\u00a0223,652 \u00a0223,652 \u00a056,156 \u00a0\u2014 \u00a0167,496 \u00a00.81 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0741,015\u00a0\n\u00a0\u2014\u00a0\n\u00a0(741,015 )\u00a0(3.58 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,416,895\u00a0\n\u00a0$745,210\u00a0\n\u00a0$671,685\u00a0\n\u00a0$638,373\u00a0\n\u00a0$137,138\u00a0\n\u00a0$(3,758 )\u00a0$497,477\u00a0\n\u00a0$2.40\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "12", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "87673ae1-375e-445b-a42d-c72fa3c8f97b": {"node_ids": ["230c6c61-aefe-47d4-9745-c445c52ffd35"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "original_text": "AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31, 2019 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,424,756 \u00a0\u00a0$1,377,191 \u00a0\u00a0$47,565 \u00a0\u00a0$18,784 \u00a0\u00a0$(9,289 )\u00a0$(938 )\u00a0$27,135 \u00a0\u00a0$0.13 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(51,976 )\u00a0\u2014\u00a0\n\u00a0(51,976 )\u00a0(51,976 )\u00a0(16,980 )\u00a0\u2014\u00a0\n\u00a0(34,996 )\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(66,805 )\u00a0\u2014 \u00a0\u00a0(66,805 )\u00a0(66,805 )\u00a0(17,137 )\u00a0\u2014 \u00a0\u00a0(49,668 )\u00a0(0.23 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nremediation\ncosts \u00a012,334\u00a0\n\u00a0(3,563 )\u00a015,897\u00a0\n\u00a015,897\u00a0\n\u00a04,927\u00a0\n\u00a0\u2014\u00a0\n\u00a010,970\u00a0\n\u00a00.05\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York State\nOpioid\nStewardship Act \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(944 )\u00a0\u2014\u00a0\n\u00a0944\u00a0\n\u00a0\u2014\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(46,594 )\u00a046,594\u00a0\n\u00a046,594\u00a0\n\u00a013,800\u00a0\n\u00a0(437 )\u00a032,357\u00a0\n\u00a00.15\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(55,389 )\u00a055,389\u00a0\n\u00a055,389\u00a0\n\u00a07,474\u00a0\n\u00a0\u2014\u00a0\n\u00a047,915\u00a0\n\u00a00.23\u00a0\n\u00a0\n13", "page_label": "13", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c492767e-4cd8-4f88-9119-1967513f7983": {"node_ids": ["a09d952e-5019-4e41-a1bb-d3f2b78a94b3", "db8d00ed-6700-4010-8eba-ab5154df3bf8", "c604e02d-5247-4aae-b19b-aeaa74430976"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n14", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a02.00\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,318,309\u00a0\n\u00a0$701,645\u00a0\n\u00a0$616,664\u00a0\n\u00a0$574,191\u00a0\n\u00a0$123,469\u00a0\n\u00a0$(1,375 )\u00a0$449,347\u00a0\n\u00a0$2.11\u00a0\n1\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.29% \u00a03.04%\nOperating expenses \u00a03.18% \u00a01.62%\nOperating income \u00a00.11% \u00a01.42%\n________________________________________\n1\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "14", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0ccd4f98-6c7d-411d-b175-39f2575e525c": {"node_ids": ["ae7284e6-1765-438a-9097-a434f757372e"], "metadata": {"window": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "original_text": "\u00a0 \u00a0Six Months Ended Mar ch 31, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income T ax\n(Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,619,321 \u00a0\u00a0$2,046,369 \u00a0\u00a0$572,952 \u00a0\u00a0$505,791 \u00a0\u00a0$(651,888 )\u00a0$(9,762 )\u00a0$1,147,917 \u00a0\u00a0$5.54 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u2014\u00a0\n\u00a0(8,546 )\u00a0(8,546 )\u00a0(2,085 )\u00a0\u2014\u00a0\n\u00a0(6,461 )\u00a0(0.03 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a037,134 \u00a0\u00a0\u2014 \u00a0\u00a037,134 \u00a0\u00a037,134 \u00a0\u00a09,059 \u00a0\u00a0\u2014 \u00a0\u00a028,075 \u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,124\u00a0\n\u00a0(36,511 )\u00a048,635\u00a0\n\u00a048,635\u00a0\n\u00a011,864\u00a0\n\u00a0\u2014\u00a0\n\u00a036,771\u00a0\n\u00a00.18\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(60,236 )\u00a060,236\u00a0\n\u00a060,236\u00a0\n\u00a014,695\u00a0\n\u00a0(871 )\u00a044,670\u00a0\n\u00a00.22\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014\u00a0\n\u00a0(107,041 )\u00a0107,041\u00a0\n\u00a0107,041\u00a0\n\u00a026,114\u00a0\n\u00a0\u2014\u00a0\n\u00a080,927\u00a0\n\u00a00.39\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(361,652 )\u00a0361,652\u00a0\n\u00a0361,652\u00a0\n\u00a088,227\u00a0\n\u00a0\u2014\u00a0\n\u00a0273,425\u00a0\n\u00a01.32\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014\u00a0\n\u00a012,153\u00a0\n\u00a0(12,153 )\u00a0(12,153 )\u00a0(2,965 )\u00a07,511\u00a0\n\u00a0(1,677 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\n f\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fabb3688-92c6-43a0-aff7-369674f3a247": {"node_ids": ["199195a7-e439-4254-b606-3d04783ce826", "9792f7e7-ecfc-4bca-9c65-c8f0a0d3b7bd", "88c00538-4f27-4f49-8bd8-1b8a2caf4700", "eb894ba0-692d-41be-b9e9-dc25127f2c17", "5b504fd4-79a2-4e6c-80c4-152126b3432e"], "metadata": {"window": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n prior year\nperiod \u00a05.5 %\u00a04.2 %\u00a07.2 %\u00a09.9 %\u00a012.3 %\u00a0\u00a0 \u00a08.9 %\u00a011.8 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.75% \u00a02.79%\nOperating expenses \u00a02.15% \u00a01.57%\nOperating income \u00a00.60% \u00a01.22%\n________________________________________\n1\u00a0Includes $741.0 million of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown\nof the PharMEDium business.\n\u00a0\n 2\u00a0The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "benefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0741,015 \u00a0\u2014 \u00a0(741,015 )\u00a0(3.57 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$2,660,033\u00a0\n\u00a0$1,493,082\u00a0\n\u00a0$1,166,951\u00a0\n\u00a0$1,099,790\u00a0\n\u00a0$234,036\u00a0\n\u00a0$(3,122 )\u00a0$862,632\u00a0\n\u00a0$4.16\u00a0\n2\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP %\nchange vs.\n", "page_label": "16", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4ba372c5-508f-45d2-87a6-176747186adf": {"node_ids": ["113f33f6-cd50-4321-aacb-3cdffe07483e"], "metadata": {"window": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "original_text": "\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2019\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterest \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$2,722,336 \u00a0\u00a0$2,196,948 \u00a0\u00a0$525,388 \u00a0\u00a0$451,340 \u00a0\u00a0$31,514 \u00a0\u00a0$961 \u00a0\u00a0$420,787 \u00a0\u00a0$1.97 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from\nantitrust\nlitigation\nsettlements \u00a0(139,255 )\u00a0\u2014\u00a0\n\u00a0(139,255 )\u00a0(139,255 )\u00a0(35,450 )\u00a0\u2014\u00a0\n\u00a0(103,805 )\u00a0(0.49 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0(69,834 )\u00a0\u2014 \u00a0\u00a0(69,834 )\u00a0(69,834 )\u00a0(17,778 )\u00a0\u2014 \u00a0\u00a0(52,056 )\u00a0(0.24 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharMEDium\nremediation\ncosts \u00a030,245\u00a0\n\u00a0(6,147 )\u00a036,392\u00a0\n\u00a036,392\u00a0\n\u00a09,264\u00a0\n\u00a0\u2014\u00a0\n\u00a027,128\u00a0\n\u00a00.13\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNew York State\nOpioid\nStewardship Act \u00a0(22,000 )\u00a0\u2014\u00a0\n\u00a0(22,000 )\u00a0(22,000 )\u00a0(5,600 )\u00a0\u2014\u00a0\n\u00a0(16,400 )\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014\u00a0\n\u00a0(91,746 )\u00a091,746\u00a0\n\u00a091,746\u00a0\n\u00a023,355\u00a0\n\u00a0(943 )\u00a067,448\u00a0\n\u00a00.32\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014\u00a0\n\u00a0(96,061 )\u00a096,061\u00a0\n\u00a096,061\u00a0\n\u00a024,454\u00a0\n\u00a0\u2014\u00a0\n\u00a071,607\u00a0\n\u00a00.34\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014\u00a0\n\u00a0(570,000 )\u00a0570,000\u00a0\n\u00a0570,000\u00a0\n\u00a0145,103\u00a0\n\u00a0\u2014\u00a0\n\u00a0424,897\u00a0\n\u00a01.99\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain on sale of\nan equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014\u00a0\n\u00a0(13,692 )\u00a0(3,485 )\u00a0\u2014\u00a0\n\u00a0(10,207 )\u00a0(0.05 )\n17", "page_label": "17", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "545df202-e6e8-4bdc-ab36-29a297e2dc77": {"node_ids": ["da0e7e1f-f8b9-47ef-b198-b5074df71827", "07e35197-99f2-43e0-95d0-282cfa9e7db3", "5ebb51d2-90fe-42ef-aaac-948633c93a52"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \u00a0\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$45,562,670 \u00a0\u00a0$41,676,164 \u00a0\u00a09.3%\n18", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a036,997 \u00a0\u00a0\u2014 \u00a0\u00a0(36,997 )\u00a0(0.17 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-\nGAAP \u00a0$2,521,492\u00a0\n\u00a0$1,432,994\u00a0\n\u00a0$1,088,498\u00a0\n\u00a0$1,000,758\u00a0\n\u00a0$208,374\u00a0\n\u00a0$18\u00a0\n\u00a0$792,402\u00a0\n\u00a0$3.72\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.07% \u00a02.84%\nOperating expenses \u00a02.48% \u00a01.62%\nOperating income \u00a00.59% \u00a01.23%\n________________________________________\n1\u00a0Includes a measurement period adjustment of the one-time transition tax on historical foreign earnings and profits through\nDecember 31, 2017.\n\u00a0\n", "page_label": "18", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5eb4e149-434d-445a-b350-30d38b695ac2": {"node_ids": ["43ec5730-1884-4f72-af03-848bbae84902"], "metadata": {"window": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "original_text": "Other \u00a01,876,593 \u00a0\u00a01,665,429 \u00a0\u00a012.7%\nIntersegment eliminations \u00a0(21,624 )\u00a0(21,991 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$47,417,639 \u00a0\u00a0$43,319,602 \u00a0\u00a09.5%\n\u00a0\n\u00a0 \u00a0Three months ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$563,097 \u00a0\u00a0$517,034 \u00a0\u00a08.9%\nOther \u00a0108,260 \u00a0\u00a099,879 \u00a0\u00a08.4%\nIntersegment eliminations \u00a0328 \u00a0\u00a0(249 )\u00a0\u00a0\nTotal segment operating income \u00a0671,685 \u00a0\u00a0616,664 \u00a0\u00a08.9%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a054 \u00a0\u00a051,976 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(23,853 )\u00a066,805 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(32,470 )\u00a0(15,897 )\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(26,670 )\u00a0(46,594 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(67,732 )\u00a0(55,389 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(223,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$309,515 \u00a0\u00a0$47,565 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.32% \u00a02.38% \u00a0\u00a0\nOperating expenses \u00a01.08% \u00a01.14% \u00a0\u00a0\nOperating income \u00a01.24% \u00a01.24% \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c1bdebf7-4513-4868-b7b9-9c94fd4323db": {"node_ids": ["c1c29696-5455-43f5-8d9f-17b358865b25", "96461443-f6b5-4d68-a5aa-01a73e65d399"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited) \u00a0\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02020 \u00a02019 \u00a0%\u00a0Change\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.15% \u00a019.60% \u00a0\u00a0\nOperating expenses \u00a013.38% \u00a013.60% \u00a0\u00a0\nOperating income \u00a05.77% \u00a06.00% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.93% \u00a03.29% \u00a0\u00a0\nOperating expenses \u00a02.27% \u00a03.18% \u00a0\u00a0\nOperating income \u00a00.65% \u00a00.11% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.99% \u00a03.04% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.42% \u00a01.42% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7431cefc-7d20-4da7-a04d-0eba392a6763": {"node_ids": ["33a9267e-7b1a-408a-953a-3c46c91d9cee"], "metadata": {"window": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "original_text": "Pharmaceutical Distribution Services \u00a0$91,599,498 \u00a0\u00a0$85,420,545 \u00a0\u00a07.2%\nOther \u00a03,723,577 \u00a0\u00a03,336,367 \u00a0\u00a011.6%\nIntersegment eliminations \u00a0(40,694 )\u00a0(44,858 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$95,282,381 \u00a0\u00a0$88,712,054 \u00a0\u00a07.4%\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating\u00a0income \u00a02020 \u00a02019 \u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$954,791 \u00a0\u00a0$890,241 \u00a0\u00a07.3%\nOther \u00a0212,739 \u00a0\u00a0198,813 \u00a0\u00a07.0%\nIntersegment eliminations \u00a0(579 )\u00a0(556 )\u00a0\u00a0\nTotal segment operating income \u00a01,166,951 \u00a0\u00a01,088,498 \u00a0\u00a07.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGain from antitrust litigation settlements \u00a08,546 \u00a0\u00a0139,255 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0(37,134 )\u00a069,834 \u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0(48,635 )\u00a0(36,392 )\u00a0\u00a0\nNew York State Opioid Stewardship Act \u00a0\u2014 \u00a0\u00a022,000 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(60,236 )\u00a0(91,746 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(107,041 )\u00a0(96,061 )\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0(361,652 )\u00a0(570,000 )\u00a0\u00a0\nContingent consideration adjustment \u00a012,153 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$572,952 \u00a0\u00a0$525,388 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.13% \u00a02.19% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d56fa770-2e81-4234-be90-9a776b41125b": {"node_ids": ["24e3e9cd-47f3-4482-9128-76b064de39fe", "8154a2fe-71de-4201-9a5a-748ae7a9808e"], "metadata": {"window": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n22", "original_text": "Operating expenses \u00a01.09% \u00a01.15% \u00a0\u00a0\nOperating income \u00a01.04% \u00a01.04% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a019.08% \u00a019.53% \u00a0\u00a0\nOperating expenses \u00a013.37% \u00a013.57% \u00a0\u00a0\nOperating income \u00a05.71% \u00a05.96% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.75% \u00a03.07% \u00a0\u00a0\nOperating expenses \u00a02.15% \u00a02.48% \u00a0\u00a0\nOperating income \u00a00.60% \u00a00.59% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.79% \u00a02.84% \u00a0\u00a0\nAdjusted operating expenses \u00a01.57% \u00a01.62% \u00a0\u00a0\nAdjusted operating income \u00a01.22% \u00a01.23% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c7fb5b92-4df5-4cb9-b691-72340ec31ceb": {"node_ids": ["2c347b52-e085-4bca-be47-30902a5f7710"], "metadata": {"window": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "original_text": "\u00a0 March 31, \u00a0September 30,\n\u00a0 2020 \u00a02019\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $3,691,938 \u00a0\u00a0$3,374,194 \u00a0\nAccounts receivable, net 14,210,170 \u00a0\u00a012,386,879 \u00a0\nInventories 11,102,566 \u00a0\u00a011,060,254 \u00a0\nRight to recover asset 1,301,108 \u00a0\u00a01,147,483 \u00a0\nIncome tax receivable 699,494 \u00a0\u00a05,859 \u00a0\nPrepaid expenses and other 175,374 \u00a0\u00a0157,385 \u00a0\nTotal current assets 31,180,650 \u00a0\u00a028,132,054 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 1,421,768 \u00a0\u00a01,770,516 \u00a0\nGoodwill and other intangible assets 8,639,581 \u00a0\u00a09,000,343 \u00a0\nOther long-term assets 800,263 \u00a0\u00a0269,067 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $42,042,262 \u00a0\u00a0$39,171,980 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $30,719,987 \u00a0\u00a0$28,385,074 \u00a0\nOther current liabilities 868,996 \u00a0\u00a01,057,208 \u00a0\nShort-term debt 522,807 \u00a0\u00a0139,012 \u00a0\nTotal current liabilities 32,111,790 \u00a0\u00a029,581,294 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n23", "page_label": "23", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7ad5fac5-6870-41f2-8187-a3d41f4e8137": {"node_ids": ["853b1cd2-6817-4179-91f8-a2790d741941"], "metadata": {"window": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "original_text": "Long-term debt 3,622,387 \u00a0\u00a04,033,880 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 279,403 \u00a0\u00a0284,075 \u00a0\nDeferred income taxes 1,843,910 \u00a0\u00a01,860,195 \u00a0\nOther long-term liabilities 479,659 \u00a0\u00a0419,330 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity 3,705,113 \u00a0\u00a02,993,206 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and equity $42,042,262 \u00a0\u00a0$39,171,980\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2020 \u00a02019\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,157,679 \u00a0\u00a0$419,826 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1643,981 \u00a0\u00a0820,403 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (2,052,216 )\u00a0(880,805 )\nInventories (152,359 )\u00a0(420,190 )\nAccounts payable 2,395,847 \u00a0\u00a01,350,728 \u00a0\nOther 2 (997,225 )\u00a0(186,630 )\nNet cash provided by operating activities 995,707 \u00a0\u00a01,103,332 \u00a0\n24", "page_label": "24", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1c70e909-f342-4ed8-88dc-fce6e0d450c3": {"node_ids": ["f2833c69-f4ba-45ae-a82e-b3193f1be0f3", "5fb3da70-63ea-4b01-87d9-0f442e911cbc", "ba550b8e-37d8-4330-9f11-3cde37d94d05", "98bf52d0-d75b-48eb-8d64-5f3e3f9a697c"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020.  Includes a LIFO credit of $69.8 million and an impairment of PharMEDium assets of $570.0 million in the six\nmonths ended March 31, 2019.\n\u00a0\n 2\u00a0Includes a $693.6 million increase in income tax receivable for the six months ended March 31, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 25", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (144,382 )\u00a0(161,488 )\nCost of equity investments and acquired companies, net of cash acquired (30,580 )\u00a0(52,398 )\nOther 7,162 \u00a0\u00a02,659 \u00a0\nNet cash used in investing activities (167,800 )\u00a0(211,227 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 947 \u00a0\u00a0(16,017 )\nPurchases of common stock 3 (407,152 )\u00a0(347,959 )\nExercises of stock options 76,757 \u00a0\u00a037,590 \u00a0\nCash dividends on common stock (170,541 )\u00a0(170,428 )\nOther (10,174 )\u00a0(12,057 )\nNet cash used in financing activities (510,163 )\u00a0(508,871 )\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash and cash equivalents 317,744 \u00a0\u00a0383,234 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at beginning of period 3,374,194 \u00a0\u00a02,492,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash and cash equivalents at end of period $3,691,938 \u00a0\u00a0$2,875,750 \u00a0\n________________________________________\n1\u00a0Includes a LIFO expense of $37.1 million and an impairment of PharMEDium assets of $361.7 million in the six months ended\nMarch 31, 2020. ", "page_label": "25", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0ce09c65-61b3-47a6-a2ce-8eb5fb78771d": {"node_ids": ["9f685e8f-09ec-4d06-9bc8-032ca1fbf336", "ce1b0717-2bd9-41a4-b993-d23da906694a", "ab0b696b-4747-4a98-b481-041f265241a5", "7cce78eb-9135-41a2-bb37-f640800ad7ff", "a35e6562-7239-405a-bcee-77a239c9858c", "75f4e486-c1db-44f6-9e9a-fdf0f83c5485", "faf0068c-750a-4543-9d45-c747c5e2867c", "25284fea-64a6-4701-889d-e4f68f62e65d", "da12fb34-8c93-41c8-84ce-3100dde2b14c", "e4535d08-b5ff-453f-bd6e-99fc99ee4b0c", "9bbeab8b-eca3-4d44-b502-1481e47ac7fc", "061b0423-3d3c-467b-9127-faf21786651d", "a0baf085-c428-4b19-b366-6c5bdc931a73", "db021644-6a1a-4f9b-8896-783bf6bf078b", "c40bd46b-3da8-4b32-bf75-153d032b101f", "ca4357c0-6f42-4aac-8ee3-c6301fe9b2ad", "bcb7dcaf-1e85-4bdb-a409-83d73ae492bb", "cdbffe04-c084-4edb-937c-18a18c77b3fa", "e32fc84b-951e-471b-bac6-528ce5df4403", "9530ff9c-d5fd-45f6-a8be-e7186e468528", "6821bdfe-9e21-4d0d-8d6b-857683d731a1", "1e20ef56-df89-40fb-841e-66859deb4f96", "bd483feb-fc24-4210-a058-c12c6b6a92a6", "4626de9f-e431-48ee-95b6-e054cd8bb2ac", "fb3451aa-4399-47e4-8316-56ab90dd403b", "a16770da-56f5-4e0c-8201-76f39cefbf9c", "f5a06b4f-5a15-446c-96c1-b27315bc5225", "3b5dbe26-e4fd-4387-8d23-5fa74642c55c", "3da6806d-8944-4334-b0ac-9e9adaa243c4"], "metadata": {"window": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019.  Purchases of common stock in the six months ended March 31, 2019 includes $24.0 million of\nSeptember 2018 purchases that cash settled in October 2018.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "\u00a0\n3\u00a0Purchases of common stock in the six months ended March 31, 2020 includes $14.8 million of September 2019 purchases that\ncash settled in October 2019. ", "page_label": "26", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8e82d079-e988-42b9-9f63-fe3f2080a397": {"node_ids": ["8c812afd-1eaa-4012-a97e-8ba86b4e0b7a", "8aa75ade-8517-43f0-af09-ccc3f0edc146", "8e241428-1a42-4141-b6be-23a8d363ac8b", "c06ff403-2aee-4e92-a54a-b95e5a7f1d4c", "062a5c65-683d-4d45-ac1c-83ee53fe29ce", "b6f76c38-2a8e-4b04-ab4f-ae38e137fde4", "9b8ad773-fb60-4b8f-af89-14e0006062d5", "3af0cbd6-4c6e-48e0-8d3e-6fcec8367481", "d6eaa803-a08c-4469-94f2-2a1ba292b7cf", "905b41fb-9598-4900-a7d6-97fbca4b1f50", "66802f4c-093e-4c9b-a80a-3d824cf5bd7d", "1d556cfb-ae2a-4f14-892c-374f20253a0a", "3a130933-3196-450e-8d4a-f99ba0263526", "d9081016-2221-4dd5-a2db-9553027a815d", "982029c8-46b0-4feb-801c-8541d0a3a3b2", "9405e8b9-a845-40d8-814e-77f705856dc4", "bd7ab5ff-dad8-4b27-bdab-1bd54613da64", "43fbc04d-9d39-4fe9-9f7b-0920ed6eb42a", "41c6791d-17fb-4505-80b2-3245b573301c", "f8c8416c-cb88-42f4-a5b5-c8f58cbdfbed", "a62d70f1-dd29-4850-b281-b42b0991e54f", "ce0bc2f8-2b42-4f77-a140-2a5cde18aecb", "74c65345-5fc5-4ed6-9c3c-f6d98fe9a0d3", "3e40cc96-3f72-4f2a-9a61-25c7fe2e5eb2", "fceab10d-f25c-4357-9535-a82a7ae71f30"], "metadata": {"window": "business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "business acquisition.\n", "page_label": "27", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ab8cc1b8-fec2-41cc-a78e-fb25ea2facee": {"node_ids": ["e669354b-5a41-46d2-8d57-0cef1b6ffbe8", "e208a950-42e9-404e-b14c-d4dab6264a60", "6dad56c0-1b53-4c92-97c1-ca3584501636", "b69f2a5c-bd6d-4571-ad78-54dac0b47f43", "c0af943c-0055-4cd3-a0dd-865e1d212823"], "metadata": {"window": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million.  The Company does not provide forward looking guidance on a GAAP basis for such metrics because\ncertain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably\nestimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or deflation of brand and generic\npharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles amortization depends on the timing and\namount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing and amount of litigation settlements is\nunpredictable and non-recurring.\n", "original_text": "consisted of net cash provided by operating activities of $995.7 million, plus $66.7 million in cash payments made relating to\nunfavorable legal settlements, minus $8.5 million in cash payments received related to favorable legal settlements, and minus capital\nexpenditures of $144.4 million. ", "page_label": "28", "file_name": "CEN-Q2-FY20-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 201956, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}